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Abstract
Contemporary technologies and user interface design enable people 
to routinely interact with data in their everyday lives. While consumer 
applications for shopping and travel often feature data-driven user interfaces, 
health resources rarely do. These resources rely on manual translation of 
medical evidence into prose instead of providing users the capacity to interact 
with underlying data. The abstraction away from details about treatment 
options, including data about efficacy, harms, and patient-reported outcomes, 
stands in the way of people who may wish to become fully informed when 
taking on important medical decisions. In spite of barriers that restrict access 
to and potential to apply medical evidence, this project explored whether 
contemporary open-source Web technologies could be adapted to create data-
driven resources for the exploration of such evidence.
A prototype platform and example applications were developed using 
JavaScript and React.js, with Google Spreadsheets as a data store for medical 
evidence related  about twelve disease-modifying antirheumatic drugs 
(DMARDs) commonly used to treat rheumatoid arthritis. Research findings 
were manually encoded from diverse sources, and a controlled vocabulary 
and data visualization components built to bridge the gap between outcomes 
and data publishing formats favored in research, and issues important to 
patients with rheumatoid arthritis. The volume and heterogeneity of source 
evidence revealed no straightforward parallel to consumer data-driven online 
applications, especially where evidence conflicts or is uncertain. Nevertheless, 
this thesis demonstrates that extant and ready-made technologies can be 
combined to create an extensible, data-driven platform and user interface 
elements to investigate and visualize certain kinds of evidence about chronic 
disease treatment options. Future research might investigate how such 
platforms might be incorporated into patient-facing decision aids, automated 
synthesis of research findings, and collaborative tools to encode evidence.
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Nomenclature
Who is a “patient?”
The term “patient” is often used to describe someone involved in an episode 
of care (Greene & Partridge, 2007) and seen to be in a ”sick” role. In general, 
I do not believe that people living with ordinary health issues—as most of us 
do—should be referred to as patients in the context of medical information, 
education, and resources. However, it is awkward to find the right noun that 
isn’t the word patient in some cases. Through this document, patient, person, 
non-specialist, member of the public, and similar plural terms are used and refer 
to the same notion—a person living with health information needs. We are all a 
patient at some point, but hardly every day. Occasionally, the terms caregiver or 
family member are mentioned to invoke the important notion that many people 
do not make medical decisions alone, but in concert with loved ones or other 
people in their lives. Similarly, the terms practitioner, clinician, and provider are 
often used in place of physician, doctor, nurse, pharmacist, and so on, in order 
to avoid awkward linguistic gymnastics and to recognize situations in which 
many care providers work together on behalf of patients.
Non-gendered pronouns
To respect gender preferences and avoid complicated use of he and she, the 
non-gendered singular pronoun they is substituted when a gender is not 
implied. For example, “if a rheumatologist does not recommend a specific 
medication, they may offer their patient a decision aid.”
Numerals
Numbers are frequently cited in this paper. Although it may be customary to 
write out numbers below 10, such writing might be confusing or unclear—for 
example, nausea was experienced by 11 percent of patients, while sleep problems 
affected three percent of men and 14 percent of women. To ensure clarity, 
numerals are used instead of writing numbers out.
x
Chapter 1
Introduction
The rise in potential medical 
information needs
People increasingly face complex medical treatment decisions related 
to chronic illness. Chronic conditions—arthritis, asthma, cancer, chronic 
obstructive pulmonary disease (COPD), coronary heart disease, diabetes, 
hepatitis, hypertension, and chronic kidney disease—are widely prevalent and 
often comorbid, meaning that they frequently accompany one another. About 
half of American adults lives with one of those chronic health conditions, and 
1 in 4 with more than one (Ward, Schiller, & Goodman, 2014), to say nothing of 
other chronic health issues like depression, pain, and anxiety. Medical research 
has advanced new and sometimes superior treatment options for many of 
these conditions, slowing or stopping their deleterious effects and permitting 
extended and higher quality of life. The obvious benefit of this medical progress 
is that not only can people live with many of these conditions, but live better 
and longer. However effective some of these interventions may be, they often 
come along with adverse events, and may be difficult for someone to integrate 
into their life (Leppin, Montori, & Gionfriddo, 2015). 
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 i The major work of this thesis project is a prototype platform to support public 
engagement with medical evidence. An example application—called the 
Navigator prototype—can be accessed at: 
http://thesis.merges.net/navigator
 i Data are encoded in a publicly visible Google Spreadsheet at: 
http://goo.gl/gdbVuf
 i The prototype is open source. Its code is checked into GitHub at: 
http://github.com/merges/abist
Alongside the rise of treatment advances for these chronic conditions, medical 
decision making has changed. An approach called evidence-based medicine 
(EBM) has emerged and contributed to the mushrooming of medical research 
data. It asserts that medical decision making based on the best available data 
from high-quality clinical trials and epidemiological research about what 
works best, instead of strictly clinical experience or pathophysiologic rationale 
(that is, theories about the mechanics of illness and treatment) is preferable 
(Guyatt, Cairns, & Churchill, 1992).
Formerly paternalistic “doctor-knows-best” medicine has somewhat given 
way to more deferential and balanced models. In the widely adopted informed 
consent model, practitioners retain decision authority, but tell patients about 
the nature, benefits, and potential harms of medical interventions—tests and 
treatments—and obtain permission to proceed from these “informed” patients 
(Emanuel & Emanuel, 1992). Recently, the notion of shared decision making 
(SDM) has gained momentum. Advocates urge that practitioners, patients, and 
family members or caregivers collaborate and make medical decisions together, 
rather than vesting authority solely in the practitioner or the patient (Charles, 
Gafni, & Whelan, 1997; Stiggelbout et al., 2012). Some suggest that the same 
evidence that underpins EBM practice is an essential part of well-informed SDM 
(Barratt, 2008; Epstein & Gramling, 2013). However, the practitioner almost 
always has better access to such information than their patient, an example of 
information asymmetry. To make a fully informed decision, the patient and 
their clinician would ideally share access to the same best available evidence to 
answer questions and explore options.
People might expect that with all the research about new treatments, medicine 
as an institution might now know all about which interventions work best in all 
situations. They might expect that there are clear “winning” treatments, and 
clear answers to almost any medical question. In some cases, that is true—and 
fortunate. In many cases, the picture is cloudy (Epstein & Gramling, 2013). A 
new treatment might be slightly more effective in one way than an established 
treatment, but carry different risks and cost more. Or all the treatment options 
for a condition might be substantially the same, where none of them work 
best. Or there may be no evidence about the impact of one course or another 
on outcomes that truly matter to the patient. Or the evidence may not be 
reliable because of bias, sourced from studies with non-representative patients, 
insufficient sample sizes, surrogate endpoints, or for a number of other reasons 
(Greenhalgh, 2014; Gordon Guyatt, Rennie, Meade, & Cook, 2008; Pannucci 
& Wilkins, 2010). These cases introduce clinical equipoise, a situation in which 
no single option is clearly the best choice, either because there is insufficient 
evidence to support one course over another, or because even if one is more 
effective for a desirable positive outcome, that its potential risks or harms may 
outweigh the benefit given the health status and preferences of a particular 
patient. Uncertainty like this plays a major role in medical decisions (G. Elwyn, 
Edwards, Kinnersley, & Grol, 2000), especially when such uncertainty prevails 
and people may be substantially under-informed about their options.
When evidence is available, it rarely exists in a form accessible and useful to 
patients. Researchers produce findings on outcomes that advance research 
interests. Those may align with concerns real people have, but they may 
not. Surrogate outcomes or endpoints—measurable but indirect indicators 
of treatment effectiveness which may not represent real patient interests—
are common (Greenhalgh, 2014; Guyatt et al., 2008). Effective translation 
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is necessary to make evidence understandable to a wide audience, so that 
it can furnish support to people making medical decisions—from the jargon 
of medical research to the plain language and issues that matter to patients. 
Furthermore, most details of findings (e.g. statistics and estimates of effect) are 
locked in the prose of peer-reviewed articles in medical journals. Sometimes 
findings are pooled and synthesized into useful data-driven systematic reviews 
or meta-analyses. Even better—but unfortunately rarely—they may be encoded 
as machine-readable data that power interactive software for practitioners 
and their patients. In machine-readable form, evidence can be computed, 
translated, and visualized in many ways. Tools built with such data can tailor 
presentation of evidence to the needs of the individual seeking information——
and kept up to date as new evidence is produced. As that is an uncommon 
scenario, much evidence remains indecipherable for patients as medical jargon, 
in expensive access-controlled academic journals. Only bespoke, expert-crafted 
summaries for lay audiences, with findings frozen from the source evidence 
contemporaneous with their production, typically find general circulation 
among patients. People increasingly search online for medical information, 
including about treatment options (Fox & Duggan, 2013). When they search 
Google to equip themselves to become informed about their experience and 
what may be best for them, they encounter the implications of this outmoded 
way of publishing findings—generally either data-impoverished resources 
(conventional online resources like WebMD) in the case of the most common 
general searches, or the scholarly literature for less common search queries.
In non-medical domains, every day non-experts in the general public realize 
meaningful information from vast quantities of technical data—through the 
power of carefully designed user interfaces (UI). Using these data-driven UIs, 
they can employ applications in decision support. In a smartphone map app, 
huge volumes of data—mapping, historical and real-time traffic, transit route, 
schedule and real-time transit departure, among other types—are brought 
together and “translated” by a well-designed UI to provide a straightforward 
user experience (UX) for navigation by public transit. Web-based flight search 
tools combine, translate, and facilitate manipulation of similarly extensive 
technical data, such that people can find the most appropriate flight for their 
needs. In both of these cases, the source (sometimes called raw) data would 
themselves be difficult to use or useless without skillfully designed UI. The 
raw data must first be made machine-readable. Then each source can be 
individually presented in an appropriate form—map, table, or otherwise. Going 
further, they can be filtered and commingled and re-presented in new visual 
and audible ways, and made interactive, responsive to individual queries. 
This approach is customary in many domains of online information-seeking. 
Or, the data could be manually interpreted, written into comprehensive 
narrative prose and published, foregoing the inclusion of real-time updates—
the prevailing approach in online health information, including public-facing 
information about medication effects.
Medical information is an online outlier: When people search to learn more 
about medications, they rarely find data-driven tools. Instead, they find 
manually translated articles—published only if certain entities (whether WebMD, 
The Mayo Clinic, or a health agency) have invested in the human effort to 
interpret evidence and synthesize it into a static, non-interactive resource. In 
this way, medical evidence is routinely translated for non-expert consumption. 
Work in other domains have demonstrated that complex technical data can 
be “brought to life” in interactive tools. These two concepts must be brought 
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together, to make data-driven, up-to-date interactive tools that provide similar 
value for medical information-seeking. That way practitioners and their 
patients can share a similar evidence base, partially addressing the in-clinic 
information asymmetry and facilitating truly informed SDM. Evidence-based 
shared decision making could increase self-efficacy, belief in treatment, 
goal concordance, and build stronger therapeutic alliances. It may also 
have detrimental effects, if patients discover data that raises confusion or 
overwhelms them.
It is not enough to imagine and describe such tools. They must be 
demonstrated, applying contemporary design and technologies to tackle 
basic problems, experiment with solutions, and prove out concepts. In fact, 
since there are many parties involved in the production and consumption of 
the medical knowledge that would underlie such tools—from researchers to 
patients, from doctors to programmers, from designers to caregivers—many 
dimensions of the problem must be explored simultaneously, so that each party 
can understand the value and possibility. The central problems include:
 Can pertinent medical evidence be encoded and made machine readable?
 Can this evidence be built into a system that can “translate” it so that it is 
relevant to medical decision making?
 Can contemporary design principles be applied to make the data or 
evidence understandable?
Ultimately, it is up to individuals to decide whether or not they want this 
kind of information; not every person desires or requires it. Some patients 
are highly motivated, and today jump through many hoops and surmount 
literacy challenges to find and interpret medical evidence. Others will continue 
to rely on their doctor’s educated and trustworthy knowledge, and some 
on plain language summaries they find in the most popular online search 
results. But there is no reason that efforts should not be made to learn about 
how to develop digital tools for people who do want evidence-based, tailored 
information to help them understand their choices and make decisions—
especially when those decisions are complex and the choices unfamiliar. 
One such diagnosis after which people may face these kinds of decisions is 
rheumatoid arthritis (RA).
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Rheumatoid arthritis and 
complex medical decisions
The 13th edition of the Primer on the Rheumatic Diseases (Klippel, Stone, 
Crofford, & White, 2008) supplies a comprehensive background on the 
clinical characteristics, pathophysiology, and epidemiology of rheumatoid 
arthritis in several book sections (Oliver & St Clair, 2008; Tehlirian & Bathon, 
2008; Waldburger & Firestein, 2008). RA is a chronic autoimmune condition 
of unknown cause. It is characterized by an inflammatory process in the 
synovium, the tissue between the joint capsule and joint cavity that permits 
smooth and full range of motion in synovial joints—the most common and 
movable in the body, including those of the hands, wrists, shoulders, elbows, 
hips, knees, ankles, and feet—but also involves other organs through systemic 
inflammation. As RA manifests over weeks or months, joints become swollen, 
painful, and stiff, and is accompanied by general fatigue. Morning stiffness—
often for up to 2 hours—is common. These symptoms impair a person’s 
ability to perform ordinary activities, from cooking to bathing to exercising to 
working. People may initially seek treatment for their symptoms—to relieve 
pain and swelling—but if the underlying RA disease process is untreated, it 
may destroy not only the synovium, but soft joint tissue (cartilage, ligaments, 
and tendons) and even bone. Such destruction results in permanent painful, 
disabling, and disfiguring joint damage. RA is a chronic condition, though it 
does not necessarily follow a single course. It is generally progressive, with 
periods of quiet and flares of disease activity.
Helmick et al. (2008) estimate that RA affects about 0.6% of the U.S. adult 
population, or approximately 1.3 million people. Women are disproportionately 
affected, at a rate around two to three times that of men (Klippel et al., 2008). 
Genetic predispositions to RA are almost certainly involved, though it remains 
uncertain what “sets off” the autoinflammatory process. Increasing age is a 
risk factor, as is smoking, the only associated environmental risk factor (Klippel 
et al., 2008). The disease process may be active for a number of weeks or 
months before a patient is referred to a rheumatologist, by which time the signs 
and symptoms may clearly point to RA. Laboratory tests for biomarkers like 
rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) may also 
be performed to add to the evidence for an RA diagnosis (Klippel et al., 2008).
Treatment
Because RA is a chronic disease of systemic inflammation that goes beyond 
the joints, it warrants holistic care involving more than just medicines. 
Symptom control—of pain, swelling, and fatigue—is important especially early 
in treatment or during a flare up, but so may be limiting stress, adjusting diet, 
exercising, managing weight, modifying work and leisure activities, building 
an emotional support network, and more. Crucially, the underlying disease 
process must be treated in order to slow or prevent joint damage and other 
sequelae (medical conditions that are a consequence of RA) (Klippel et al., 
2008). The disease process can be slowed or arrested by one or more of a host 
of medicines, called disease-modifying antirheumatic drugs (DMARDs). Many 
of the medications that relieve acute symptoms are not DMARDs—for example, 
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over-the-counter anti-inflammatory drugs. See Table 1 for a sample of some of 
the most common drugs used to treat RA.
In the past several decades, medical therapy for RA has changed substantially. 
New treatments have emerged approximately every quarter century for the 
past hundred years: Aspirin at the turn of the 20th century, gold salts in the late 
1920s, corticosteroids and sulfasalazine in the 1950s, use of methotrexate in the 
1980s, and biologic DMARDs in the 2000s (Abramson, n.d.). Thanks to a better 
understanding of the disease process, strategies for its treatment, and in some 
cases new medications that target specific pro-inflammatory factors in RA, it is 
possible to significantly slow disease progression (Klippel et al., 2008; Smolen 
et al., 2013)—especially important for people with RA since it is associated 
with significant premature mortality from multiple complications, including 
cardiovascular disease (Kvien, 2004). However, for many people treatment is 
a winding road. The first treatment may not work well, or it may not work on 
a long-term basis. DMARDs are most certainly not free of harms, ranging from 
nausea to liver injury to serious infection resulting from immunosuppressant 
action. These adverse reactions may make a drug intolerable or harmful.
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Kind Purpose Subtype
Route of 
administration Examples
Common risks 
and side effects
Disease-
modifying 
antirheumatic 
drug (DMARD)
Slow disease 
progression, 
consequently 
relieving symptoms 
and preventing 
long-term damage.
conventional 
synthetic DMARD 
(csDMARD)
Usually oral, 
sometimes 
injection
Auranofin (Ridaura) 
Azathioprine (Imuran) 
Hydroxychloroquine 
(Plaquenil) 
Leflunomide (Arava) 
Methotrexate (Rheumatrex) 
Sulfasalazine (Azulfidine)
Immune 
suppresion, 
gastrointestinal 
issues, liver injury 
(methotrexate, 
leflunomide)
Biologic agent 
(bDMARD)
Injection or 
infusion
Abatacept (Orencia) 
Adalimumab (Humira) 
Anakinra (Kineret) 
Certolizumab (Cimzia) 
Etanercept (Enbrel) 
Golimumab (Simponi) 
Infliximab (Remicade) 
Rituximab (Rituxan) 
Tocilizumab (Actemra)
Immune 
suppression, 
serious infection
Janus kinase 
( JAK) inhibitor
Oral Tofacitinib (Xeljanz)
Corticosteroid Relieve acute severe 
inflammation, 
especially RA “flare-
ups.”
Oral or injection Cortisone 
Dexamethasone 
Hydrocortisone 
Prednisone
Immune 
suppression, loss 
of bone density, 
weight gain
Non-steroidal 
anti-
inflammatory 
drug (NSAID)
Relieve 
symptomatic 
inflammation and 
pain.
Oral Aspirin 
Celecoxib (Celebrex) 
Diclofenac (Zorvolex) 
Ibuprofen (Motrin, Advil) 
Indomethacin (Indocin) 
Naproxen (Aleve, 
Naprosyn)
Bleeding, 
gastrointenstinal 
issues
Analgesic Relieve acute pain. Non-opioid Oral Acetaminophen (Tylenol) Liver injury
Opioid 
(and opioid 
combination)
Oral Acetaminophen/Codeine 
(Tylenol #3) 
Aspirin/Oxycodone 
(Percodan) 
Fentanyl 
Hydrocodone 
Hydromorphone (Dilaudid) 
Morphine (MS Contin) 
Ibuprofen/Hydrocodone 
(Vicoprofen) 
Oxycodone (Ocycontin) 
Tramadol (Ultram)
Physical 
dependence 
and abuse, 
gastrointestinal 
issues
Table 1
Medications 
commonly used to 
treat rheumatoid 
arthritis.
Treatment frequently involves polypharmacy (the use of multiple medications 
at once), raising the risk of interactions and hazards related to drug interactions 
or inadvertent incorrect use. Use of five or more medications at once is 
common, although some may be taken for comorbid conditions rather than 
for RA (Filkova et al., 2015; Treharne et al., 2007). Longer-term use (months 
to years) of DMARDs may be combined with short-term use (weeks to months) 
of corticosteroids to quickly relieve inflammation or augment the primary 
DMARD, and over-the-counter (OTC) or more potent prescription medications 
to relieve pain (Klippel et al., 2008). The advantage of recent medical progress 
is that if the medications work well, some people can experience remission 
and defer longer-term health consequences. The disadvantage is that the 
treatment process can be substantially more complicated to manage, with 
significant impacts on daily life—all of which must be considered in the context 
of living with a condition that itself has a huge impact on someone’s life 
(Barton, 2009). The challenge of recruiting cooperation into an optimal care 
plan is complex. As Matteson (2001) says, “The health-related beliefs, goals, 
and desires of patients are important predictors of compliance with treatment 
and outcome. A willingness on the part of health care providers to understand 
and work with these beliefs, and to educate patients about the disease, is as 
fundamental to the successful treatment of RA as any medication that can be 
prescribed.” Recent clinical practice guidelines entreat physicians to engage 
in such shared decision making, with the European Union League Against 
Rheumatism treatment recommendations saying that “treatment of RA patients 
should aim at the best care and must be based on a shared decision between 
the patient and the rheumatologist,” and going as far as to note that “the Task 
Force [who created the guidelines] decided that decision-sharing by patient and 
rheumatologist is of such overwhelming importance that it should spearhead 
the recommendations” (Smolen et al., 2013).
Disease-modifying antirheumatic drugs (DMARDs)
DMARDS are agents that act on the disease process underlying RA. They can 
slow disease progression, reduce inflammation, and prevent or limit joint 
damage. Consequently, they can lead to RA symptom relief. Generally, they 
work by suppressing or inhibiting various immune functions that would 
otherwise be involved in the inflammatory and destructive RA disease 
process, through a range of mechanisms of action (Brenner & Stevens, 2013). 
DMARDs vary widely in terms of side effect profile, route of administration, 
contraindications, cost, and impact on daily routine. Two commonly used 
types of DMARD are conventional synthetic DMARDs (csDMARDs) and 
biologic agents (bDMARDs). Most conventional DMARDs are taken orally, 
and are available in generic versions. Biologic DMARDs—so-called because 
they are engineered using living tissues and mimic substances like human 
antibodies—are a newer class of medication, first approved for use in the late 
1990s. Biologic agents target a specific mechanism in the immune response 
in RA. Most are protected by patent (some expiring within months of this 
research paper’s writing) and therefore only available as relatively costly brand 
name products. The first generic (called biosimilar) versions are just being 
approved and may alter the treatment landscape by increasing access to such 
DMARDs. csDMARDs are the mainstays of treatment, though biologics play 
an important role, especially when first-line drugs like methotrexate do not 
work well (Klippel et al., 2008; Singh et al., 2016; Smolen et al., 2013). DMARDs 
can produce adverse effects that range from the relatively benign (nausea and 
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gastrointestinal issues) to very serious (liver damage, immune suppression, and 
rarely, development of certain cancers).
Glucocorticoids (corticosteroids)
Glucocorticoids also have an effect on the underlying RA disease process. These 
drugs have wide systemic effects, including inhibition of proinflammatory 
factors and lowering levels of chemicals that are involved in immune response. 
While they can quickly and significantly reduce inflammation and provide 
relief, at larger doses they can cause serious harms (Brenner & Stevens, 2013), 
so they are typically used alongside DMARDs either early in treatment to ease 
symptoms or to help control flare-ups of RA. They may also be used for a longer 
duration at low doses in concert with DMARDs, although there is debate over 
whether they are safe even at low doses (Smolen et al., 2013).
Non-steroidal anti-inflammatory drugs (NSAIDs)
This is a large group of drugs that includes OTC medications like aspirin, 
ibuprofen (Advil or Motrin), and naproxen (Aleve), and prescription 
medications such as celecoxib (Celebrex). They can reduce inflammation and 
pain associated with RA, but do not slow disease progression and joint damage, 
and are not considered DMARDs (Brenner & Stevens, 2013). Someone who 
finds relief from NSAIDs of early and mild symptoms could believe that they 
are better, or getting better, but an unrecognized disease process could still be 
progressing toward joint damage.
Medical treatment strategies with DMARDs and corticosteroids
The right medical treatment depends on the interplay between the specific 
characteristics of someone’s RA, their beliefs about the disease and treatment, 
and their life. Although there is no single best course of treatment, there are 
standards of care and up to date evidence-based clinical practice guidelines 
for RA treatment. They set out strategies and entire courses of treatment, with 
rules for evaluating, adding, removing, and switching medications. People with 
relatively mild RA might be treated with hydroxychloroquine or sulfasalazine, 
oral DMARDs with relatively few side effects. However, methotrexate is the 
“gold standard” and cornerstone of treatment for most people with RA. If 
someone doesn’t respond to a low dose of methotrexate, its dose may be 
increased, or it may be supplemented with a low dose of a glucocorticoid like 
prednisone. For severe RA or if methotrexate does not work well, a biologic 
agent might be tried. This is a “step-up” approach to treatment, where DMARDs 
are added to a treatment regimen until the desired response is observed. A 
“step-down” approach would be to try more aggressive treatment to achieve an 
early response, and then lower doses or remove medications and still maintain 
the response. So-called “double therapy” and “triple therapy” using multiple 
oral DMARDs—methotrexate, sulfasalazine, and hydroxychloroquine—may 
confer a rapid benefit for aggressive RA. However, initial DMARD monotherapy 
remains the standard of care (Oliver & St Clair, 2008; Singh et al., 2016; Smolen 
et al., 2013).
A treat-to-target (TTT) strategy—similar to one that may be used when people 
are prescribed medications to reduce their blood pressure to a specific figure 
(e.g. below 140/90)—suggests that treatment should aim to achieve a specific, 
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measurable goal (Atar, Birkeland, & Uhlig, 2010). Rather than relieving 
symptoms or slowing disease progression generally, specific target values of 
certain measures or biomarkers are the goalposts. TTT depends on goals that 
can be derived from an extensive and high-quality (low bias and rigorous) 
evidence base that clearly shows the relationship between these markers and 
beneficial outcomes. The “ultimate goal” of RA treatment may be remission 
(Oliver & St Clair, 2008), but remission itself is difficult to define. In order to 
treat to target, surrogate indicators of low disease activity must be the targets. 
And while it may be that successful retardation of RA requires aggressive 
treatment to a target, that might involve polypharmacy with relatively toxic 
DMARDs that are difficult for some people to tolerate. The “right” targets 
would ideally be defined in a shared decision making process between clinician 
and patient, taking into account the patient’s own goals and the potential for 
tolerable and appropriate treatments to help meet targets and the patient’s 
needs. With surrogate endpoints—not necessarily patient-important or patient-
defined outcomes—TTT and patient goals may not align well.
Regardless of the treatment approach, if someone does not take their 
medication regularly, as prescribed, the potential benefits can not be 
conferred. Beliefs about the medication—which may be influenced by a 
constellation of factors ranging from individual values to physician trust to 
medication knowledge—influence adherence to treatments. Horne & Weinman 
(1998) found that people who felt strongly that their treatment was necessary 
reported higher adherence rates, while those who has strong concerns about 
their medications (e.g. about side effects) reported lower adherence rates. 
Data-driven online resources might play a role in educating people about why 
medications are necessary to control RA, and how well they work. But they 
might also raise alarm and greater concerns. In principle, though, it is hopeful 
that an agreeable decision and knowledge about a treatment’s benefits and 
harms could lead to greater confidence.
Preferences for treatment and involvement in treatment decisions
Patients do not have uniform needs and preferences for both treatments 
and involvement in decision making. In addition to concerns unique to each 
individual, there are documented differences among certain populations. 
One study demonstrated that black RA patients in the U.S., for example, 
prefer more conservative treatment and are more harm-averse than white 
patients, who are relatively more concerned with the potential benefits of 
treatment (Constantinescu, Goucher, Weinstein, Smith, & Fraenkel, 2009). 
Constantinescu et al. remark “studies attempting to explain racial variability in 
patient preferences have found that differences in spirituality, health beliefs, 
perceptions of benefit, and trust all influence patients’ treatment preferences 
for medical interventions.” In a review of patient preferences in RA treatment, 
Barton (2009) notes that variation in preferences and beliefs about medications 
may partially explain disparities in health outcomes, due to their influence 
on adherence. Socioeconomic factors—including educational attainment and 
household income—may account for significant disparities in RA outcomes in 
some populations (Baldassari et al., 2014) and hamper access to information 
and care, influencing preferences. Data-driven educational tools could play a 
role in “changing minds” about benefits (related to treatment necessity) and 
risks (related to treatment concerns) of RA treatments (Liana Fraenkel et al., 
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2012), though it is very hypothetical to say that they might also play a role in 
reducing these outcome disparities.
Nota et al. (2014) found that around 60% of inflammatory arthritis patients 
prefer to participate in shared decision making, but point out that “Upon 
receiving the diagnosis, the patient needs to process a lot of information (about 
the influence of this chronic disease on daily life, starting aggressive treatment, 
etc.) in a short time. Not being aware of having a choice, little time, and/or an 
overload of information may be a barrier for patient involvement.” For these 
people, resources they can process in a place and at a pace of their choosing 
may be beneficial—especially, perhaps, if they were shared by their physician. 
Perhaps the “short time” for processing could be extended.
Living with RA
This project addresses but a narrow “slice” of living with RA—seeking 
information about a new medical treatment. (And even then, only a subset 
of DMARDs.) The “best” care, and living with RA, is much larger than this 
decision. Hopefully, networks of friends, family, and healthcare professionals 
provide critical emotional support. Someone with RA may undertake significant 
lifestyle changes—some to accommodate symptoms of RA. Stress, diet, day-
to-day symptoms, exercise, daily activities, and plenty of other more urgent 
considerations are likely to prevail over a few questions about medications. 
Nonetheless, because of the critical role that RA medications play in that 
larger milieu, such questions deserve attention by designers and researchers 
who make online resources for patients to learn about their options. Effective 
medical treatment is part of enabling someone with RA to thrive, and brings 
on real implications—such as a potential financial burden, regular laboratory 
tests to monitor for potential adverse effects (e.g. liver injury), and lifestyle 
changes (e.g. perhaps stopping drinking alcohol), to say nothing of unwelcome 
side effects and anxieties. The following scenarios illustrate complex medical 
decisions around starting and changing DMARD therapy.
Scenarios
Kim (new RA)
Kim, a married 36 year-old mother of two young children—a pre-schooler and a 
toddler—and professional caterer, has just received a diagnosis of RA from her 
rheumatologist, after several months of otherwise unexplained joint stiffness 
and fatigue that have interfered with Kim’s daily activities. Since a visit to her 
primary care physician, she has been treating her pain and inflammation with 
over-the-counter ibuprofen. That hasn’t been enough to help her pain and 
stiffness some days, and Kim has had to cancel several catering engagements 
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with clients to stay at home—foregoing her income and making her feel 
depressed. Her rheumatologist noted that Kim has a relatively high number 
of tender and swollen joints and severe self-reported pain and stiffness, 
which may be signs of early active disease. As such, the rheumatologist’s 
recommendation was that she undergo treatment with methotrexate, taken 
orally once a week, in order to mitigate the disease process and hopefully 
bring Kim to a state of remission, in which she would be relatively free of 
symptoms and able to live comfortably. However, Kim and her husband have 
been planning to conceive, and methotrexate is not safe during pregnancy, nor 
lactation. Furthermore, Kim is not a fan of taking medication at all. She would 
rather treat any illness in a more holistic way, limiting use of medications. 
Methotrexate scares her, because she knows of it as a cancer treatment and 
has also heard of people injecting it. The rheumatologist explained that initial 
treatment with methotrexate is understood to be a relatively safe and effective 
way of achieving remission, though not benign—methotrexate carries with it the 
risk of side effects that may equally interfere with everyday life. It might take 
several months to take effect, and impact Kim’s family planning. As she’s in her 
mid-30s, Kim and her husband are wary of delaying their planned pregnancy.
Kim, her husband, and her rheumatologist are together facing a complex 
medical decision with multiple potential courses of action. They include:
 Treating Kim’s RA now with methotrexate, and delaying their planned 
pregnancy. The benefits of this course of action may include rapid 
induction of disease remission and relief from pain, fatigue, and stiffness. 
But it is a course of action that carries risks, ranging from relatively 
common methotrexate side effects like nausea, vomiting, and even 
fatigue (which she’s been dealing with already), to long-term risks of 
blood disorders or liver injury. Even with a plan to reconsider pregnancy 
when and if her RA improves significantly—perhaps in months or years—
Kim will be older and potentially face greater challenges in terms of 
conception, successful pregnancy, and birthing a healthy baby. Whether 
the methotrexate works or not, she’ll face another treatment decision—
discontinuing methotrexate, and finding an appropriate alternative or 
halting treatment entirely—when she and her husband decide to pursue 
their planned pregnancy. 
 Using a pregnancy-safe alternative medication to treat Kim’s RA, so 
that she and her husband can pursue their planned pregnancy. Her 
rheumatologist told Kim that there are several alternatives, which may 
be used independently or in combination. They range from oral DMARDs 
like sulfasalazine or hydroxychloroquine, to steroids like prednisone, to 
injectable DMARDs like etanercept. Each of these medications carry their 
own variable potential to heal, and also to harm. Each also will have to be 
integrated with Kim’s daily life in one way or another besides the obvious 
questions of efficacy and side effects. The oral DMARDs are relatively 
inexpensive, but may need to be taken twice a day. If prednisone is 
needed to treat a flare-up of RA symptoms, dosing might be complicated 
and produce short-term side effects that prevent Kim from working or 
taking care of her kids. Etanercept is very expensive, and because both 
Kim and her husband are self-employed, they have limited insurance 
coverage for prescription drugs and will have to pay a significant amount 
out-of-pocket for these medications. That could seriously interfere with 
their household budget and intent to save money. 
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 Not treating Kim’s RA at all, but continuing to use pregnancy-safe 
medications to reduce inflammation and pain. Her rheumatologist 
doesn’t recommend this course of action because it will leave the 
underlying disease unaffected, which means that it could continue 
to damage her joints and produce the potential of longer-term health 
consequences—even while the symptoms could be masked. It would allow 
Kim and her husband to proceed with their planned pregnancy, though. 
And Kim’s rheumatologist has told her that being pregnant might even 
attenuate her RA symptoms temporarily. There is a chance that her RA 
could remit naturally over the course of several years, but there’s no way 
of knowing. Kim and her husband aren’t too fond of this non-treatment 
option, but it’s on the table. 
In Kim’s situation, there doesn’t seem to be one obviously best course of 
action. It is not clear that delaying their planned pregnancy and treating with 
methotrexate is ideal, nor proceeding with pregnancy but using a different 
medication. Her rheumatologist is relatively familiar with evidence about 
the benefits and harms of these medications, and has a good deal of clinical 
experience with patients choosing many different courses of action. But even 
that rheumatologist cannot tell Kim what to do. Kim has questions about what 
might happen if she chooses one course of action or another:
 If she doesn’t treat with methotrexate now, will her RA permanently 
disable her or ever be as treatable again? 
 Will “pregnancy-safe” medications potentially save her from pregnancy 
risks related to RA treatment, but mean that she will suffer worse RA long-
term? 
 How will side effects from medications make her feel during pregnancy? 
 Is methotrexate that much better than the alternatives? 
 Is it worth considering a really expensive medication like etanercept? 
 What would it be like to inject a medication every week? 
 How long will it take for any of these medications to work and for her to 
feel better? 
 Is it worth putting off pregnancy to get her RA “under control?” Will she 
be able to get pregnant later? Is she risking a miscarriage, or an unhealthy 
baby? 
Some of these questions are exceedingly difficult to answer. There may be no 
data, or it may be a matter of intuition. For example, even when there are data 
about how well medications work it is more or less impossible for “medicine” 
or “medical research” to answer that final question about whether it’s worth 
delaying a planned pregnancy.
Jerry (established RA)
Jerry is a married 63 year-old retiree, with two grown children. His wife 
is slightly younger than him, and still working. He is a tinkerer and a 
woodworker—he makes knick-knacks like birdhouses for friends and family—
and general household handyman. He also likes to play baseball with his young 
grandkids, and weekly tennis with his wife. However, he has also suffered 
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from RA for several years. And recently, after being relatively symptom-free 
(though not in remission) with methotrexate, his RA has progressed and the 
methotrexate no longer seems to be working effectively. Recently, Jerry has 
not been able to work in his workshop or around the house, or play with his 
grandkids. He has been stiffer than usual every morning, tired, and feeling 
depressed. He hasn’t been active and has been eating poorly, which is doubly 
bad for Jerry, because he has also suffered a minor heart attack and is taking a 
statin for high cholesterol, a medication to lower his blood pressure, and daily 
aspirin—to prevent a second heart attack or stroke, which he is at higher risk for 
because of both his history and his RA.
Jerry’s rheumatologist explained to him that sometimes methotrexate does 
stop working, which has upset and perplexed him since it had been working 
so well for so long. Suspecting a flare-up, Jerry’s rheumatologist a few months 
ago prescribed a short-term course of prednisone. However, that didn’t seem 
to affect the general worsening of Jerry’s RA and led to the suspicion that the 
methotrexate that had been both well-tolerated and effective, was no longer 
going to be sufficient for both relief of RA symptoms and to prevent progressive 
joint damage. But because of the impact the medication failure has been having 
on Jerry’s life, his rheumatologist has recommended that Jerry either add a 
medication to his treatment regime or try replacing the methotrexate with 
an alternative. His rheumatologist has presented several general options to 
Jerry, all of which are fairly expensive medications and new to Jerry, who is 
uncomfortable with starting a new medication. Among the courses of action 
Jerry could take are:
 Adding another injection medication that Jerry can take at home once 
or twice a week, such as etanercept or adalimumab. These are also 
expensive medications with known serious side effects. 
 Discontinuing the methotrexate, which his rheumatologist thinks may no 
longer be helping much anyway, and trying one of the above medications 
alone (without methotrexate). Jerry is concerned about this option 
because of his historical success with methotrexate and because he had 
gotten used to his routine with it. 
 Similar to the above options, Jerry’s rheumatologist explains that 
there are other medications may work differently than the injectable 
medications adalimumab or etanercept, but which can be taken just once 
a month or every two months at a clinic. It would mean sitting down for 
a couple of hours and having an IV placed. Jerry likes that it seems as 
though it would be a relatively infrequent activity—better than taking two 
more pills every day—but does not like that it would “make him feel like a 
cancer patient,” revealing fear of feeling overly medicalized. 
 Adding a low dose of a steroid to complement the methotrexate. This 
would be a relatively inexpensive option, but the rheumatologist is less 
confident that it will work well since using prednisone to treat what they 
both thought was a flare-up didn’t seem to have a lasting effect. 
 Changing nothing, continuing to take methotrexate and carefully 
attending to both his symptoms and the progression of his RA. 
Jerry wants to take the advice of his rheumatologist, but his rheumatologist 
didn’t give him a single option. Because neither he nor his wife are particularly 
savvy with medications or medical decisions, they enlist the help of their 
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daughter who is a graduate school-educated biologist and more comfortable 
navigating these kinds of decisions. Again, there is no clear best path. Jerry 
has to decide how comfortable he is with the idea of taking a new medication, 
and if he does that, what kind of medication he is willing to try in terms of the 
ways in which it might interfere with his life. He wants to know what will work 
the best, because his ultimate goal is simply to be as free as possible from RA 
problems, health problems generally, and the bother of medications and side 
effects.
Both of these scenarios illustrate complex medical decisions, in which there 
is no obvious “best” course of action. In order to make an informed decision, 
the patients—and frankly, their providers—might reasonably be expected to 
ask and desire information on the consequences of particular choices before 
making a decision. They also underscore the very human experience at the 
heart of medical decision making. If their doctors were to recommend a 
particular course of action, they might want to know more about that course, 
or alternatives. What they want to know might not be easily answered during a 
single clinical visit.
The overloaded clinical 
encounter
“The perfect physician is one who knows all the science and technology relevant to 
medicine, who knows how to apply it skillfully for the benefit of one’s patients, and, 
at the same time, is a wise compassionate counselor who earns his or her patient’s 
trust and provides comfort in times of illness and need.”
(Wacker, 1984)
This project’s premise is that self-directed online search should yield data-
driven applications—at least for those who want them. Helping those people 
become informed participants in their own medical decision making is one 
important rationale, but so is relieving pressure on the clinical encounter, when 
patients and practitioners meet in the proverbial clinic. The encounter is, in 
principle, a good place to seek answers about medications. It goes without 
saying that a trusted, knowledgeable physician who understands a patient’s life, 
goals, preferences, and health status is a good partner for helping that person 
process medical information. However, to locate education and question-
asking only in the clinic demands much of an expensive, time-limited , and 
often emotionally charged moment naturally suffused with an information 
and power asymmetry (the doctor knows more, and is not the person who is 
“sick”). It seems unlikely that all the question-asking and answering, all the 
information-absorption, and all the critical details of a person’s health inquiry 
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can be addressed in a 20-minute doctor’s visit—or perhaps a 45-minute visit, or 
even two such visits (Dugdale, Epstein, & Pantilat, 1999). The visit may be days 
or weeks away from the moment of first concern, and that is imbued with the 
stress of resulting in a clear diagnosis or treatment decision. Perhaps only in 
rare and ideal circumstances will a patient come prepared, perfectly articulate, 
with an agenda that they and their provider agree on and have time enough 
to cover, ensuring that all the patient’s questions are asked and answered 
accurately—with persistent and accurate absorption of information. Many 
barriers exist to an ideal encounter (Schattner, 2014). More likely is a modestly 
successful visit in which the doctor and patient roughly agree on what to cover, 
and how, and the patient leaves with perhaps some questions—but not too 
many. Nevertheless, some queries might remain unasked or unanswered.
Similarly, locating all education in the clinic places an enormous burden on the 
clinician’s shoulders. While one’s doctor is a highly trusted source of medical 
information (Hesse et al., 2005), it’s unrealistic to expect any clinician to be 
exhaustively knowledgeable about every topic that a patient might graze—
especially considering the “doorknob phenomenon.” (Imagine the patient just 
about to leave, putting on their coat, saying “oh, by the way, there’s one more 
thing I wanted to ask about…”) It is unreasonable to expect every provider to 
be intimately familiar and up to date with the vast body of medical evidence—
and to be able to contextualize it, summarize it, and clearly communicate it to 
the patient who’s just asked an important question on their way out the door. 
Even if the patient arrives with an articulate, well-researched question, and 
is prepared to have a discussion about it, there may not be enough time, and 
the provider might not be prepared to discuss it. Furthermore, clinicians are 
expected not only to provide excellent, high-quality, and medically sound care, 
but to provide emotional support too—an extant, challenging burden.
Time before, between, and after visits is crucial. These moments are spaces 
for absorption, consideration, and independent research. There may not be 
the presence of a knowledgeable partner (a trusted healthcare provider), but 
there might be less pressure, and a friend or family member instead. Querying 
a search engine about one’s own health may be an informative, but also very 
private and emotional experience. We are free to express or ask about things 
that we might not feel comfortable divulging in other circumstances. Out of the 
clinic, questions can be asked at a pace under the patient’s control, and new 
avenues can be explored at will. People can make use of multiple kinds and 
sources of evidence—from the high quality evidence that underpins modern 
medical practice to the unverified and anecdotal—and learn by way of whatever 
modalities suit them best—graphical, interactive, textual and narrative, aural, 
and by way of videos and animations. Clarification can be sought without fear 
of interrupting a physician during a time-limited clinical encounter. A “better” 
Dr. Google, prospectively, is one that supplies resources that are based on 
evidence that patient and practitioner might both value highly.
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Online health search and trends 
in medical decision making
Though RA may only affect just over 0.6% of U.S. adults (Helmick et al., 2008), 
there may be more search interest in it than for more prevalent chronic 
conditions (see Chapter 2). Online health search today is dominated by results 
from Web sites like WebMD—primarily static, non-interactive, narrative, and 
text based. That is particularly true for searches about RA medications, which 
ordinarily have no details about improvement outcomes and limited data about 
incidence of side effects. Some of the richest user experiences and data-driven 
resources come from RA drug manufacturers, which as paid advertising results 
may appear “disguised” to an ordinary person. Rarely, resources are data-
driven and may even include patient-reported data—such as with the Web site 
PatientsLikeMe. Data from clinical trials and systematic reviews of the best 
available research on RA medications is much harder to come by in “consumer-
facing” health resources. (Chapter 2 has more detail on online search for RA 
medication information, and commonly used Web sites.)
Meanwhile, non-health search and Web applications are often data-driven. 
Products like Google Maps for navigation and Kayak or Hipmunk for travel 
planning feature visualization-heavy UIs that facilitate interaction with rich 
multivariate datasets, from which people make meaning. With these services, 
one can easily find a public transit route to the airport, and the cheapest flight 
with the shortest connection. Admittedly, the data powering such resources are 
much less complicated to interpret than outcome data about RA medications. 
Nevertheless, they are indicators that well-designed UI can help ordinary 
people interact with large volumes of data.
While online health resources appear to “lag” behind non-medical 
counterparts, the practice of medicine itself is changing rapidly. In addition 
to some of the aforementioned changes around sharing clinical trial data 
which might directly affect availability of evidence useful for the creation of 
data-driven online health resources, the increasing engagement of patients 
themselves in decision making may provide an impetus for more such 
resources. Alongside the movement for practitioners to adopt evidence-based 
medicine (EBM)—in which the best available evidence from clinical trials or 
clinically applicable epidemiological studies provide the rationale for medical 
decisions (Eddy, 2005; Guyatt et al., 1992)—so-called patient-centered practices 
that shift focus from treatment of disease to care of a person, are equally 
being promoted and taken up. For example, shared decision making (SDM), 
in which patients are invited to participate in medical decisions in concert 
with their clinicians (Charles et al., 1997; Stiggelbout et al., 2012), which is a 
suite of concepts around communication, education, and decision making 
that is intended to respect the individual needs, preferences, and values of 
the patient. Increasingly, there is a recognition of the need for practitioners 
and their patients to find common ground on care plans—especially those that 
are truly manageable to patients. Patient-reported outcomes—those which 
patients measure themselves directly, on outcomes that are perceptible to 
them—are becoming more important in RA and other conditions ( J. R. Kirwan, 
Newman, Tugwell, & Wells, 2009). Clinical practice guidelines for RA, which 
outline standards of care and make recommendations around diagnostics and 
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treatment, promote both evidence-based practice and shared decision making 
(Singh et al., 2016; Smolen et al., 2013).
There is a good deal of research on patient-oriented decision aids (DAs), which 
are artifacts or tools designed to help people understand and make informed 
medical decisions in line with their needs and values (Stacey et al., 2012), and 
which may be used in consultation with clinicians. DAs based on the very 
same evidence practitioners use might help with patient-centered decision 
making, as might online resources—like those envisioned by this thesis project—
developed with the same evidence (and more), but designed explicitly for use 
at home, to complement or ultimately replace outmoded, static resources.
The RA Choice decision aid
The RA Choice decision aid (Barton et al., 2014) forms the basis of the prototype 
that is the primary output of this thesis project. Indeed, the first version of 
a user-facing application built with the prototype was a digital version of RA 
Choice (thesis.merges.net/ptda). This decision aid (DA) was designed for use 
when a patient with established RA for whom at least one trial of methotrexate 
had been ineffective. It is similar to Mayo Clinic decision aids (see Chapter 2) in 
that it presents medications in a similar visual position across 5 “issue” cards 
(see Figure 1-1). The title of the article describing the DA—The design of a low 
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Figure 1-1
RA Choice decision 
aid. These are 3 of 
the 5 issue cards. 
The remaining 
cards are about 
side effects and 
frequency of 
administration.
literacy decision aid about rheumatoid arthritis medications developed in three 
languages for use during the clinical encounter—explicitly addresses the rationale 
underlying the design. Barton et al. point out that “disparities in RA outcomes 
and reports of poor shared decision-making communication among vulnerable 
populations” bespeak a need for tools to hopefully address such disparities. 
Like the Mayo Clinic DAs, there is an emphasis on graphics and plain language.
The DA was developed using a rigorous user-centered process with constant 
input from designers, clinicians, and patients of multiple literacy levels in the 
service of a DA that is not necessarily self-contained, but instead expressly for 
the purpose of facilitating a conversation in the clinic (Barton et al., 2014). The 
resulting set of 5 issue cards and their content, including the dimensions of the 
“considerations” card in Figure 1-1, is the product of extensive literature review 
and synthesis, and design iteration with patients.
Since this DA is the basis of the prototype—it supplies the set of 12 medications, 
and some of the key dimensions along which they can be “filtered”—it is 
unfortunate that some of its low-literacy design qualities have been abandoned 
in the present state of the prototype. However, an “enhanced” version 
of the RA Choice DA, preserving the initial design intent and low-literacy 
features but elaborating on it with the capacity to explore evidence for each 
medication, could relatively easily be built using the prototype as a platform. 
Nevertheless, the question that prompted the development of the prototype 
is: What evidence might complement this DA? And what stands in the way of 
incorporating that evidence about these 12 medications? Barton et al. write that 
they experimented with the design of a card with visualizations of efficacy but 
ultimately rejected it due to lack of head-to-head trials for all medications, and 
that such a card could mislead patients. Those challenges are front and center 
in this thesis project.
Factors that shape or limit access 
to medical evidence
“The paper is not the discovery. The data are the discovery.”
Dr. Ruben Abagyan, Professor of Pharmacology, University of California San 
Diego at a presentation to the Council of Science Editors annual meeting in 
2010.
There are few sources of specific medical data (e.g. an estimate of how effective 
aspirin is for pain relief after a particular injury) accessible to the general 
public. Desirable real-world data (not from clinical trials sponsored by drug 
companies) about real-world side effects—such as their magnitude, frequency, 
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onset, and duration—is difficult or impossible to find. Equally difficult to 
find are data about patient satisfaction with intervention options. Numerous 
barriers separate an interested patient and medical evidence of almost any 
sort. Most people do not have the means to read medical literature, which is 
mostly published in costly, access-controlled scholarly journals (though there 
are a few prominent open access peer-reviewed journals). The literature is 
written in domain-specific jargon suitable to its audience—for the most part, 
other researchers. Research findings may be only indirectly applicable to real-
world decision making, one reason being that it can be difficult to measure and 
communicate information of value to patients for medical decisions. In many 
cases, even published research that is directly applicable, comprehensible to 
someone with adequate health literacy, and freely accessible is only partially 
complete. Instead of publishing data or conclusions in a systematic way, 
researchers may publish only a few of the most salient or novel findings, leaving 
the full suite of data in a desk drawer. Some of these issues are germane to this 
project and explored in the prototype and discussion on subsequent pages. 
Although this is the context from which the prototype springs, a full discussion 
of the social and technical complexities preventing wider access to medical 
evidence is far beyond the scope of this project.
In many cases, a summary of the best available evidence is readily found 
online or in patient educational literature. For instance, none of the most 
commonly prescribed antidepressants (SSRIs, SNRIs, bupropion and a few 
others) has been found superior for the treatment of depression. This very 
general summary is repeated in many consumer resources. WebMD says “no 
antidepressant works better than another” (WebMD, n.d.) and the Mayo Clinic 
Depression Medication Choice decision aid says “the antidepressants presented 
in this decision aid all work the same for treating depression” (LeBlanc A, 
Herrin J, Williams MD, & et al, 2015). However, that is not the whole picture, 
parly because it focuses on just one broad outcome. If one wishes to learn in 
some detail how effective these medicines are, for whom they may be most 
effective, or estimates of potential harmful effects, there are fewer accessible 
resources. Slightly richer plain language summaries of evidence, such as 
those found in the first few pages of systematic reviews published by the 
Cochrane Collaboration, are published by companies who sell access to them 
by subscription or expensive one-time payments (often $30 per publication). 
Clinical trials, real-world patient experiences, epidemiological studies of data 
from patient registries, and other types of research are all valuable sources 
that enrich medical knowledge. Rarely are machine-readable systematic data 
published, though; in the majority of literature, findings are communicated 
in written language and in tables. For researchers, educators, designers, 
and others to be free to turn the findings that might shed light on details into 
resources that do—whether written, visualized, interactive, paper-based, digital, 
jargon-filled, jargon-free, low-literacy, animated, static, dynamic, or otherwise—
the data underlying these publications must be shared and machine readable. 
With the data, one can choose to write a paragraph summary, perform a 
statistical analysis, or build an app.
Data sharing
As a matter of discussion and policy, the imperative of sharing clinical trial 
data has ascended in recent years. In early 2016, the editors-in-chief of many of 
the world’s most prominent medical journals published an editorial outlining 
19
requirements for data sharing and proposing that authors be required to 
“share with others the deidentified patient data (IPD) underlying the results 
presented in” submitted articles, “including tables, figures, and appendices 
or supplementary material” (Taichman et al., 2016). This follows similar calls 
from institutions like the National Institutes of Health (Hudson KL & Collins 
FS, 2015), the WHO (World Health Organization, 2015), and the British Medical 
Journal (BMJ) (Loder & Groves, 2015). These proposals—and in some cases, new 
rules—are an enormous accomplishment, especially given the inertia of medical 
research as an institution. They typically describe such sharing as an ethical 
imperative, with a scientific rationale: Original data are necessary so that other 
researchers can perform analyses on the widest available set of data about 
interventions—not just “positive” results—in order that dissemination bias can 
be attenuated, and the truest state of the science can emerge (Moorthy, Karam, 
Vannice, & Kieny, 2015). Clinical trial data are among the most important data 
for understanding the true effects of medical interventions, but they are not 
unique. Data underlying systematic reviews, post-hoc epidemiological studies, 
post-marketing adverse effects surveillance—truly, any kind of research—are 
potentially useful for painting the most complete picture possible. Data 
sharing, however, is beset by so many social and technical issues it remains an 
aspiration. A 2015 publication on the subject by the Institute of Medicine (IOM) 
of the National Academies of Science (Institute of Medicine, 2015) begins with 
this unequivocal statement: “Patients and their physicians depend on clinical 
trials for reliable evidence on what therapies are effective and safe.” However, 
even the simplest requirements for sharing—such as submission of a lay-
language summary of results, required by U.S. law since 2007—are often unmet 
challenges. Quoting Saito and Gill (2014), the IOM authors write that “a 2012 
study found that the results of 30 percent of 400 clinical trials had neither been 
published nor reported on ClinicalTrials.gov 4 years after study completion.” 
Just a few of the publication’s 300-odd pages are devoted to the exceedingly 
complex technical challenges of data sharing; it is almost entirely about the 
social, political, and regulatory practices that may be necessary to implement 
such a vision. While we wait for the social machinery to enact its de-biasing 
science, it is worth investigating other strategies to extract existing machine-
readable findings that can be developed into useful patient-centered resources.
The data: Machine-readability
If data are not machine readable—stored and encoded in a format useful to 
computer programs—they effectively cannot be used to develop interactive, 
tailored, digital resources for the general public, not to mention decision 
support tools that might equally benefit clinicians. Consider the data sharing 
declarations of 2016 in light of this description from one of the first scholarly 
articles about evidence-based medicine from 1992, in which a junior medical 
resident is treating a 43-year old man who experienced a grand mal seizure, 
under the heading “The Way of the Future:”
The resident asks herself whether she knows the prognosis of a first 
seizure and realizes she does not. She proceeds to the library and, using 
the Grateful Med program, conducts a computerized literature search. 
She enters the Medical Subject Headings terms epilepsy, prognosis, and 
recurrence, and the program retrieves 25 relevant articles. Surveying 
the titles, one appears directly relevant. She reviews the paper, finds 
that it meets criteria she has previously learned for a valid investigation 
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of prognosis, and determines that the results are applicable to her 
patient. The search costs the resident $2.68, and the entire process 
(including the trip to the library and the time to make a photocopy of 
the article) took half an hour.
The results of the relevant study show that the patient risk of 
recurrence at 1 year is between 43% and 51%, and at 3 years the risk 
is between 51% and 60%. After a seizure-free period of 18 months his 
risk of recurrence would likely be less than 20%. She conveys this 
information to the patient, along with a recommendation that he take 
his medication, see his family doctor regularly, and have a review of 
his need for medication if he remains seizure-free for 18 months. The 
patient leaves with a clear idea of his likely prognosis.
(Guyatt et al., 1992)
Guyatt et al. say that this kind of practice, “which involves using the medical 
literature more effectively in guiding medical practice, is profound enough that 
it can appropriately be called a paradigm shift” per Thomas Kuhn’s notion of 
a scientific revolution. Sadly, however, their description of the future—reading 
high-quality, clinically relevant articles—barely describes the state of the art a 
quarter-century later. Their humble technical vision, written just as the first 
laptop computers appeared, before widespread Web access and Internet-
enabled mobile devices, has not entirely come to fruition, while in other 
domains it has been surpassed by mind-boggling advances in data-driven 
applications. Summaries of medical evidence do exist, and they are being used 
to inform clinical practice. Partly because of the social and technical issues 
that have heretofore limited data sharing—to say nothing of the generation 
of relevant findings—there are few sources of clinically and patient-relevant 
machine-readable medical evidence that can be, or are, used for data-driven 
resources. Enormous effort has been expended to build computer systems—
through artificial intelligence, machine learning, and natural language 
processing research of all sorts—that might sift through vast quantities of data, 
such as unstructured findings hidden in the text of the scholarly medical 
literature, and extract useful meaning. Despite the popular press praising 
IBM’s Watson project, no breakthrough has yet emerged that can substitute for 
well-encoded machine-readable data. Researchers have produced intriguing 
findings when Watson machine learning technology was applied to tens of 
thousands of abstracts of basic research articles about a kind of human protein 
called kinases, in order to predict which kinases modify another protein, p53 
(Spangler et al., 2014). It is unclear whether these methods would produce 
valuable results on a much smaller dataset, to help guide a decision about 
which RA medication is appropriate. State of the art evidence-based medicine 
resources from the Cochrane Collaboration that can inform clinical decisions 
as Guyatt et al. envisioned in 1992 do exist on paper, and in digital paper 
(PDF) format—but even that group has not produced a machine-readable data 
solution, only presentations and blog posts that gesture at the outlines of such a 
solution (See “Cochrane Linked Data,” Cochrane Collaboration, n.d.-a).
In order to get around the absence of established standards and practices for 
machine-readable findings from medical evidence, the prototype demonstrates 
ways in which findings can be encoded by a modestly knowledgeable reader 
of clinical trials, systematic reviews, and other sources. Discussed later, the 
approach is limited, but it is straightforward and reproducible, and in that 
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it can be used to develop a wide variety of data-driven resources for both 
clinicians and patients, it is worthy of investigation and as a demonstration.
Translation and design
If the findings from medical research were machine-readable and shared, would 
they be applicable and understandable to people making medical decisions? It 
depends. In many cases, research is not relevant to an individual’s life—about 
outcomes that may not be of decision-making value or are one step removed. In 
other cases, the information is likely valuable but may still require translation to 
make it understandable. Where research has been standardized—for example, 
on a set of relatively consistent clinical trial outcomes such as the OMERACT 
outcomes for RA medication research (Boers, Kirwan, & Tugwell, 2014)—it is 
certainly easier to harmonize multiple sources or present them side-by-side, 
as a first step. Even still, a great deal of translation is necessary from data to 
visualization and text, from jargon to plain language, from dataset to Web 
application, and so forth. With machine-readable evidence, the disciplines 
concerned with this translation, from health education to programming to 
data visualization to UX design, can focus their efforts on helping people make 
meaning from it, rather than manipulating or extracting findings from it. In this 
way, the full promise of evidence-based medicine is predicated on machine 
readable data with which specialists can work to translate and design for 
practical use.
Non-scholarly sources
Although scholarly research—in the form of data from clinical trials, meta-
analyses, epidemiological studies, qualitative studies, and so forth—are critically 
important, they are not the only kinds of evidence that may matter to people 
seeking medication information. Real-world medication experience data, 
patient testimonials, doctors’ opinions, prescription drug formularies, real-
world cost surveys, and other kinds of evidence may be desired by patients. 
Similar social and technical barriers stand between these kinds of data and 
their use in online health resources. They must be properly shared or available, 
encoded, and translated (or put in context).
Since this thesis project could not hope to tackle the social, political, and 
economic complexities that shape access to medical evidence, it instead centers 
on encoding data and demonstrating translation and design on top of those 
data. In the spirit of sharing machine-readable data, the source code and all 
data presented in this thesis and in the prototype are online and available for 
others to use, echoing one of the project’s primary objectives.
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Project objectives
Against the backdrop presented thus far emerged this thesis project, which 
explores practical problems in how best to make medical evidence available 
and understandable to the general public. It demonstrates in a limited way 
how certain contemporary technologies and UX design can be used to 
encode, communicate, and facilitate interactive exploration of research about 
medications that treat RA. The project is about those medications specifically, 
but conceptually the work transfers to other medical domains, including 
treatment for other chronic conditions.
The practical problems center on these three themes:
 A lightweight technological architecture that can accommodate relevant 
medical evidence, including arbitrary new data.
 A basic automated translation and harmonization system that helps the 
general public make meaning out of medical evidence, such as by re-
describing idiosyncratic outcome measures in plain language.
 Appropriate design (user interfaces and visualizations) to make the data 
understandable.
As mentioned in the introduction, merely discussing the shape of systems that 
could hypothetically address access to medical evidence is insufficient. Just 
as the (probably apocryphal) Martin Mull quote goes, “writing about music is 
like dancing about architecture,” so writing about design is like dancing about 
architecture. Only a built artifact—even if it fails in many ways—can stress the 
ideas in practice. The prototype—the design project—is the discovery, if you 
will—a concept not dissimilar to the divide between journal articles and the 
underlying data.
This project’s overriding objective was to create an open-source interactive, 
expandable, malleable, data-driven tool for the general public to explore 
medical evidence about rheumatoid arthritis medication options. Its further 
objectives were to:
1. Demonstrate an end-to-end technical architecture, based primarily on 
open-source technology, for the creation and deployment of data-driven 
medication information applications or Web sites.
2. Demonstrate some strategies for automating the difficult work of 
translating from opaque evidence (e.g. jargon-filled, or using oblique or 
surrogate outcomes) to understandable forms (of language and visual 
design).
3. Demonstrate and discuss tradeoffs in user interface design choices and 
rationale, as they relate to making medical evidence accessible.
It should be noted that this project was developed by one person (with 
feedback from academic supervisors), absent participation from patients, 
practitioners, or programmers. Due to time and research constraints, 
evaluation of these objectives’ success in practice must be relegated to future 
work. However, each of these audiences can now be engaged to build on the 
prototype.
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Audiences
The prototype has three audiences. It is intended to demonstrate different 
notions of value to each respective audience, and may be seen as the basis for 
future work in each of these thematic areas.
Patients and caregivers
For people with RA or their caregivers, the prototype demonstrates how 
a publicly available Web app could provide data to help them learn more 
about medication options. While it cannot answer difficult questions—such as 
those presented in the earlier scenarios—it does illuminate details on various 
treatment options. The prototype might show this group that there are ways 
to learn from data about medications, other than reading academic articles or 
static pamphlets or Web pages.
Doctors, nurses, pharmacists, researchers, or other contributors from 
the medical community
These potential users might recommend this kind of application for patient 
education or use in SDM. More importantly, they could contribute to it by 
encoding findings from research simply by reading articles and adding rows 
to a spreadsheet. It is intended to show this group that medical evidence can 
be designed effectively for the general public, and that free, lightweight, and 
easy to use technologies like spreadsheets are sufficient for encoding and 
communicating medical evidence—as opposed to expensive, bespoke, and 
difficult to maintain custom-programmed computer systems. When new data 
are added to this prototype, they show up immediately. Further, it is a platform 
on which infinite applications or visualizations can be built. One person built 
this prototype; it can be much more with the contribution of specialists in the 
medical community.
Designers, programmers, and educators
For these users, the whole “stack” of technology—from data encoded in 
spreadsheets, to the translation layer and controlled vocabulary in the middle, 
to the ultimate user interface—may be of interest. It can be used as a model for 
encoding other kinds of medical evidence, or for other conditions, or the UI 
components in the prototype can be re-used in other, related projects. Because 
it is open source, this audience can see how the whole system works, can 
replicate it, and pick and choose parts that are valuable for their own work.
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Chapter 2
Context, rationale, and 
related work
Online health information search
Before and after clinical encounters, the information found Googling becomes 
a part of the milieu of knowledge involved in medical decisions—especially 
relevant when patients are making complex medical decisions. Online search 
is convenient, can reinforce concepts or knowledge imparted during clinical 
encounters, and supply details that were missing. In 2012, 59% of the U.S. adult 
population searched online for health information and 43% of adult Internet 
users specifically sought information about a certain medical treatment or 
procedure (Fox and Duggan, “Health Online 2013”, 2013). Just what they 
search for varies by health condition. Since nearly 50% of adult Americans 
have been diagnosed with at least one chronic non-mental health condition 
(Ward et al., 2014), it is illuminating to look at how RA-related searches (and 
possibly consequent informational needs) compare to other conditions. 
Looking at Google query trends is not unknown to medicine (Harsha, Schmitt, 
& Stavropoulos, 2014). Search volume data are trade secret, although Google 
provides coarse estimates of monthly average query volume through its freely 
available AdWords Keyword Planner application (Google, n.d.).
One way of examining relative interest in online information about certain 
medical conditions is to obtain estimates of search activity for general search 
queries (or keywords) related to those conditions. Those estimates can be 
contextualized in prevalence data. Conditions with a higher number of 
estimated searches per person (i.e. patient) per year suggest more interest, and 
therefore a greater need amongst that population—although it must be noted 
that online searches for terms like depression and rheumatoid arthritis are not 
necessarily by or for people diagnosed with those conditions. Nevertheless, 
assuming a similar distribution of topical patient and non-patient queries for 
these very general terms, it is instructive to look at these searches-per-patient as 
a rough indicator of interest, understanding that their reliability is limited.
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Table 2
Estimated chronic 
condition search 
volume. These are 
estimates for broad 
search terms only, 
and therefore a 
very rough guide to 
search interest.
Condition Search term(s)
Yearly estimated 
U.S. Google search 
volume
Based on February 
2016 average
U.S. adult 
prevalence
Estimated 
U.S. Google 
searches per 
patient per 
year
asthma 4,417,200 6.69%1 0.27
asthma 1,620,000
major depression 4,334,400 3.40%2 0.52
depression 3,612,000
major depression 397,200
major depressive 
disorder
325,200
COPD 4,417,200 6.07%3 0.29
copd 2,952,000
chronic 
obstructive 
pulmonary 
disease
145,200
emphysema 1,320,000
diabetes 7,644,000 8.86%4 0.35
diabetes 3,612,000
type 1 diabetes 1,620,000
type 2 diabetes 2,412,000
heart failure 2,899,200 2.06%5 0.57
chf 594,000
heart failure 325,200
congestive heart 
failure
1,980,000
high blood pressure 6,012,000 29.10%6 0.08
hypertension 1,620,000
high blood 
pressure
1,980,000
blood pressure 2,412,000
osteoarthritis 3,732,000 12.33%7 0.14
arthritis 2,412,000
osteoarthritis 1,320,000
rheumatoid arthritis 4,572,000 0.61%8 3.05
ra 1,620,000
rheumatoid 
arthritis
2,952,000
HIV/AIDS 3,300,000 0.49%9 2.75
hiv 1,980,000
aids 1,320,000
1. Current Asthma Population Estimates 
(Centers for Disease Control and Prevention, 
2014).
2. Current Depression Among Adults—United 
States, 2006 and 2008 (Centers for Disease 
Control and Prevention, 2010).
3. Chronic obstructive pulmonary disease 
among adults—United States, 2011 (Centers 
for Disease Control and Prevention, 2012).
4. Number of Adults - Diagnosed Diabetes - 
Diabetes DDT (Centers for Disease Control 
and Prevention, n.d.)
5. Heart Disease and Stroke Statistics (Go 
et al., 2013)
6. Hypertension among adults in the United 
States (Nwankwo, Yoon, Burt, & Gu, 2013)
7. Based on Estimates of the prevalence of 
arthritis and other rheumatic conditions 
in the United States—Part II (Lawrence et 
al., 2008)
8. Estimates of the prevalence of arthritis 
and other rheumatic conditions in the 
United States—Part I (Helmick et al., 2008)
9. Prevalence of Diagnosed and 
Undiagnosed HIV Infection—United States, 
2008–2012 (Centers for Disease Control and 
Prevention, 2015)
Table 2 shows general search query terms, average yearly search volume, 
estimated U.S. adult prevalence data from sources cited by the Centers for 
Disease Control and Prevention, and relative interest (searches per patient) 
for several chronic conditions. There are is more than an order of magnitude 
difference between relative interest in very widespread conditions (like 
hypertension and osteoarthritis) and RA. From these data there is no way to 
infer why there is a difference between conditions, but it may be that some 
may produce unfamiliar symptoms, are 
treated with unfamiliar medications, 
or have an unfamiliar course. All may 
motivate someone to search online in an 
effort to understand these symptoms, 
treatments, and outcomes. Common 
and burdensome conditions (in terms of 
symptoms and treatments) like diabetes, 
chronic obstructive pulmonary disease, 
and congestive heart failure have higher 
relative search interest. HIV/AIDS, similar 
to RA in terms of prevalence, has a similar 
relative search interest—again noting 
that people may search for these general 
search terms even if they do not suffer 
from HIV/AIDS, which may overestimate 
search interest among people living with 
the condition. Repeated searching could 
be another explanation. In all these cases, 
searches for specific treatments were 
omitted; search interest for a selection of 
medications that treat RA can be seen in 
Table 3.
Looking more closely at RA medications, 
the Google AdWords Keyword Planner 
suggests that there are approximately 6.5 
million queries per year in the United 
States for the some of the most commonly 
used DMARDs, including methotrexate, 
the most well-known biologics, and 
tofacitinib. These estimates are based on a 
limited set of queries for each medication—
the generic name and one brand name. An 
additional estimated 280,000 queries per 
year are categorical in nature, representing 
searches for the general type of medication 
in question—DMARDs and biologics. 
Estimated volume for more specific terms 
like disease-modifying antirheumatic drug 
and TNF inhibitor was very low (around or 
under several thousand queries per year) 
and excluded from this table. It must be 
noted that many of these medications are 
used to treat multiple conditions, including 
cancer, malaria, psoriasis, Crohn’s disease, 
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Medication/group
Estimated yearly 
U.S. Google search 
volume
Based on February 
2016 average
Estimated 
yearly U.S. 
Google searches
Methotrexate 1,320,000 1,332,000
Rheumatrex 12,000
Humira 888,000 985,200
Adalimumab 97,200
Hydroxychloroquine 397,200 991,200
Plaquenil 594000
Rituximab 217,200 483,600
Rituxan 266,400
Infliximab 145,200 631200
Remicade 486,000
Etanercept 79,200 476,400
Enbrel 397,200
Sulfasalazine 325,200 378,000
Azulfidine 52,800
Leflunomide 177,600 274,800
Arava 97,200
Tofacitinib 52,800 270,000
Xeljanz 217,200
Abatacept 43,200 188,400
Orencia 145,200
Tocilizumab 43,200 140,400
Actemra 97,200
Certolizumab 15,600 134,400
Cimzia 118,800
Golimumab 22,800 102,000
Simponi 79,200
Anakinra 34,800 63,600
Kineret 28,800
biologics 97,200 192,000
biologic 79,200
biologic drugs 15,600
DMARDs 34,800 87,600
DMARD 52,800
Total for all drugs 6,730,800
Table 3
Estimated RA-
related medication 
search volume.
among others. Not all search interest in these medications is related to RA. 
Nevertheless, since the medications are frequently used in RA treatment, these 
estimates provide a reasonable signal of online interest—whether on the part of 
patients, caregivers, or even practitioners.
While search volume estimates provide a signal of interest, they do not speak 
to the kinds of resources people find. First, it is instructive to examine the 
distribution of clicks on individual search results—called click-through rate or 
CTR. Unsurprisingly, people do not click equally often on all search results. 
A Google search for methotrexate on February 8, 2015 produced “about 
7,850,000 results” (“methotrexate - Google Search” n.d.), which at 10 results 
per page is hundreds of thousands of search results pages. Authoritative CTR 
data is not available from search engine companies like Google, as it is trade 
secret information, and click-through rates differ depending on the particular 
query and results—for example, one would expect an exceptionally high CTR on 
the Facebook home page result for the query facebook. However, the company 
does provide limited data to Web site owners on queries, click-through rate, 
and average position in search results. One informal, non-scholarly analysis of 
thousands of such Web sites’ data by Petrescu produced the broad estimates 
in Figure 2-1 of click-through rates for organic (unpaid, non-ad) result positions 
(Petrescu, 2014). It suggests that about 50% of users click on one of the first 
three results, and 70% on one of the first ten. Some 23% of queries result in no 
organic, unpaid clicks. In those cases, users are assumed to have abandoned 
the search, refined it, clicked on a paid ad, or perhaps found the answer in a 
search result “snippet” or summary directly on the search results page. In any 
case, although the estimates are rough, they indicate just how important the 
first few search results are.
There is no guarantee that search results will be the same from search to 
search, or from person to person. Which particular results appear on a given 
search result page in response to a query varies with location, personal search 
history, algorithm changes, and other factors. However, searches in a non-
personalized (i.e. fresh or so far anonymous) browser window can produce 
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Figure 2-1
Estimated click-
through rate (CTR) 
on Google search 
results. Screenshot 
from from 
Petrescu, P. (2014).
a reasonable approximation of typical search results. The first few results for 
queries like dmards, methotrexate, and enbrel are representative of the kinds of 
online health resources most searchers will interact with. WebMD, Wikipedia, 
Drugs.com, and pharmaceutical manufacturer resources rank highly.
Online “consumer” health 
resources
A few resources dominate the first page of search results when people query 
for medications that treat RA. These are the resources that most people will 
encounter, because of the tendency for searchers to click through to top 
results first. Most—like WebMD and its affiliate Web sites, Drugs.com, and 
Mayo Clinic—feature static prose, paragraph upon paragraph of text. In many 
cases these resources include restatement of pharmaceutical manufacturer-
provided monographs, or text licensed from a medical content provider like 
Micromedex or First Databank. Because they rarely include data-driven UIs for 
exploring and querying medical evidence, they lag behind online resources 
in other domains. They are a fixed perspective on their underlying evidence. 
Some resources are different, either in the quality and type of information they 
provide, or in that they are data-driven resources—but these are rare. Following 
is a brief survey of the most commonly found resources, and a few that are less 
common but related conceptually to the prototype. Each is summarized and 
cursorily critiqued to emphasize the outsized role they play, and to illustrate 
how deliberate design decisions shape medication information presentation 
and the ways in which people can and cannot interact with such information.
WebMD
webmd.com
WebMD is a well-known online health information resource. It features 
uncountable articles, slideshows, and tools about medical conditions, tests, 
interventions, general health and well-being, among other topics. A Google 
search on February 11, 2016 for the term site:webmd.com (which seeks all pages 
indexed by Google on WebMD’s Web site) returned “about 16,200,000 results.” 
Compete, an online tool that estimates visitors numbers to Web sites, estimated 
that more than 26 million unique American desktop computer users visited 
WebMD in December 2015 (“webmd.com”on Compete, n.d.). It is undoubtedly 
an expansive and widely used resource.
Figure 2-2 shows WebMD’s page about oral methotrexate. The screenshot 
was taken in a browser with no browsing history or cookies. Of the usable 
visual space (highlighted in yellow), about 25% is devoted to advertising—for 
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Figure 2-2
WebMD’s general 
methotrexate 
information page. 
Methotrexate-
related content 
is highlighted in 
green. Advertising 
content is 
highlighted in red.
products as diverse as a medical practice, a luxury health resort, an injection 
medicine for knee pain from osteoarthritis, physician listings, a sublingual 
synthetic opioid pain reliever, and sponsored links to WebMD pages authored 
by companies like Monsanto, Pfizer, and Bristol-Meyers Squibb. Just over 
15% is devoted to methotrexate-related content; so little that repeated clicks 
are necessary to fully consume the available information, each resulting in a 
new page load, and new advertising. The remainder of the space is empty or 
features elements that navigate the visitor to other areas of WebMD. There is 
valuable information about methotrexate on this page (in prose), but the design 
choices may belie the page’s true purpose. On an RA-specific methotrexate 
page (“How Does Methotrexate Treat Rheumatoid Arthritis?” WebMD, 2014) 
more obviously pertinent information is presented on a similarly divided page. 
Methotrexate is described as “one of the most effective medications to treat 
rheumatoid arthritis,” but no data are supplied to contextualize it. Similarly, 
benefits are described in a deterministic fashion—for instance, “it will help ease 
symptoms like joint pain, fatigue, redness, and swelling.” A few common side 
effects are listed, without any details about magnitude, frequency, or duration. 
Sources used to write the article are listed, but this is a typical, static, non-
data driven resource. While further inquiry into advertising and other WebMD 
content is invited by hyperlink, there are no options to tailor the information or 
compare methotrexate to other treatments.
General resources like WebMD, with lengthy prose, stand in stark contrast 
to many decision aids—artifacts explicitly designed to facilitate medical 
choices, which will be discussed subsequently. Decision aids often feature 
brief and straightforward language, pictures that communicate information or 
quantitative data, and visual organization that emphasizes discrete intervention 
options or information dimensions. WebMD and similar resources occasionally 
use bulleted lists, tables, or illustrations, but most critical data is peppered 
among long sentences, in multi-paragraph and multi-page articles.
Although WebMD has been singled out for this analysis—because it is frequently 
the top search result—it is representative of the status quo in online health 
resources. Hereafter, descriptions of similar resources will be shorter and less 
in depth.
Drugs.com
drugs.com
This popular medication information Web site is not dissimilar from WebMD. 
Figure 2-3 shows its page for etanercept, a biologic DMARD. It is entirely 
textual, and features mostly general information that would ordinarily be 
covered in a clinical visit—contraindications, for instance. Side effects are 
presented with no sense of frequency or magnitude, although serious reactions 
are called out. There are no data about efficacy, and besides administration 
information very little about impact on daily routine. The content is licensed 
from a third-party provider of general medication information, Cerner Multum.
Since contraindications and risks are promoted on this page, it is worth noting 
that if someone has a specific concern (planning to become pregnant, or 
infected by hepatitis B, for example) the only way to learn whether etanercept 
is safe is to read through the content. There is no button that one can click to 
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indicate a concern, and get at least a preliminary but straightforward answer. 
Instead, a good deal of literacy is required and an investment of time to process 
each sentence of dense medical information—including much that is probably 
spurious or unnecessary. This may be considered the “kitchen sink” of text 
approach to medication information: Assemble it all into paragraphs, and let 
the patient sort it out.
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Figure 2-3
Drugs.com’s 
general etanercept 
information page.
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Figure 2-5
RxList’s general 
etanercept 
information page.
Figure 2-4
Mayo Clinic’s 
general etanercept 
page.
Mayo Clinic
mayoclinic.com
Mayo Clinic pages on medications, such as their etanercept page in Figure 
2-4, are similar to those of WebMD and Drugs.com. This Web site also 
licenses content from a drug information provider, Micromedex. Similar to 
Drugs.com, the bulk of information is about precautions and contraindications. 
Limited side effect information is available, again with no sense of frequency, 
magnitude, or duration. On Mayo Clinic’s RA treatment overview page (see 
Figure 2-4), there is a straightforward description of lifestyle, medical, and 
surgical treatments. As far as medication information is concerned, only the 
briefest overview of RA drugs is presented. The content is entirely textual.
RxList
rxlist.com
Another resource frequently found on the first page of general medication 
search results is RxList, which is part of the “WebMD Network” of Web sites. 
That network includes other top search results MedScape and MedicineNet. 
Figure 2-5 shows a typical drug information page on RxList. In addition to 
ads and a large number of links and pointers to unrelated content, the page 
is effectively a modified version of the 
SPL supplied by the manufacturer when 
the drug. It has information entirely non-
relevant to patients (such as the apparent 
molecular weight of the etanercept protein) 
along with extensive textual information. 
In general, the text is long and filled with 
jargon. Practitioner-targeted information 
coexists with patient-targeted information 
in a potentially confusing way; there are 
also menu items for both “consumer” 
and “patient,” which repeat and rephrase 
much of the information found elsewhere, 
with slightly different organization. 
Finding specific information, such as 
whether the drug is safe given a particular 
contraindication or compatible with a 
lifestyle preference, requires reading much 
of this content.
Because this resource essentially 
republishes the SPL, if it contains 
quantitative data about efficacy or adverse 
reactions RxList features these data. 
However, they are represented exactly 
as the manufacturer supplied them, not 
redesigned to be more understandable by 
the general public. The adverse reactions 
table in Figure 2-6 is typical of such data. 
It includes terms like pruritus, pyrexia, and 
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Figure 2-6
A side effect table 
from the product 
SPL on RxList.
urticaria, which are almost certainly unfamiliar to an ordinary person seeking 
information about RA medications. It is also likely that the data here are difficult 
for someone with lower health literacy to make sense of. For instance, multiple 
frequencies are reported for the same side effect. Careful reading of footnotes 
is necessary to understand that the studies were of different configuration and 
duration. This is precisely the kind of data that needs translation to be part 
of a data-driven health resource for the general public. It is worth noting that 
even here, the tabular data are not encoded in machine-readable form, so such 
translation is not possible from this representation of the data. Also, data like 
these—supplied by manufacturers—are not systematically produced, and may 
be less reliable to due bias, as discussed in the previous chapter.
MedicineNet
medicinenet.com
Yet another top search result resource is MedicineNet, also part of the WebMD 
family of Web sites. Its etanercept page (see Figure 2-7) is representative, and 
promises to “Bring Doctors’ Knowledge to You.” A superficial gloss of its design 
reveals choices remarkably similar to WebMD. Content about etanercept 
itself is textual. Only a fraction of the available screen space is even devoted 
to that content. Much more prominent and eye-catching are ads, “suggested 
reading” on other topics, and pictures captioned with phrases like “Don’t 
Wreck Your Teeth.”
PatientsLikeMe
patientslikeme.com
Unlike the most common online health information resources, PatientsLikeMe 
is not premised on “traditional” medical evidence (scholarly literature) but 
instead on real-world experience. Their medication page centers on data 
reported by its users—patients and their caregivers—for dimensions as varied 
as perceived effectiveness, side effects, burdensomeness, cost, and treatment 
regimens, among others (PatientsLikeMe, n.d.). The data are collected and 
encoded in a machine-readable way, enabling data-driven UI and visualizations. 
Thus PatientsLikeMe is an unusual resource because it is both data-driven, and 
based on a non-scholarly source of medical evidence.
General drug information (see Figure 2-8) is textual and licensed from a content 
provider, Cerner Multum. It is nearly identical to the content on Drugs.com 
and other online resources. The lack of UI parity—data-driven UI for self-
reported information, and plain paragraphs of text for “official” information—is 
unfortunate, because it makes comparing across datasets difficult. For example, 
PatientsLikeMe has graphical presentation of patient-reported perceived 
medication efficacy, but no similar interface for data from medical literature. 
Indeed, efficacy would be reported using different measures, and therefore 
difficult to harmonize. But the point is that it is not even possible without 
accessible machine-readable research data to complement PatientsLikeMe’s.
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PatientsLikeMe has a page for RA (see Figure 2-9). As of mid-February 2016, 
it had 9406 users who reported having RA (89% female), including 5675 
who claimed to be “diagnosed,” although it is not clear how many had 
provided reports on symptoms and medications. However, it is a guide to 
symptomatology and relative perceptions of treatment effectiveness for 
those specific symptoms. The most common symptoms, ordered by “how 
bad” they are perceived to be, are stiffness in morning, joint pain, fatigue, 
pain, insomnia, depressed mood, and anxious mood. Patients report taking 
specific treatments to deal with those symptoms; unsurprisingly, none of 
them are csDMARDs or bDMARDs. However, people do report taking a diverse 
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Figure 2-7
MedicineNet’s 
etanercept page.
range of medications—for pain, opioids like tramadol and hydrocodone/
acetaminophen, and gabapentin, which is used to treat neuropathic pain; for 
anxiety, benzodiazepines, and even amphetamines (i.e. Adderall) for fatigue. 
This emphasizes the polypharmacy that many patients experience with when 
living with RA.
Under the heading “Compare treatments taken by people with Rheumatoid 
Arthritis (RA),” DMARDs are compared, along with glucocorticoids, pain 
relieving medications, and others. Although factors that would ordinarily 
be controlled in a clinical trial are absent (e.g. whether patients were taking 
other medications), it is possible to get a relative sense of the perceived 
efficacy and side effect burden of commonly used medications. For example, 
methotrexate, hydroxychloroquine, and sulfasalazine seem to be perceived 
as similar in effectiveness, with methotrexate and sulfasalazine apparently 
more burdensome in terms of side effects, especially nausea, which may be an 
especially concerning side effect for many patients (L. Fraenkel et al., 2004). 
Etanercept and adalimumab appear to be perceived as more effective, and 
slightly less burdensome in terms of side effects. Prednisone—a powerful anti-
inflammatory agent—is perceived as much more effective, and surprisingly 
with a less severe side effect burden. For each treatment (for example, the 
etanercept page in Figure 2-10) PatientsLikeMe has a similar data-driven UI.
Because PatientsLikeMe does not have a publicly available API, it is not possible 
to digitally incorporate their machine-readable patient-reported data with the 
prototype, which would be an interesting complement to evidence from the 
scholarly literature.
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Figure 2-8
PatientsLikeMe’s 
etanercept drug 
information.
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Figure 2-9
PatientsLikeMe’s 
RA page. Patients’ 
experiences 
with different 
medications can be 
directly compared 
with these 
visualizations.
CureTogether
curetogether.com
CureTogether is a Web site that collects patient experience data on therapies, 
and presents them in slightly interactive (sortable) visualizations (see Figure 
2-11 for their page about treatments for RA). Their home page says that 
CureTogether is “the smarter way to find the best treatments,” and that people 
can “get access to millions of ratings comparing the real-world performance 
of treatments across 637 health conditions.” Like PatientsLikeMe, this service 
focuses on patient-reported data. An enormous variety of treatments are 
presented, from medicines, surgical procedures, and occupational therapy to 
dietary adjustments, deep breathing, and even hypnosis. Since each treatment 
has a certain modality and perspective on how it might improve living with RA 
(e.g. psychological or self-perception, disease modification, symptom relief, 
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Figure 2-10
PatientsLikeMe’s 
etanercept patient 
experience page.
improving general health, etc.) it is uncertain how to compare treatments to 
one another. For example, what does it mean that both “exercise” and “heat” 
have similar effectiveness profiles? On this resource, prednisone is perceived 
to be the most effective treatment—but again, that may be unsurprising 
considering its potency, and is potentially a misleading notion absent of the 
context that it is a potentially harmful medication when used for a long period 
of time at high doses.
CureTogether has no API, so its patient-reported data cannot be harmonized 
with similar data from a site like PatientsLikeMe, nor can it be included in the 
prototype alongside data from peer-reviewed medical literature.
Healthtalk
healthtalk.org
Healthtalk.org (Healthtalk) is a Web site produced by a group at Oxford 
University that conducts qualitative research (see Figure 2-12 for its page 
about DMARDs). It blends brief textual summaries of up to date medical 
knowledge with extensive summaries, videos, and transcripts of interviews 
with people with RA about their experiences with everything from diagnosis 
to family impacts to treatments to attitude and psychosocial effects of living 
with RA. Although the video interviews are anecdotal, they are intended to be 
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Figure 2-11
CureTogether’s 
RA treatment 
comparison page.
representative of the “full range of experiences that might be connected with a 
health condition” (See About healthtalk.org on healthtalk.org, n.d.) presumably 
among the British population from which its sample of patients was drawn.
This resource is unique in that it has an information set based on qualitative 
research that is rigorously collected and reviewed by experts, as opposed to 
a freewheeling discussion or set of posts from patients. A patient experience 
resource with unrestricted membership might suffer from a kind of selection 
bias if only a particular subgroup of the population at large were represented; 
if the factors that made those members unique were not explicitly collected 
and communicated, it would not necessarily be easy to generalize information 
to the general public. For instance, because PatientsLikeMe indicates that 
about 89% of its RA members are female, it is not necessarily fair to say that 
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Figure 2-12
Healthtalk’s 
DMARD page.
its “findings” are typical of the male population, or population at large. While 
Healthtalk has its own bias in terms of the population that was interviewed, its 
creators do apply greater rigor in order to build a representative resource.
As is the case with many decision aids, the information in Healthtalk’s pages 
are in effect fixed to a point in time, when the interviews were conducted and 
the pages created. Because much of its information is general in nature (e.g. 
perceptions of body image while living with RA) that may not be an issue. 
However, when it comes to information about diet, medications, treatment 
regimens, and so forth, it may be advantageous for a resource like this to 
accommodate new, machine-readable evidence.
Healthtalk’s information (such as textual summaries, transcripts, and video 
interviews) are themselves not machine readable data, which limits the ways 
in which they can be easily automatically incorporated with other data. Even 
qualitative information—about attitudes, preferences, and so on—can be 
systematically encoded in machine-readable formats, but it is not obvious just 
how that should be done. For example, without sufficient metadata for the 
video interviews (descriptive, discrete data about the video, such as the topics 
covered, the patient demographic data, treatments the patient was on, etc.) it 
is not easy to “pull” the data into another resource such as the prototype, to 
appear alongside other evidence. Regardless, Healthtalk does not have an API, 
so there is no easy machine-machine interface for bringing its information into 
another resource.
Product Web sites
Alongside the resources described so far, medication Web sites published by 
their manufacturers are commonly found on the first page of Google search 
results. Sometimes they are “organically” ranked highly, alongside resources 
like WebMD, but often they are marked as paid (advertising) links. Drugs that 
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Figure 2-13
A Google search 
results page 
with masked 
manufacturer 
results.
Points to a product 
Web site for 
Humira, the brand 
of adalimumab 
manufactured by 
AbbVie.
Points to a 
product Web site 
for Orencia, the 
brand of abatacept 
manufactured 
by Bristol-Myers 
Squibb.
Points to a product 
Web site for 
Xeljanz, the brand 
of tofacitinib 
manufactured by 
Pfizer.
are recognized by their brand names and protected by patent dominate such 
results. Searches for RA medication are liable to return a search results page 
with paid links to manufacturer sites. The links are often disguised in that they 
do not mention that the name of the medication, or the manufacturer, directly 
on the search result page. For example, in Figure 2-13, the first paid link points 
to the Xeljanz product Web site, an oral DMARD marketed by Pfizer. The link 
title is “Rheumatoid Arthritis Info,” and the URL (Web site address) is “www.
ra-rxmedicine.com” with a snippet (description) that says “Learn About An Rx 
Treatment Option For Rheumatoid Arthritis.” As of February 2016, according 
to the Google AdWords Keyword Planner tool, the “suggested bid” price for a 
single click on a paid search result for the search query RA medication—which 
had an estimated 880 searches per month in the U.S.—was $28.84.
The product Web sites that these links point to may be more interactive, 
thorough, and even data-driven than other Web sites. The Xeljanz Web site (see 
figure 2-14), for example, has an interactive and visual explanation of different 
classes of medications used to treat RA, how they may be used together, 
and that describes when biologic and alternative DMARDs (like Xeljanz) are 
generally considered (i.e. if methotrexate does not work well). It features data 
from (presumably favorable) clinical trial results—data absent from resources 
like WebMD. It would be worth studying whether people understand that these 
Web sites are published by manufacturers, what their perception is of the 
potential bias or influence of those manufacturers is, whether the data they see 
are convincing, and whether they consider these resources trustworthy.
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Figure 2-14
A page from the Xeljanz product Web site.
Data-driven non-medical online 
applications
Outside the health and medical domains online, data-driven resources 
commonly populate the first few search results. Web sites and apps for sports, 
shopping, travel, weather, news and politics, mapping and navigation, and 
day-to-day business often feature rich multivariate data. Often, these resources 
incorporate historical and real-time data; they can therefore represent the 
current state of affairs, rather than a static, fixed perspective of some point 
in the past. Certainly, many of these resources are built with data that are 
not subject to the same review and analytical rigor that medical data are. 
Nevertheless, there are lessons to be learned from their UIs and how they 
help non-experts make meaning from their underlying data. Deliberate design 
decisions again shape information presentation, and the ways in which people 
can and cannot interact with it.
Fundamentally, the best such resources employ data that can directly answer 
user questions. For example, questions of cost can be answered with accurate 
price data and clear, unambiguous presentation. Many non-health consumer 
resources are thus at an advantage compared to potential online health 
counterparts, for which straightforward data are often unavailable. Still, even 
directly applicable data need translation, recombination, and appropriate UIs 
to visualize, restrict, and clarify meaning. An exaggerated example illustrates 
the central problem.
Before the advent of smartphone apps and GPS for transit navigation, how 
would one make sense of the data which underlie such apps?
 Mapping data. The raw data describe the coordinates—longitude and 
latitude—and shape of roads, along with tables recording the speed limit 
on road segments.
 Traffic data. Raw historical traffic data might be recorded as tables 
describing the average speed of vehicular traffic on road segments. Just 
a few short years ago, real-time data might be found only ephemerally in 
live radio traffic reports.
 Transit route data. Such raw data would record the direction that routes 
travel on road segments, along with the location of stops.
 Transit schedule data. Most likely, such data would be recorded as 
scheduled departure times at certain stops, or at certain coordinates.
To make sense of these data, each source must first be translated into an 
initially useful form. If the data were presented in tables on paper—or worse, 
each type individually as a narrative—it would take a great deal of work to make 
meaning from them. Imagine trying to piece together a bus route by reading a 
table describing the road segments it follows, or a description of its route: “…
continues northeastward on Folsom St. for 760 feet, then turns left onto 9th 
St. Continues northwestward on 9th street for 1930 feet, then merges onto…” 
Cartography neatly handles such road and transit route data in the form of 
familiar maps. Historical traffic speed data could be presented on a separate 
map, or in a table. The transit schedule would most likely be found in a table. 
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Real-time estimates, if available, might be available by 
phone, just as real-time traffic reports could be tuned into 
on the radio.
Given a simple problem—which buses should I take to get 
to my destination, how long will it truly take me to get 
there, and when must I leave to catch the first bus?—there 
are a couple of approaches. One is to gather the various 
sources and assemble the information. In this case, that 
is not an exceedingly difficult task but would probably 
require a few minutes, cross-referencing, likely and some 
double-checking. Consultation of the real-time broadcast 
traffic report—for a more accurate estimation of travel 
time—would not be possible on-demand, so depending 
on when the report is broadcast one might have to wait 
awhile for the information. In the end, the gist of the 
answer would emerge. Another approach would be to 
consult an expert—to telephone the transit agency’s 
information service, or ask a knowledgeable friend—who 
could express the navigation plan and estimated arrival 
time narratively. (And one could take down notes of that 
narrative, to refer to in transit.) Individual knowledge of 
the roads, traffic and travel times, routes, and schedules 
would factor into the ultimate analysis, too.
It almost goes without saying with machine-readable data 
and a clever UI, a computer can do much of this work 
on behalf of the traveler—still allowing space for their 
individual knowledge and judgement. Instead of looking at a map on which 
the routes in question are not highlighted or differentiated, the information 
can be tailored. A map can be produced showing just the segments of the 
routes the traveler needs to take, with annotations showing real-time departure 
information and guidance that helps one know what to expect from the trip 
(see Figure 2-15 for such an example from the Google Maps application for 
iPhone).
While this example is admittedly difficult to transmute to medicine, it 
represents an essential point: Non-experts can work with “data” if they are 
encoded for machine-readability, and brought together in appropriate UIs. 
Because an inventory of such products is beyond the scope of this project, a 
few examples of data-driven resources are subsequently briefly reviewed to 
discuss their design and applicability.
Kayak
kayak.com
Kayak is a Web-based travel booking tool—for flights, hotels, rental cars, and 
vacation packages. Its users interact with vast quantities of data to filter and 
narrow options and support travel decisions. The rest of this brief discussion 
focuses on its ordinary flight search. It features a faceted search UI, which 
means that it provides user interface controls to filter or limit flight results, 
for example, along dimensions like airline, number of stops, price, flight 
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Figure 2-15
Integrated 
navigation data on 
Google Maps.
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Figure 2-16
Kayak flight search results. Purchasing advice accompanies faceted search and multiple data 
visualizations to filter and make sense of available flights.
duration, origin and destination airports, class of service, and so on. Results are 
presented in a more or less textual format, with greater visual weight given to 
certain pieces of information that are presumably more valuable for decision 
making. Price is the largest data element in a search result, and flight times 
boldest; when a certain filter is applied, results update immediately, hovering 
the cursor over a filter highlights data elements related to that filter in orange. 
Kayak features sophisticated analysis tools, such as a 7-day-by-7-day matrix 
that highlights relatively inexpensive and relatively expensive flights. It also 
automatically draws attention to factors that may impact a traveler’s decision 
but that are not obvious. Common situations include when the departing 
and returning airports are different, when a layover is especially short, when 
an aircraft is a turboprop where a turbojet may have been expected, and 
when a flight spans the international date line. Although each search result 
incorporates more than a dozen individual data elements, low-contrast color 
helps less critical data recede. Progressive disclosure is employed to reveal 
even more information that is usually irrelevant to the first pass of decision 
making, such as the flight number and aircraft type. A “purchase advice” 
visualization shows a historical price sparkline (seen in the top left of Figure 
2-16), accompanied by an unambiguous recommendation—“BUY” if Kayak’s 
forecast of prices suggests that the price will rise in the coming days.
Kayak facilitates interaction with data that are dissimilar from most of the kinds 
of outcome evidence someone might encounter in the course of researching 
medications. However, it does demonstrate techniques for manipulating and 
filtering data, and presentation of the data in ways that can supply meaningful 
information to a decision—in ways that are presumably accessible to the general 
public, which Kayak serves. Notably absent is experiential knowledge (e.g. 
challenges getting to and from airports, whether one will have to pass through 
customs for international transfers, or reviews of flights or aircraft) that could 
also aid decisions.
Hipmunk
hipmunk.com
Hipmunk, like Kayak, is a travel booking Web site. Its flight search UI (see 
Figure 2-17) is also faceted, but differs in that it relies more heavily on 
visualization. Individual flights are visualized on a timeline, so that the number 
of segments, layovers, and relative duration can be compared by their length 
on screen. Additional details—like aircraft type, on-board amenities, and so 
forth—are revealed only upon request. In this way, Hipmunk’s designers have 
made deliberate decisions to focus on information that they either believe 
or have found are important to travelers. Price is, of course, prominent, and 
relatively inexpensive flights highlighted in green. Like typical search result 
UIs, Hipmunk’s can be sorted by facets like price, duration, and takeoff time. 
However, it also introduces a novel sorting algorithm—called agony—which is 
the default method by which flights are sorted, suggesting that the first result is 
the least agony-inducing. On its frequently asked questions page, Hipmunk says 
“we know that price isn’t the only factor that goes into purchasing a flight,” and 
that its notion of agony is “primarily a combination of price, flight duration, 
and number of stopovers” (Hipmunk, n.d.). Here, Hipmunk demonstrates a 
kind of synthesis of multiple pieces of data into a gist which attempts to map 
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to the mental model of its traveler users. It features a similar system for hotels, 
called ecstasy. Both concepts are examples of translation from jargon (or raw 
data) to a form that is intended to help an audience make meaning with the 
data.
Snake Oil Supplements
www.informationisbeautiful.net/visualizations/snake-oil-supplements
Snake Oil Supplements (SOS) is an interactive data visualization (see 
Figure 2-18 for a static snapshot) that summarizes evidence about 191 pairs of 
a non-pharmaceutical supplement or remedy and a specific health concern. 
For example, it has information about St. John’s wort for the treatment of 
depression, based on data from a systematic review published by the Cochrane 
Collaboration. Each supplement-health concern pair is represented by a 
“bubble” on the visualization. The bubble is roughly positioned vertically 
according to the strength of evidence for tangible health benefits, according 
to a score marked by the visualization authors, who manually reviewed the 
evidence. The scale has 7 discrete categories: Harmful, none (no evidence of 
health benefit), slight, inconclusive, promising, good, and strong. The bubble 
is sized according to either relative popular interest (measured by estimated 
Google search query volume for a query related to the supplement-health 
concern pair) or scientific interest (measured by the number of citations on 
Google Scholar from 2000 to 2012 for a query related to the supplement-health 
concern pair). Like the prototype, SOS uses a Google Spreadsheet as its “back 
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Figure 2-17
Hipmunk flight 
search results.
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Figure 2-18
Snake Oil 
Supplements.
end” or data store. Anyone can look at the visualization, and the provenance of 
evidence that populates it. For each pair, one can find links to the literature and 
quotes or abstracts that elaborate on the summarization of the evidence. Like 
Kayak and Hipmunk SOS features a faceted filtering UI to restrict results.
Effective translation is at work in more than one way in this visualization. First, 
the evidence is summarized in a way that maps onto a simple question: “Is this 
supplement helpful for this health condition?” Summarizing evidence in this 
way is complicated and eliminates almost all nuance from its final presentation. 
However, one can look at this and see at a glance that there is a good deal 
of scientific interest in vitamin D supplementation for general health and to 
reduce all-cause mortality, for which strong evidence for a benefit (according 
to the SOS authors’ review) has been found. St. John’s wort for depression, 
by comparison, has seen relatively little scientific interest but is backed by 
similarly “strong” evidence. Second, a line called the “worth it line” bisects 
the visualization. Supplement-health concern pairs with at least “promising” 
evidence are above the line, suggesting that they are more likely to be good for 
health and worth taking. Below that line, the evidence suggests that it may not 
be worth it, either because there is conflicting data or because the supplement 
has been found ineffective or harmful—regardless of the level of interest in it. 
This is a novel and straightforward way of mapping the data onto an ultimate, 
very human decision about whether to take a supplement or not.
The visualization raises a host of questions about evidence selection, 
summarization, and so on. Because as a whole it is a system so similar to the 
prototype, most of those questions are dealt with in detail in Chapter 3. How 
this product differs is that it is not a generalized or systematized platform 
for developing further visualizations based on the same data. Instead, it 
is a bespoke visualization built on an expandable “evidence base” with 
summarizations encoded in a spreadsheet. Because the summarizations—of 
“promising” evidence of health benefits—are encoded in the spreadsheet 
instead of individual findings—of specific depression relief outcomes for 
St. John’s wort, for instance—only those encoded summarizations can be 
compared. That is suitable for a visualization that is intended to communicate 
a high-level notion about dozens of disparate supplements, but not as suitable 
for a platform on which more detailed visualizations might be built to explore 
specific findings in the source evidence.
How Likely Is It That Birth Control Could 
Let You Down? (The New York Times)
www.nytimes.com/interactive/2014/09/14/sunday-review/unplanned-pregnancies.html
Another data visualization project produced by a news organization, this 
birth control visualization by The New York Times (see Figure 2-19) is more 
akin to the kind of resource that might one day be available for general 
medical inquiries. It is outcome-oriented, in that it communicates a potential 
outcome (unplanned pregnancy or contraceptive failure) given certain 
conditions (typical or perfect use of the contraceptive method). It uses multiple 
visualizations and annotations, along with a distinctly interactive UI (hovering 
the cursor over visualizations reveals data that facilitates understanding of 
the charts). The repeated and consistent presentation for each contraceptive 
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method promotes comparison from one method to another. It is data-rich, 
and probably requires significant health or data literacy for full understanding. 
Nevertheless, it is an example of a resource that might inspire outcome-
oriented resources in other domains—for example, it is relatively easy to 
imagine how the same scaffolding could be applied to estimates of effect about 
RA medications given specific conditions of medication adherence, dose, or 
other factors.
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Figure 2-19
New York 
Times birth 
control efficacy 
visualization.
Related work in medicine
Evidence-based medicine
In the 1990s, alongside the emergence of the Internet for the general public, 
evidence-based medicine (EBM) began ascent. It is a widely adopted model 
of medical decision making that prioritizes high-quality medical evidence 
over clinical experience or pathophysiologic rationale (Davidoff, Haynes, 
Sackett, & Smith, 1995; Eddy, 2005; Guyatt et al., 1992). High-quality evidence 
is that which is ideally free of bias, statistically sound, and applicable to the 
decision at hand. Well-conducted and transparent randomized clinical trials, 
systematic reviews or meta-analyses of large bodies of evidence, and clinically 
applicable epidemiological studies might all be sources of such evidence. 
With EBM, clinical decisions can be made with current best evidence made 
visible to the patient, instead of strictly by intuition. EBM is practical in that 
it can be practiced today, however it depends on extant evidence for the 
decision at hand. When there is no good evidence available to help answer a 
clinical question, and yet a decision must still be made, clinical intuition and 
pathophysiology may be all that a practitioner can rely on. An illustration 
depicts why evidence-based practice can be beneficial:
I would like to retell a story that was told to me by Sir Iain Chalmers – 
one of the people who have worked so hard to make Archie Cochrane’s 
vision a reality in the form of the Cochrane Collaboration. Chalmers 
told me how as a young doctor he bought a copy of Benjamin Spock’s 
famous book Baby and Child Care. Spock was an American paediatrican 
and his book, first published in 1954, has sold 50 million copies in 39 
languages and has been described as one of the most influential books 
of the 20th century. The young Dr. Chalmers marked the passage that 
advised mothers to put their babies to sleep on their tummies, advice 
he duly passed on to his patients. The rationale given by Spock was that 
babies put to sleep on their tummies would be at lower risk of inhaling 
vomit and choking, should they happen to vomit in the night. However, 
by the 1970s and 1980s evidence was accumulating that this, untested 
theory, was lethally bad advice. We know now that around 50,000 cot 
deaths worldwide were caused because of it. In fact it is much safer 
to sleep babies on their backs, a finding which completely reversed 
Spock’s health care advice on the topic.
(Barratt, 2008)
An increasing volume of evidence is produced every year (Davidoff et al., 
1995). For it to be applied, it must be systematically reviewed and incorporated 
into resources that clinicians—and perhaps patients—can use. For many of 
the reasons cited in the earlier section “Factors that shape or limit access to 
medical evidence,” much necessary evidence remains out of the reach of 
medical practitioners.
When high-quality evidence is available, it must still be considered in light of 
the individual needs of a patient. While a patient might “fit” the mold of one 
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in a population for which there is good evidence about an intervention, that 
person is still an individual—with individual capacities, needs, values, and 
preferences; a unique life.
Patient-centered care
The constellation of ideas that may be conceptualized as patient-centered 
care (or patient-centeredness) are those that promote care of the whole 
person, a positive therapeutic alliance between the patient and clinician, and 
often shared responsibility for decision making (Balint, 1969; see review in 
Holmström & Röing, 2010). The goal of patient-centeredness defined by the 
Institute of Medicine in Crossing the Quality Chasm: A New Health System for 
the 21st Century, is “to customize care to the specific needs and circumstances 
of each individual, that is, to modify the care to respond to the person, not 
the person to the care” (Institute of Medicine, 2001). These notions may be 
understood in contrast to care that excludes the patient’s experience of illness, 
that is directed or guided by needs or impetus other than the patient’s, or that 
is about treating a pathology or a disease. If the patient is seen as host to an 
illness, care is probably not patient-centered. Put another way, curing an illness 
at whatever cost is insufficient for care to be patient-centered. The patient’s 
needs, irrespective of their illness, must factor into the practice of care.
A related but different notion is patient empowerment, which according to a 
review of the concept by Holmström and Röing (2010) deals more with patients’ 
assumption of authority to enact health-related decisions, and with ensuring 
that people have the agency and freedom to educate themselves about and 
“own” such decisions. The empowered patient may not take control of medical 
decisions, but may feel capable of educating themselves and acting on their 
own behalf.
Achievement of patient-centeredness requires practices and health resources 
that acknowledge the person being treated, inform and educate, elicit needs 
and preferences, facilitate good working relationships and communication, 
provide physical and emotional comfort, and shape and deliver appropriate 
care. If someone wishes to be more informed and involved in medical decision 
making, ideally it should be so. If someone wishes to be less informed and not 
involved in medical decision making, ceding as much authority as possible to 
their clinician, ideally it should be so. In both cases, the patient is in charge. 
Similarly, a certain degree of patient empowerment depends on a medical-
social willingness to recognize a patient’s prerogative to take on and encourage 
a sense of self-efficacy in care responsibilities. Patient-centeredness and EBM 
could be seen as potentially conflicting (Barratt, 2008), but only if EBM is 
adopted in a dogmatic fashion, where a decision can only be made according to 
the best available evidence, instead of considering the best available evidence. 
Practices like shared decision making (SDM), aiming for goal concordance 
between physician and patient, and minimally disruptive medicine (MDM), 
along with tools like decision aids (DAs), and research oriented around patient-
centered or patient-reported outcomes (PROs), are all part of the contemporary 
patient-centered context in which the prototype—and all online health 
information resources—are situated.
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Shared decision making
Shared decision making (SDM) describes a model of medical decision making 
in which clinicians and patients collaborate on decisions (Charles et al., 1997; 
Stiggelbout et al., 2012). It is not a single method, but a way of practicing 
that involves give and take between providers and patients according to the 
individual values, needs, and preferences of both parties—and often additional 
participants, like caregivers and family members. Patients may “share” the 
decision by agreeing to vest authority with their clinician (Kon AA, 2010), but in 
effective SDM patients may be more likely to engage in a discussion about what 
may work best with their provider and more truly “share” the decision.
Because it is a patient for whom a medical decision—to perform a test, to start 
or stop a medication—has the greatest consequences, it seems obvious that 
they should be informed participants and ultimately decide what is right for 
them. But neither patients nor their providers can be expected to have all the 
answers, as is clear from the complex decision scenarios outlined in Chapter 
1. Important medical decisions “must be made in complex, ambiguous clinical 
situations, in which clinical evidence is insufficient, goals and options are not 
clearly defined, and preferences are contextual, provisional, and conditional” 
(Epstein & Gramling, 2013). Though no single definition of SDM exists, it can 
be understood as the process by which these decisions can be made by the 
provider and patient sharing information, discussing the benefits, risks, and 
implications of intervention options (including doing nothing, if desired), and 
ultimately coming to a preferred option in line with the patient’s individual 
needs. SDM is inherently a subjective, very much human endeavor that reflects 
the beliefs of every participant—that is, both clinicians and their patients. Some 
believe that persuading patients with evidence is an imperative (Shaw & Elger, 
2013) especially where their beliefs may conflict with the state of scientific 
knowledge, while there remain significant challenges in bringing EBM and SDM 
together (Barratt, 2008). A good deal of the inquiry into SDM has to do with 
tools by which clinicians and their patients can use evidence to make informed 
decisions, including research on decision aids (more to follow below).
Inquiry into SDM—how patients and clinicians collaboratively make decisions, 
including by integrating medical evidence and tools like decision aids—has 
shown that various implementations improve the quality of clinical interactions 
from the patient perspective, although it does not necessarily produce better 
outcomes (LeBlanc A et al., 2015; Lin & Fagerlin, 2014; Shay & Lafata, 2015; 
Stacey et al., 2012). Regardless of the impact of SDM on health outcomes, 
because it is a present model of decision making, whatever resources (from 
WebMD to decision aids) patients use to inform themselves play a role in it.
Goal concordance
An issue key to collaborative medical decision making is goal concordance, or 
the degree of alignment between clinicians and patients on care objectives. 
It cannot always be assumed that these stakeholders’ treatment goals are the 
same. While it may be clear to a physician that there is a single most effective 
course of treatment for the underlying disease, it may not be clear that the 
physician’s patient or the patient’s family agrees that it is the best option. 
Opposition could be due to overall treatment burden, cost, side effects, 
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unwillingness to change from a current therapy, lack of confidence in the 
treatment, or any number of other reasons. Although there is limited research 
on goal concordance, Heisler et al. (2003) found that in a sample of diabetes 
patients and their providers, there was considerable lack of alignment on 
goals—only 5% of patients and provider pairs independently agreeing on their 
top 3 treatment goals, with 19% having no overlap at all. Similar discordance 
was found for treatment strategies. However, they also found that patients who 
more strongly believed in the efficacy of their treatment were more likely to 
share goals with their provider; patients who agreed with their provider on the 
top treatment strategy had a greater sense of self-efficacy.
Greater goal concordance might play a role in effective SDM and greater 
patient-centered care. A natural question is whether it is plausible that a shared 
understanding about treatment options, built from a shared base of evidence, 
could contribute to alignment on treatment goals. In the case of RA treatment, 
could clear physician-to-patient communication about treatment strategies (e.g. 
recommendation of methotrexate as a first-line treatment, treat-to-target, use 
of multiple DMARDs)—along with provision or availability of online resources 
explaining how well these treatments might work, their side effects, and their 
bearing on other life concerns (issues)—lead to greater alignment and a stronger 
sense of self-efficacy?
Minimally disruptive medicine
Living with even one chronic health condition like RA places a significant 
burden on someone. It entails lifestyle changes, enlistment of support, 
psychosocial stress, dealing with symptoms, treatment management, potential 
changes in health status, among other consequences. One’s life changes. 
This burden is only increased if a person has to deal with multiple chronic 
conditions, a situation faced by 1 in 4 American adults in 2010 (Ward, Schiller, 
& Goodman, 2014). Clinical practice guidelines and the best available evidence 
may suggest an optimal care plan, but implementation of that plan may exceed 
the capacity of someone to execute it in the realty of their day-to-day life. Such 
is the rationale behind minimally disruptive medicine (MDM) (Leppin et al., 
2015). It promotes a process by which the “right care” can be identified and 
implemented, by working “with patients and caregivers to design care that 
advances patient goals with the smallest possible healthcare footprint on their 
lives.” The theory goes that the best care is that which the patient can truly 
integrate into their life. It requires that the capacity of the patient to integrate 
that care be expressly acknowledged (Leppin et al., 2015).
In principle, resources that help people understand the potential impact 
of treatment choices on their lives can help facilitate MDM. If a patient 
understands the daily routine changes or potential side effects that a therapy 
might entail in balance with its putative benefits, they might be able to more 
confidently accept or reject it. MDM posits as an explicit “care model” with 
specific inputs and dimensions along which patient needs and care options 
can be analyzed (Leppin et al., 2015), including the patient’s capacity to adopt 
care and the burden that specific care options necessitate. These could be 
(in a limited way) directly translated into a user interface. Unfortunately the 
prototype does not incorporate MDM principles in this way. Nevertheless, it 
can be understood in the context of MDM: For a patient, exploring evidence 
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about a treatment option that reveals information about that option’s burden, 
can participate in finding what MDM calls the “right care.”
Of course, the “right care” may not be the most effective therapy for a 
particularly disease management outcome. Considering RA, for example, it 
may be that the “ideal” goal of treatment with a DMARD is relatively aggressive 
treatment to a target of disease remission. (That would, of course, be alongside 
a wide range of other accommodations that a patient needs to make in order 
to live with RA.) Perhaps the “best” medication makes this particular patient 
sick, and interferes with their ability to work. If they cannot work, they cannot 
afford to live and eat. The “right care” for that person might not be the best 
medication to treat-to-target, but an alternative that achieves the best possible 
disease mitigation and permits the patient to keep working.
Patient reported outcomes
Quoting guidance from the U.S. Food and Drug Administration, Deshpande 
et al. (2011) say that a PRO is “any report of the status of a patient’s health 
condition that comes directly from the patient, without interpretation of 
the patient’s response by a clinician or anyone else.” PROs represent an 
opportunity to deepen patient-centeredness, by acknowledging a patient’s 
experience as they experience it—though mediated by an instrument of some 
sort, such as a visual pain scale or a categorical questionnaire response.
Measuring outcomes in a disease as complex and encompassing as RA is 
challenging. There is no single measure. Success is a combination of effects: 
Patient self-report of feeling well (e.g. less pain, less stiffness, and less fatigue), 
adequate function (e.g. capacity to perform tasks of everyday life, work, and 
leisure), physician assessment (e.g. their patient’s overall health and of tender 
and swollen joints), lower disease activity (e.g. low levels of inflammatory 
factors in blood assays and evidence of slowed disease progression by 
radiography), and tolerance of therapy (e.g. effective lifestyle changes, no 
evidence of toxicity or unacceptable side effects from medications)—and more. 
Many of the existing measures—discussed in Chapter 2—may not be intuitively 
understandable; for instance, what does it feel like to take oral methotrexate 
and have a 20% improvement in a combination of tender and swollen joint 
counts, self-reported pain, and physician assessment of disease activity? That 
is an example of a typical outcome measure in research on RA treatments—a 
composite measure called ACR20 (Boers et al., 2014)—and sufficient for a 
pharmaceutical company to claim that a drug effects a “reduction in the signs 
and symptoms of RA” (Food and Drug Administration, 1999). Not only may such 
measures be difficult for non-specialists to understand, or difficult to translate 
into a meaningful form for patients, but they may not accurately reflect 
their priorities either (Rendas-Baum et al., 2014). OMERACT, an organization 
dedicated to systematization of methodologies and measurement of outcomes 
in RA research, has made development of instruments to soundly collect PROs 
a priority, and says that “capturing the patient perspective is an important part 
of research since the objective is to ultimately improve clinical outcomes for 
patients” (Boers et al., 2014). However, just as with other outcome measures, 
PROs are subject to the same rigor necessary to validate them—a non-trivial 
exercise. A PRO must be proven to consistently (from patient to patient) 
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measure an underlying concept (e.g. fatigue) reliably, be sufficiently sensitive to 
change to matter to patients, and reasonably easy to measure.
PROs bring with them the promise of assessing and communicating evidence 
about RA medications in terms that ordinary people might understand. They 
may focus research on what patients find valuable, and help answer questions 
that really matter to people—for example, whether interventions have a 
meaningful effect on sleep quality ( J. R. Kirwan et al., 2009). 
Summarizing a systematic review of PROs in RA by Kalyoncu et al. (2009), 
Gossec et al. note that only 4% of 50 trials included PRO data on fatigue, 2% 
on sleep, 2% on work and social life (and even then, only on productivity 
loss), and none on overall well-being, even though these are important to 
patients (Gossec et al., 2015). Absent such direct measures, additional effort is 
necessary to translate the “meaning” of existing measures which are perhaps 
suited to researchers but not so well to patients. As this project initially set 
out to communicate evidence about the effect of RA medications on patient 
experiences of domains like exercise, sleep, work and overall well-being, the 
lack of both PROs or research on these topics in general was an acute practical 
problem.
Decision aids and similar instruments
Decision aids (DAs) and decision support instruments (DESIs) are artifacts 
designed to help people understand choices and make decisions. They may 
take forms as diverse as brochures, checklists, tables, narrative videos, or 
interactive digital applications. Patient-facing medical decision aids are often 
static, paper artifacts. They typically are text-based, with some graphics 
or illustrations, and occasionally data visualizations. DAs may be used to 
explain any kind of intervention or health choice, such as a screening test or a 
treatment option, or several of these, usually oriented to a specific decision that 
a patient might face—for example, deciding whether to take a screening test, 
or starting a new medication. They may precisely describe a decision-making 
process, or they may simply furnish information useful in a decision-making 
process. They might include a facility for explicitly capturing patient values 
and preferences in the context of presented options (Stacey et al., 2012). Some 
DAs are designed for use during clinical encounters, sometimes to stimulate 
conversations about intervention options (Barton et al., 2014; Montori, Breslin, 
Maleska, & Weymiller, 2007). Others are designed for evaluation at home, 
outside the clinic.
Evidence underlying DAs may come from sources as diverse as clinical 
practice guidelines, clinical trials, epidemiological studies, and patient 
stories or interviews. Selection of evidence for DAs is inherently editorial; the 
International Patient Decision Aid Standards collaboration (Glyn Elwyn et 
al., 2006) maintains quality measures for decision aids which state that DAs 
ought to “base their information on comprehensive, critically appraised, and 
up-to-date syntheses of the scientific evidence…this refers to the information 
about the various relevant options, and about the descriptions and likelihoods 
of those options’ effects on the outcomes of most importance to patients” 
(Montori, LeBlanc, Buchholz, Stilwell, & Tsapas, 2013). Patient-reported 
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outcomes (PROs) might enhance DAs that otherwise would be “limited” to 
difficult-to-translate findings from research.
Like any artifact that patients might encounter that confers information about 
medical choices, DAs are subject to bias due to presentation choices. IPDAS 
guidelines say that DAs should be balanced, and there is evidence that certain 
ways of presenting information are more likely to be perceived as balanced 
(Abhyankar et al., 2013). However, most presentation modes are still subject to 
interpretive bias on the part of viewers; for instance, there are many ways in 
which quantitative information about risks can be misinterpreted (Trevena et 
al., 2013).
Especially with paper-based, non-interactive DAs, there are limits to what can 
be presented. With limited space, editorial decisions about what to include and 
how to include it are particularly important. This may be a strength—research 
can reveal that which is most valuable to include—but also a weakness: New 
treatment options, new PROs that could be even more valuable than earlier 
evidence, or new evidence in general, cannot be easily added. If a team had 
been convened to review evidence and build a DA, but then disbanded after the 
DA was printed, it may have a limited shelf-life. Unfortunately, little research 
has been conducted on DAs built for use online (Hoffman et al., 2013), and 
especially little on resources like DAs that one might encounter in typical 
Google searches. DAs or similar resources are generally intended and especially 
valuable for decisions in which there is likely to be a state of clinical equipoise, 
when decisions are very sensitive to patient preferences, when potential risks 
are serious, or when options are unfamiliar.
The focus of this thesis project is non-clinical resources (i.e. for use outside 
of clinical encounters, at home, perhaps without clinician involvement at 
all). However, there may be special value in resources that are used in clinical 
encounters—should clinicians feel prepared to use them (Abadie et al., 2009), 
and time permits. As observed by Elwyn et al. (2013), When the paper DA is 
handed to a patient, it may “signal the clinician’s respect for patients as relevant 
contributors to the process of making decisions” and a shift in power from 
doctor to patient. Perhaps if a digital DA were running on a tablet computer 
and handed to a patient, it could function similarly. It is unlikely that the same 
digital resource discovered and accessed at home could function similarly, 
though it vests similar agency for exploration and navigation of medical 
evidence in the patient. In either case, DAs may enhance decision making by 
empowering patients to be more knowledgeable participants in decisions, or 
as artifacts to support better conversations. They have been shown to have 
positive benefits in terms of knowledge and comfort with medical decisions, but 
not necessarily better intervention adherence or health outcomes (Stacey et al., 
2012). Ultimately, their efficacy has not only to do with their design, but with 
how they are used in the social processes of patient-provider communication 
and decision making.
Option grids
Not all questions people have when they face a complex medical decision are 
general in nature, as broad as “how well does this medication work?” They 
may be very specific and intimately tied to the choice at hand. Intuitively, if one 
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of the options is major surgery on one’s knee, a natural question is how the 
surgery will affect walking, and how long recovery may take. An option grid 
(OG) is a special kind of DA (see Figure 2-20) that answers specific common 
questions people have, for each of several courses of action in a medical 
decision (Elwyn et al., 2013). Like many DAs, option grids are designed to 
be used during the clinical encounter, to help answer questions that arise in 
conversation between provider and patient. An advantage of OGs is that they 
contextualize evidence and are tailored to pointed questions that real patients 
ask. They summarize the best available evidence to directly and clearly answer 
those questions. In that way, they differ from the prototype, which is intended 
to accommodate general evidence, and present it in a general way. Option 
grids are well-designed to illuminate such direct answers. As Elwyn et al. (2013) 
note, OGs make options concrete and literally visible (textually), illuminating 
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Breast cancer: surgical options
Use this Option Grid™ decision aid to help you and your healthcare professional talk about how best to treat
breast cancer.
Frequently Asked Questions
c Lumpectomy with radiotherapy Mastectomy
What is removed? The cancer lump is removed, with
some surrounding tissue.
The whole breast is removed.
Which surgery is best for
long-term survival?
Survival rates are the same for both
options.
Survival rates are the same for
both options.
What are the chances of
cancer coming back in the
breast?
Breast cancer will come back in the
breast in about 10 in every 100
women (10%) in the 10 years after a
lumpectomy. Recent improvements in
treatment may have reduced this risk.
Breast cancer will come back in
the area of the scar in about 5 in
every 100 women (5%) in the 10
years after a mastectomy. Recent
improvements in treatment may
have reduced this risk.
Will I need more than one
operation on the breast?
Possibly, if there are still cancer cells
in the breast after the lumpectomy.
This can occur in up to 20 in every
100 (20%) women.
No, unless you choose breast
reconstruction
How long will it take to
recover?
Most women are home within 24
hours of surgery.
Most women are home within 48
hours after surgery.
Will I need radiotherapy? Yes, for up to six weeks after surgery Radiotherapy is not usually given
after mastectomy.
Will I need to have my
lymph glands removed?
Some or all of the lymph glands in the
armpit are usually removed.
Some or all of the lymph glands in
the armpit are usually removed.
Will I need chemotherapy? You may be offered chemotherapy,
but this does not depend on the
operation you choose.
You may be offered
chemotherapy, but this does not
depend on the operation you
choose.
Will I lose my hair? Hair loss is common after
chemotherapy.
Hair loss is common after
chemotherapy.
Figure 2-20
An option grid.
information that supports decisions by “[focusing] on the attributes that 
support relevant comparisons.” They have been created for dozens of medical 
decisions, from amniocentesis tests to insulin treatment options for type I 
diabetes in children (The Option Grid Collaborative, n.d.). In some cases, they 
contain a breadth and depth of information that would be nearly impossible to 
spontaneously and completely cover in a clinical encounter, without the aid as 
a prompt.
Like most paper DAs, OGs have a few weaknesses. One is that they are only 
current when they are published, up to date with whatever evidence was used 
to create them. They are static and cannot accommodate options—such as new 
treatments or diagnostic choices—that were not explicitly included at the time 
they were made. Similarly, they only answer a limited set of questions deemed 
important by the authors—as well-founded and valuable as they may be to the 
practical decision that the patient faces.
Option Grids are built around evidence documents that show which sources 
were used to answer the questions. They are also distributed according to a 
Creative Commons attribution license which means that they can be widely 
accessed (The Option Grid Collaborative, n.d.). Both of these features mean that 
they function as a way to improve transparency and access to evidence that can 
support complex medical decision making.
Mayo Clinic decision aids
Several DAs developed by the Mayo Clinic Shared Decision Making National 
Resource Center—including one for statins (cholesterol-lowering drugs), type 
2 diabetes medications, osteoporosis medications, and antidepressants—
influenced the design of the prototype. They are typical of DAs in that they 
cannot arbitrarily accept new evidence. The aids are accompanied by a bold 
disclaimer: “Caution: This application is for use exclusively during the clinical 
encounter with your clinician,” clearly indicating that they are intended for 
use during the clinical encounter. Both the antidepressant and diabetes DAs 
are static: They feature a fixed set of options and fixed design (see Figures 2-21 
and 2-22). Although a digital version of the diabetes DA is available, it simply 
replicates the paper cards. Users cannot interactively query the DA to limit to a 
medication suitable given a certain comorbidity, for example. The Bone Health 
Choice (osteoporosis) and Statin Choice DAs are digital, data-driven resources. 
They are tailored to the patient’s specific situation to estimate the baseline risk 
of a negative health outcome—a heart attack in the case of Statin Choice. The 
putative benefit of the intervention—prevention of a heart attack—is expressed 
in the context of that baseline risk (see Figure 2-23). However, they also do not 
accept new evidence. In both, the intervention is a class of medications (e.g. 
the only “choice” is taking a statin or not)—reasonable since the medications 
may be equally effective for the particular outcome of interest—rather than 
individual medications. In that way, the DA cannot be tailored, to limit to a 
medication suitable given a certain preference or comorbidity.
These DAs feature an issue-centric design. Data are presented in the context 
of issues relevant to people facing the particular decision, or that are unique 
to the treatment options, alongside general concerns like side effects, cost, 
and daily routine, as the Diabetes Medication Choice image in Figure 2-22 
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illustrates (Mayo Clinic Shared Decision Making National Resource Center, 
n.d.-b). Like the frequently asked questions in OGs, these issues are germane to 
the choice being made. For example, a single potential serious risk associated 
with the choices may be elevated to the status of an issue and become its 
own card—such as the risk of low blood sugar with antidiabetic medications. 
Similarly, top antidepressant side effect concerns—such as sexual side effects 
and weight gain—are elevated to the status of a “first-class” issue in the 
Depression Medication Choice DA. In the paper, card-based DAs, medications 
are generally found in the same vertical position on each card, so that multiple 
issue cards can be used as “lenses” to compare medications side by side. Or, a 
single card can be used to compare multiple options along a single dimension. 
Visually, these DAs employ symbols, graphical representations, relatively 
little text, and visualizations like icon arrays that may ensure more effective 
risk communication and comprehension for lower literacy patients (Galesic 
et al., 2009). With a clinician present, patients can ask for clarification or 
discuss anything they do not understand. The DA is an artifact that facilitates 
conversation about the choices and issues (Montori et al., 2007).
As these DAs are designed for use during clinical encounters, practitioners 
must learn about them, trust them, and find a way to integrate them into 
usual care. And, as Breslin et al. note in their discussion of the diabetes DA, “a 
conversation-based decision aid relies heavily on the communication skills and 
knowledge of the clinician, attributes that may vary greatly across clinicians” 
(Breslin, Mullan, & Montori, 2008). Omitting information that would be 
necessary to make a fully informed decision is a clever and deliberate design 
choice, given the conversation philosophy—the clinician and patient together 
complete the DA. The authors note that a “stand alone decision aid” (such as 
the thesis prototype) could “overwhelm patients with complex information 
61
Figure 2-21
Mayo Clinic 
antidepressant 
decision aid. These 
are a subset of 
the “issue” cards 
that comprise the 
decision aid.
and deprive patients of the clinician’s stories of other patients’ experiences and 
their expert judgment,” which is a legitimate possibility.
Cochrane methotrexate decision aid
http://musculoskeletal.cochrane.org/decision-aids/
One of several DAs published by the Cochrane Collaboration, this methotrexate 
DA (see figure 2-24) is a paper-based, linear, narrative document explicitly 
designed for the choice explicated in its title: “Should I take methotrexate 
(Rheumatrex) alone or with other disease-modifying anti-rheumatic drugs for 
rheumatoid arthritis?” (Rader et al., 2011). It is intended for people who have 
been taking methotrexate but whose RA has not improved. It features explicit 
values elicitation (i.e. an exercise to help people identify “what matters most” 
to them), icon arrays to communicate risk information (about benefits and side 
effect risk), a knowledge quiz, and specific “next step” options (including “I 
will take methotrexate with other disease-modifying anti-rheumatic drugs”). 
This document is bespoke and up to date only with the evidence cited (a single 
source), and offers no specific side effect risk information or information about 
the “other” DMARDs. In this way, it feels incomplete even though it points 
patients towards a very specific decision to which the missing information 
is germane . The evidence on this DA suggests that few people who have not 
improved already with methotrexate will improve after another 1 to 2 years, 
62
Figure 2-22
Mayo Clinic 
diabetes 
medication 
decision aid. This 
online version 
replicates the 
equivalent printed 
cards.
while people who take methotrexate with another DMARD are more likely 
to improve, while there is no difference in terms of the estimated number of 
people who would stop treatment due to side effects with either therapeutic 
option. However, parts of this DA may be confusing. For instance, in the values 
elicitation exercise, it suggests that people who consider avoiding adverse 
events or side effects unimportant would likely prefer to use methotrexate 
alone, while people who consider it very important to avoid adverse events or 
side effects might prefer methotrexate with another DMARD—even though the 
DA itself says that people on the combination therapy do not stop treatment at 
a rate any different than those who take methotrexate alone, and even though a 
new medication introduces the risk of new side effects that might be unfamiliar. 
This suggestion may be because RA disease progression itself may result in 
serious adverse events, although that is not clear from this exercise.
Like most DAs, because this one is paper-based, it cannot be kept up to date 
with new evidence. It also cannot itself be used to explore the other DMARD 
options. While the Cochrane group publishes similar DAs for a few other 
DMARDs, each new one needs to be crafted by hand.
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Figure 2-23
Mayo Clinic statin decision aid. In this interactive decision aid, issue cards are supplemented by 
tailored risk visualizations (icon arrays) showing the relative risk of having a heart attack without 
taking a statin versus taking a statin.
Clinical practice guidelines
A clinical practice guideline (CPG) is in principle an evidence-based document 
that makes recommendations methods for diagnosis and treatment of patients 
with a certain illness (Krahn M & Naglie G, 2008), although not uniformly 
rigorous in their formulation or recommendations (Guyatt & Vandvik, 2013). A 
CPG principally designed for use by clinicians. Recommendations may cover 
domains like diagnostics, treatment strategies, dosing, follow-up, patient 
engagement techniques, and more. A CPG documents consensus among 
specialists based on a review of evidence (Weijden et al., 2010), and indeed 
may be vehicles for the standardization of evidence-based care: If they are 
thorough, up to date, and clinicians do their best to follow guidelines, they 
may help the best care to be delivered to all patients. However, they may not 
explicitly include PROs or include much discussion of patient beliefs, needs, 
and preferences and the central role they may play in effective care (Krahn 
M & Naglie G, 2008). In such cases, CPGs may appear to be more focused 
on treating the disease rather than the patient, though clinicians can apply 
recommendations in the context of their patient‘s individual needs.
With respect to design, CPGs are often long, narrative documents with some 
diagrams and tables, but not machine-readable data nor digital and interactive. 
This can present a problem for practitioners who may need to rapidly look 
up a recommendation germane to a patient, to help them make an evidence-
based decision (Vandvik et al., 2013). The Institute for Clinical Systems 
Improvement (ICSI) guideline for treatment of adult depression in primary care 
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Figure 2-24
Cochrane 
methotrexate 
decision aid. These 
are the central 2 
of 4 pages of this 
4-step linear DA, 
which also includes 
an introduction, 
explicit knowledge 
quiz, and next steps 
section.
(i.e. intended for primary care physicians) is 88 pages long—plus a bibliography 
(ICSI, 2013). The more compact American College of Rheumatology 2015 
guidelines for the treatment of RA are 20 pages, plus references (Singh et al., 
2016). Because CPGs have actionable information that impacts patient care, 
it is reasonable to believe that they could be useful sources of evidence for 
patient-facing resources (Raats, van Veenendaal, Versluijs, & Burgers, 2008). 
That the actionable recommendations and data in guidelines may be “locked 
up” in lengthy text and not machine-readable parallels the situation with much 
evidence, and in consumer health resources. Guyatt and Vandvik describe key 
challenges in CPG creation and use in a 2013 article called “Creating clinical 
practice guidelines: Problems and solutions,” saying: 
Rigorously developed guidelines face other problems of optimal 
usefulness. Newly published evidence may render recommendations 
outdated shortly after publication. Clinicians cannot easily access many 
recommendations published in lengthy PDF formats and unavailable 
in electronic medical records at the point of care or in devices such as 
smartphones and tablets. Finally, most guidelines cannot be directly 
used for shared decision-making.
Solutions to this latter set of challenges (ie, adaptation, updating, access 
at point of care, use in shared decision-making) may be imminent. 
Electronic authoring tools can facilitate both a rigorous, structured 
approach to guideline development and local adaptation and updating. 
The output of such an electronic authoring process can appear on 
smartphones and tablets and be easily integrated into electronic 
medical records.
(Guyatt & Vandvik, 2013)
These arguments very closely mirror the rationale for the prototype. 
Fortunately, efforts are underway to demonstrate solutions to these problems.
MAGIC & SHARE-IT
There are examples of pragmatic data-driven evidence-based electronic 
tools—including decision aids—that begin to address the problems noted by 
Guyatt and Vandvik. One constellation of projects investigating creation and 
implementation of evidence-based clinical practice guidelines in the context of 
shared decision making stands out. The MAGIC (Making GRADE the Irresistible 
Choice) collaboration “was established in 2010 to facilitate the authoring, 
dissemination and updating of trustworthy CPGs” and, following a rigorous 
design process, has demonstrated working applications (Kristiansen et al., 2014; 
Vandvik et al., 2013). The data-driven MAGICapp system ingests summaries of 
evidence for CPGs (including data, not just recommendation text) and makes 
them available in electronic version of CPGs; these electronic CPGs favor a 
certain presentation of the evidence and recommendations but are not limited 
to that presentation. The guidelines can be accessed on a desktop computer, a 
mobile app, downloaded as a PDF (not dissimilar from a traditional CPG), and 
they are even made available for export in JSON, readily used by the prototype 
or in other online resources. These are indeed the benefits of starting with 
machine-readable data. Furthermore, the collaboration has even developed 
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tools under the banner “SHARE-IT” that can facilitate “semi-automated 
production of a large number of decision aids” that use the very same evidence 
base as the CPG (Agoritsas et al., 2015). These decision aids are interactive; they 
support exploration of one finding at a time, with progressive disclosure—for 
example, one can look at the absolute risk (chance of benefit) of an intervention 
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Figure 2-25
A MAGIC 
decision aid. This 
interactive icon 
array visualization 
facilitates 
comparison of 
the relative risk 
of having a heart 
attack taking low 
dose aspirin versus 
not taking it.
Figure 2-26
“Practical” issues 
in a MAGIC 
decision aid. These 
are similar to 
the issue cards 
in Mayo Clinic 
decision aids, 
and the “basic 
issues” feature 
of the Navigator 
prototype.
as a figure alone or including an icon array visualization (see Figure 2-25). 
These DAs feature a “practical” issues screen (see Figure 2-26) that can provide 
context around questions about the life impact of choosing one intervention 
or another, not dissimilar to the Mayo Clinic decision aids and the RA Choice 
decision aid. More than a dozen electronic CPGs are publicly available, some 
with accompanying decision aids (see the list of currently available CPGs at 
magicapp.org, MAGIC, n.d.).
These semi-automatically generated DAs are—in fact, the entire system that 
produces them—philosophically aligned with the thesis project in that they 
demonstrate how machine-readable data and systematized tooling can be 
used to produce multiple updatable resources for different audiences, rather 
than paper-based bespoke resources that quickly become dated. One can get 
the data into the system, and relatively easily build resources for different 
audiences that use those data. Like the prototype built for this thesis project, 
the MAGIC DAs and CPGs could share the same evidence, be continuously 
updated, and complement one another outside of and in the clinical encounter.
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Chapter 3
Prototype
A platform for public engagement 
with medical evidence
The major work of this project was development of a prototype platform on 
which can be built UIs for exploring medical evidence. The primary activities 
undertaken were:
 Researching and encoding findings from medical literature and other 
sources of evidence in an original data schema.
 Building a software system to process those data.
 Designing and prototyping user interfaces for exploration of those data, 
using the re-usable components of the software system.
The product of this work is an open-source Web-based system for encoding 
medical evidence about RA treatments, “translating” it to higher-level patient-
centered issues and graphic representations, and UIs to facilitate exploration by 
members of the general public. Its scope is limited (it presently contains only 
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 i A demonstration application—called the Navigator prototype is at 
http://thesis.merges.net/navigator
 i Data are encoded in a publicly visible Google Spreadsheet at 
http://goo.gl/gdbVuf
 i The prototype is open source. Its code is checked into GitHub at 
http://github.com/merges/abist
a tiny fraction of suitable evidence, and just a few incomplete user interfaces 
and visualizations) but it is a complete end-to-end demonstration platform. It 
comprises the following:
 A spreadsheet “back-end” with “findings” from various sources of 
evidence, including general information about 12 medications used to 
treat RA.
 A technical layer to interpret and transform the data, including separable 
modules for presentation of evidence.
 Public-facing Web applications that can be accessed from desktop 
computers, tablets, or mobile devices. These could be provider-
facing tools to explore all evidence, highly narrative decision aids 
that incorporate evidence, tightly focused tools for looking at one 
particular kind of evidence, and so forth. Several examples were built to 
demonstrate how the platform works.
The Navigator prototype application
This is a demonstration of the kind of application that can be built using the 
prototype platform (see Figure 3-1). It is effectively a decision aid, though it 
was not developed with a deliberate methodology and would require much 
refinement before it would be suitable for clinical use. It instead represents a 
superficial example of a data-driven resource for exploring medical evidence. It 
supports two key activities.
The first is filtering—choosing a medication based on individual needs or 
preferences (such as preferred dosage form, cost, or lifestyle considerations), 
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Figure 3-1
Screenshot of 
the Navigator 
prototype 
application.
and the second is exploration of evidence through the lens of high-level issues 
(e.g. overall improvement or pain).
The whole platform, but especially the Navigator example, began as a simple 
digital version of the existing RA Choice decision aid (Barton et al., 2014). That 
DA’s set of 12 DMARDs—methotrexate, hydroxychloroquine, sulfasalazine, 
leflunomide, golimumab, adalimumab, certolizumab, etanercept, rituximab, 
infliximab, abatacept, and tocilizumab—serves as the basis for the prototype. 
Some medication-specific information from the RA Choice DA was encoded and 
plays a role in the prototype, including typical cost, some of the common risks 
and warnings, and route of administration, administration routine, and delay 
of onset of effect—issues that were discovered by Barton et al. to be important 
to patients. Further information about risks was sourced from systematic 
reviews (Ramiro et al., 2014) (Richards, Dowell, Quinones, & Kerr, 2015). These 
data power the preference-driven filtering UI—so that one can limit to oral 
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Figure 3-2
Schematic diagram 
of the prototype 
platform.
medications, or those that are safer given a certain comorbidity, or that have a 
generic version available. Most of the “evidence” related to each medication is 
in the publicly viewable Google spreadsheet.
Figure 3-2 is a schematic illustration of the platform. It is a rough approximation 
of the parts of the platform and how they connect with one another. Before 
discussing the methods and design choices that underpin the prototype and the 
Navigator prototype, it is necessary to briefly explore a set of guiding principles 
that structured the development process.
Guiding principles
A suite of mutually reinforcing principles guided design, technology choice, 
and methods employed in developing the prototype. They were derived from 
a mixture of established theories, professional experience, and notions that 
arose from reading related literature. Since one major goal of the project 
was to demonstrate an extensible platform, an overarching principle was to 
ensure that a variety of products could be built with it for further evaluation—
applications as diverse as a highly visual low-literacy data-driven decision aid, 
or a comprehensive “viewer” for all available evidence. With respect to an ideal 
data-driven online health resource for the general public, this author believes it 
would be sensitive to context, personalized, responsive to literacy and learning 
style, alive with the latest evidence, furnish the person making a decision 
with useful information, increase knowledge and confidence, and strengthen 
conversations between patients, caregivers, and clinicians. That tall order is 
beyond the scope of this project, but the prototype hopefully has taken steps 
towards a platform that can help build such resources.
Sufficiency
This principle conveys the idea that solutions—to technical problems, design 
problems, etc.—which work well enough should be adopted, rather than seeking 
a comprehensive or perfectly flexible alternative. In this way, sufficiency stands 
in opposition to exhaustiveness and thoroughness. It serves several conceptual 
and practice purposes here:
 It reflects the reality that medical decisions are made with imperfect 
information.
 It promotes effective work, rather than perfect work.
 It emphasizes iteration and improvement, and limits are quickly 
discovered.
Practicing design with sufficiency in mind resulted in a highly iterative design 
and development process, discussed further in a later section. Because 
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evaluation with real users was outside the scope of this project, it is not 
possible to claim that any of the prototype’s “patient-facing” design choices are 
sufficiently effective for furnishing value to people making medical decisions. 
In the context of evaluation, sufficiently effective might mean: Do people get the 
gist of the finding, is their understanding reasonably faithful to the data, and do 
they report it being helpful to their decision?
 How much detail about an outcome should be revealed? Only enough to 
help someone compare or make a decision. Confidence intervals might 
only introduce confusion, for example, and if uncertainty is comparable 
from drug to drug, just showing a point estimate is sufficient. Indeed, 
in many cases uncertainty in estimates of effect has been omitted from 
presentation (although still encoded, and easily switched on with a few 
lines of code).
 How comprehensive should the data schema be? Only enough to take in 
evidence at the level of detail that would likely be used in a tool for the 
general public.
 Is a spreadsheet good enough as a data back-end, as opposed to a 
database? Yes, because it is semi-structured (i.e. data are machine-
readable), and it is sufficiently rapid and easy to work with (for both the 
author, and for the potential audience of contributors from the medical 
community). It satisfies basic needs.
Common technologies and tools, which are “off-the-shelf,” free to use and 
extend, and readily used by less-expert participants in the production 
and dissemination of medical evidence (researchers, physicians, writers, 
bioinformaticists, designers, students, epidemiologists, and so on), are more 
than sufficient for the creation and development of an extensible platform. 
These imperfect but sufficient tools were always preferred during development.
Emergence
Closely related to sufficiency is the principle of reliance on emergence, as 
opposed to comprehensive planning. In this context, emergence refers to 
design solutions that come into being as a result of iteratively working with data 
and developing the prototype. In effect, they are revealed as the whole is built, 
and cannot be defined in advance. With sufficient tools and structures—those 
that meet minimum requirements, but that are flexible and can accommodate 
change—optimal solutions can emerge from experimentation. For example, 
rather than adopting a specific data schema a priori, the current (but not final) 
schema “revealed itself” as development and design practiced, with new data 
and prototyping work continually stressing its limits. Occasionally, boundaries 
were discovered that meant reworking the schema, an inherent risk to relying 
on solutions to emerge through experimentation.
Systematization
Most design decisions were made with an eye towards systemization, in 
order to reflect the goal of a platform or system to support data-driven health 
resources for the general public. The goal was not to make a bespoke artifact 
that only the author could understand, but instead a shareable suite of artifacts 
that can be reassembled, re-used, or at least examined by interested outside 
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parties. Here are a few examples of how that played out during development of 
the prototype:
 Technical decisions. Contemporary, open-source technologies so that 
people other than the author could read, adopt, and work with them.
 Social decisions. Using spreadsheets, so that other people could easily 
be brought on board to participate in adding evidence to the prototype.
 Development decisions. Creating reusable components for common 
elements that might be re-used, like absolute risk visualizations — usable 
across all kinds of resources. Creation of a fairly general data schema that 
can be used for many kinds of outcomes, not just those in RA or those 
encountered during the course of research conducted for this thesis 
project.
 Design decisions. UI that can in a basic sense accommodate a 
continually expanding number of data points, etc. The visualizations, for 
example, are largely data-agnostic—for instance, they can accommodate 
any outcome for any medication, although they may not be optimally 
suited for such purposes.
 Whenever possible, a general and re-usable systematic approach was used 
instead of a bespoke process that could only be applied once to a very 
specific problem. For example, none of the designs implemented so far 
are uniquely tied to rheumatoid arthritis medications.
Elasticity
One potential shortcoming of DAs—both paper-based, and even digital examples 
such as the Mayo Clinic aids—is that they represent a fixed perspective on the 
evidence at a certain point in time. To be sure, new sweeping and conclusive 
data that would radically change a typical DA are not being published 
and verified on a weekly basis. So the core of a DA might remain relatively 
unchanged. But new data—about a specific comorbidity, for example—does 
come out from time to time. It would be nice if any DA that offered tailoring 
based on one’s individual health status would immediately update after new 
evidence had been reviewed and approved for addition.
During the course of the prototype’s development, one of the author’s 
supervisors forwarded a new article about the safety of biologic DMARDs for 
patients with certain comorbid conditions (Richards et al., 2015). Relevant 
findings from that article were encoded in the prototype in just a matter of 
hours, improving the medication filtering. Similarly, new “outcome” findings 
(of the sort on which the prototype is based) can be incorporated by adding one 
or two lines to a spreadsheet. Elasticity—in this case, capacity to accommodate 
new evidence—was central to the prototype. There were implications in terms 
of design (for instance, the design could not assume a fixed number of drugs 
or data points or outcomes), data (the schema had to be flexible), and tooling 
(adding findings had to be relatively easy). The data schema that has emerged 
so far can accommodate most but not all outcome-type findings from medical 
research.
73
Why design for this elasticity? Consider this excerpt from the American College 
of Rheumatology 2015 update to their guidelines for treating RA:
Due to rapidly evolving knowledge for the treatment of RA, some 
recommendations may be outdated by the time they are published 
due to the emergence of new evidence. Examples include new data 
on tapering and discontinuation of therapies in early RA and treat-to-
target. The short half-life of treatment recommendations is also related 
to the rigorous and time-consuming process of guideline development 
used by the ACR, which complies with guidance from the National 
Academy of Medicine (formerly the Institute of Medicine) and the 
Council for Medical Subspecialty Societies. Additional time is also 
required for review and endorsement of each guideline document by 
ACR committees, journal reviewers and editors, and the ACR Board 
of Directors. However, the ACR regularly updates RA guidelines and 
strives to shorten the time between the end of the literature review and 
the publication of guidelines, to make them as relevant and current as 
possible.
(Singh et al., 2016)
It is clear that the rigorous review process—a socially complex process involving 
possibly dozens of people and intensive literature review and discussion—
takes time, preventing new evidence from changing guidelines as it becomes 
available. And it is reasonable to only want guidelines to be “rubber stamped” 
after a thorough review in which all of the evidence is considered together (a 
kind of synthesis). However, there is an advantage to all such resources being 
“living documents” that can grow and accommodate new evidence as it is 
discovered.
Reusability
Although this principle could not be fully realized, wherever possible parts of 
the prototype system were designed for adaptation and reuse as individual 
elements. Instead of designs and technical choices intimately tied to this 
prototype and RA only, features of the platform—the data schema, data 
visualization code, and so on—can be reused in other contexts. Indeed, several 
prototype applications have already been built with it, although the reusability 
of the prototype’s components have not been tested by other developers.
Evidence agnosticism
In principle, it could be considered an ethical imperative that patient-facing 
online resources use trustworthy, high-quality or highly certain sources of 
evidence. (Some of the challenges in evaluating trustworthiness and quality are 
elaborated later in this chapter.) However, buttressing the principle of elasticity, 
the prototype is deliberately agnostic to the source and quality of evidence. It 
can accommodate a new finding from a potentially quite biased clinical trial, 
or a highly certainestimate of effect from a low-bias and well-conducted meta-
analysis. It does support encoding of the quality of that particular finding, and 
links to the source material; also, reusable UI components for communicating 
quality and source have been built, and the example applications (including 
the Navigator) show the provenance of data. The hope is that applications built 
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with the platform would be able to decide on what kind of data to include. For 
example, it can be as simple as adding a checkbox to only show findings that 
come from a particular kind of source, or an express design decision to exclude 
certain kinds of data. In this way, the burden of which evidence is appropriate 
is shifted to humans, rather than restricted by the prototype in some technical 
way. However, it would ultimately be up to the designers and developers and 
users to decide which sources are appropriate.
With respect to communicating the certainty of evidence, the prototype so far 
only supports one system, GRADE (G. H. Guyatt et al., 2008). A useful future 
addition to the prototype would be a harmonization layer to communicate a 
unified notion of quality or certainty to patients, regardless of the system used 
to evaluate it. However, this is a difficult and unsolved problem since there are 
many ways in which these can be evaluated.
Harmonization, not synthesis
Synthesis—in this case, combining evidence and producing a kind of intelligent 
composite whole picture or interpretation—was an anti-principle guiding the 
project. While it is probably the ultimate goal of a patient-facing tool (after all, 
it would mean arrival at something closer to an answer like “this medication 
works best” or “this medication might work best for you”), it is exceedingly 
difficult and if poorly executed, potentially misleading and dangerous. Because 
the prototype is elastic, and can accommodate arbitrary new evidence, any 
algorithms for synthesis would be required to accommodate those data and 
incorporate them faithfully and accurately. There are a number of reasons why 
that was impractical:
 Heterogeneity. Evidence is heterogeneous in innumerable ways, 
including outcomes, measures, metrics, uncertainty around data, 
methods of production, populations studied, intervention details, 
methods of analysis, implicit or explicit biases, etc. In order to synthesize 
these data, explicit decisions must be made about how to address 
inconsistency, variation, and missing information.
 Encoding challenges. Equally challenging is finding suitable ways 
to encode all the qualities and quantities relevant to synthesis—all the 
dimensions of heterogeneity, for example. Each may open a pandora’s 
box of complexities related to faithfully recording the core data, 
inconsistency, variation, and missing values. Comprehensively encoding 
the intervention a population received in a trial is illustrative: The 
treatment may include multiple drugs, at multiple doses, on multiple 
schedules, with switching strategies employed at certain time points 
or given certain conditions. Development of an ontology and schema 
suitable for such data is itself worthy of a research project.
 Incomplete evidence. Necessary data (or dimensions of data) may be 
nonexistent, or difficult or impossible to obtain. Even when the data 
do exist, without advanced natural language processing or an army of 
data-entry volunteers, it would simply take too long to encode relevant 
data. (Systematic reviews in the Cochrane database include detailed 
data for included trials along a number of dimensions like population, 
intervention, comparison, sources of bias, etc.—in prose, although it is 
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systematically presented in printed tables.) With details missing, it may 
be more difficult to produce a trustworthy and reliable synthesis of data.
 Advanced knowledge required. Synthesis—such as a network 
meta-analysis—demands advanced medical knowledge and advanced 
biostatistics knowledge, often on the part of the reader as well as the 
producer. It is far beyond the scope of an undergraduate thesis project 
to take this challenge on, especially in a generalizable way. However, it 
is absolutely reasonable that algorithms could be encoded and applied 
in an automated way to solutions built with the prototype, just as simple 
statistical calculations can be performed with its machine-readable data.
Communication challenges. Communicating synthesized “conclusions,” 
with all the uncertainty, heterogeneity, missing data, and so forth, is another 
pandora’s box of complexity. Only in the most unequivocal case, where all 
such questions were resolved, would it be possible to provide an unambiguous 
answer.
The prototype had to “take in” new findings and display them alongside similar 
findings, without worry about how they relate to one another. Differences—in 
source, in quality, in intervention, etc.—can be shown rather than interpreted. 
That is sufficient for demonstration. Thus a systematic approach to accepting 
and presenting evidence was adopted. However, this approach brings with it 
risks of different sorts. Editorial decisions about which dimensions of a finding 
to show (e.g. should the information be quality rated, and should that quality 
rating be shown?) are a source of bias, as are visual design decisions (e.g. how 
prominent to make the quality information, and how to communicate it). It 
places the burden of understanding on the user, who must interpret the various 
dimensions and make meaning of them as a whole. No finding is considered 
more important or relevant than another; data are unweighted, so that a 
less reliable finding about a certain drug may appear next to a much more 
reliable one. The process of “aligning” disparate data for consumption can be 
called harmonization. They may be made to conform in presentation, if not in 
underlying format.
Translation
Because the prototype deals with data about outcomes useful to researchers, 
but not necessarily to patients, translation is a fundamental principle. It is 
not enough to take findings from evidence and present them as is. For one 
thing, it is likely that with a high-level issue in mind—“I’ve been sleeping badly. 
Will methotrexate help me sleep better?”—a patient might not know which 
“research outcome” to hunt for, nor where to find it. Translation begins with 
a layer of UI that orients ordinary people to the high-level domain or concept 
(sleep) first, and subsequently finds appropriate evidence to display. However, 
because the prototype is intended to be elastic and systematized, it would be an 
anti-principle to manually re-encode sleep-related findings, and build a bespoke 
sleep-oriented UI. Instead, the roots of an automated way of this translation 
is necessary. Similarly, translation in this sense includes replacing jargon with 
plain language. And using visualizations to translate statistical findings into 
graphical representations that might be more understandable than the statistic 
as a number.
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This principle guided the creation of a simple controlled vocabulary for 
retrieving appropriate findings for given high-level concepts. It also led to a 
text-light UI with as little narrative text as possible; in general, data points 
stand alone, devoid of significant context. That could make elements harder 
to understand, but it also means that the UI components are more flexible. 
For instance, a general relative risk comparison visualization component was 
developed that shows the risk relative to baseline for any outcome. It has a very 
general design that can accommodate evidence about RA improvement after 6 
months for multiple medications compared to placebo, or show the relative risk 
of a single adverse event. It is optimized for neither—it translates from a relative 
risk statistic to a visualization, but probably does not translate in an optimally 
understandable way for either case.
Cognizance of bias and framing effects
A discussion of the many potential sources of bias in the prototype, from the 
methodologies employed in seeking evidence to encode, to the data schema, 
to technical decisions and tool choices, to UI and visualization choices, could 
be a lengthy thesis of its own. Suffice it to say that there are many sources of 
bias in the authorship and development of this thesis project, and that live on 
in the prototype platform. However, this principle insisted only that bias be 
explicitly acknowledged when possible, even when it decisions were made that 
introduced a non-ideal bias.
Objectivity is impossible, so there were explicit decisions to guard against bias 
in areas as diverse as:
 Evidence (e.g. quality, selection, inclusion, omission, and level of detail 
encoded).
 Balance of gist and precision.
 Visual design (e.g. color, scale, text vs. image, ordering and position of 
elements).
 Cultural references.
 Linguistic choices (e.g. grouping certain outcomes under a plain language 
term like “overall improvement”—a deliberate, biasing positive framing).
 Use of data (e.g. inclusion, omission, numbers and charts vs. narrative, 
dealing with missing or unavailable data).
There are many ways in which end-user interpretation of health information 
can be biased by design decisions. The way in which a finding is presented—
if it is “framed” positively or negatively, made larger, colored red or green, 
displayed visually or as a number, expressed as an absolute value instead or 
as relative odds, and so on—can introduce a framing effect, a cognitive bias 
that tends to lead understanding one way or another. All design decisions 
are editorial in this way; an understanding of known best practices from risk 
communication literature (Akl et al., 2011; Perneger & Agoritsas, 2011; For 
example Trevena et al., 2013), as well as general design training (e.g. in gestalt 
psychology) can help during the intuitive design process.
Reinforcing the principles of systematization, elasticity, re-usability, and 
the notion that the prototype is a general system, essential design decisions 
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were made to both adopt certain best practices, and to make an effort to 
avoid some framing effects (while accepting the introduction of others). For 
example, the Navigator application prototype is a greyscale UI, and has little 
framing text. Both of these decisions are intended to “let the data” speak 
without introduction of color or significant persuasive rhetorical language as 
potentially biasing elements. However, those choices themselves introduce a 
potential framing effect—the attempt to be “neutral” and to focus user attention 
on the data (findings) themselves may bias how meaning is made. Study of 
the prototype and its present visualizations with real patients and clinicians 
would uncover some of these effects. On the other hand, much literature 
(including articles referenced above) have pointed to the less-biasing effect of 
presenting health-related outcomes as absolute risks, and using icon arrays 
(Galesic, Garcia-Retamero, & Gigerenzer, 2009) to help low-numeracy people 
understand such data, and so the Navigator opts to show those data more often 
than relative risks. The first re-usable UI components are those that take into 
account some of the best practices from that risk communication literature.
The best way to summarize the state of bias and framing effects in the 
prototype platform and example applications like the Navigator is that there 
are such issues. One immediately obvious example is that it presently contains 
a tiny sliver of evidence about RA medications, but does not (and can not) 
clearly communicate the boundaries of that sliver of evidence in a quantitative 
way. A layperson could easily be fooled into thinking that data they see in 
the Navigator are complete and authoritative, when they are not. Ultimately, 
each tool built with such a platform should do its best, given its purpose, to 
address bias. The next step for uncovering the details about bias and framing 
effects in the prototype would be research and discussion with outside parties—
specialists, end-users, and so on.
Tailorability
Health information and guidance tailored to its audience, and sometimes 
entirely personalized to “speak to” its audience as an individual, is often more 
effective than a generic equivalent (Hawkins, Kreuter, Resnicow, Fishbein, & 
Dijkstra, 2008; Kreuter, Oswald, Bull, & Clark, 2000). Here, tailoring might be 
about the user interace itself (how the evidence is presented), and also about 
highlighting evidence that is (either directly or in an inferred way) applicable 
to the end user. The capacity to so personalize the prototype—to as many 
dimensions as possible, such as age, sex, gender, lifestyle, values, health 
history, sociocultural setting, literacy level, numeracy level, and physical 
capacities—was a desired quality, but difficult to support. While this principle 
was considered early on in development, supporting it with appropriate atomic 
data encoding was deliberately avoided to focus on other problems. Because 
population details—for example, demographic and health status data about 
participants in trials—are reported so heterogeneously, and often do not resolve 
to an easily encodable pattern or conclusion (like mostly women with severe 
active RA of > 5 years duration), it was not clear that the additional difficulty that 
finding a suitable way to capture those data would “pay off” for the purposes 
of the prototype. However, the prototype does allow some tailoring in terms 
of filtering: For example, the medication list can be limited to those that are 
suitable for a basic set of preferences around dosage form and whether one 
drinks alcohol regularly. On the other hand, little effort was made to tailor 
messaging or the presentation of findings themselves.
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Working with evidence
There is a dizzying array of sources of potentially valuable evidence about 
RA medications. This project was largely inspired by the lack of available 
numerical, machine-readable data from biomedical research with which to 
create rich, interactive create data-driven resources. Thus sources from the 
scholarly literature were prioritized. Other kinds of evidence—patient-reported 
data from Web sites like PatientsLikeMe (see Chapter 2), or interviews from 
sources like Healthtalk.org (also discussed in Chapter 2)—could complement 
the scholarly sources quite nicely in an online resource were it possible to 
incorporate them.
Outcome data from systematic reviews or meta-analyses was preferred over 
findings from individual clinical trials, product literature, observational 
studies, and other sources—although there are data from such sources in the 
spreadsheet. Despite the name systematic review, not all findings or results in 
systematic reviews are reported as systematically as they are reviewed. One 
review of conventional DMARDs’ effects on pain in inflammatory arthritis 
(Steiman et al., 2013) illustrates the challenge of working with such sources. In 
some cases, systematic funnel plots and tables were shown for interventions 
on a per-disease basis, and in other cases the data were selectively reported 
in sentence form. Systematic reviews and meta-analyses tended to report 
on included trials’ quality, assessing them for randomization, blinding, and 
other sources of bias. Many (especially Cochrane Collaboration reviews) 
employed the GRADE estimate-rating system (G. H. Guyatt et al., 2008). Even 
still, some reviews and meta-analyses were of concern because of author links 
to pharmaceutical companies (For example Jansen, Buckley, Dejonckheere, 
& Ogale, 2014) although these links were usually disclosed. Some systematic 
reviews, and especially network meta-analyses employed complex biostatistical 
methods that were beyond the comprehension of a beginner in this domain, 
casting doubt on whether it was appropriate to encode findings from them. For 
the practical purpose of finding data for the prototype, descriptions of many of 
the more complex methods had to be glossed over. Ultimately, little data were 
encoded from such sources, illuminating a weakness of “independent study” of 
this domain. “On-the-ground” collaborators with specialized knowledge would 
be necessary to build on the prototype thus far.
Selection of evidence
In the event that a “real” platform were to grow from this prototype, the 
review and selection of evidence would become a much larger methodological 
concern. For the purposes of the prototype, evidence about RA medications 
was selected according to these heuristics, always with the guiding principle of 
sufficiency in mind:
 Is it specific (about a specific DMARD, rather than a group of 
medications)?
 Is the population general enough for the data to be relatively widely 
applicable?
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 Is it relevant to a domain of health of concern to RA patients? For 
the moment, this heuristic meant that findings about erythrocyte 
sedimentation rate were excluded, for instance.
 Is the finding relatively easily encodable? In a few cases, findings are too 
complex to encode—but that is rare.
 Is the finding high quality? This heuristic required a good deal of reading, 
since the humble author of this thesis project is a newcomer to the world 
of medical evidence. However, in general findings that came from sources 
with lower risk of bias were preferred.
 Are the heterogeneity and uncertainty in the finding acceptable? (See 
below for an elaboration.)
Statistical literacy
There are simple heuristics to evaluate the quality of sources of evidence—for 
instance, preferring peer-reviewed meta-analyses and systematic reviews whose 
authors have few or no ties to the pharmaceutical industry. However, these 
heuristics are ultimately inadequate, both for a first-pass selection of evidence 
and for the future work of aggregating and synthesizing data. Statistical 
methods—such as those employed in the production of network meta-analyses—
are so specialized that there exists a scholarly discipline—biostatistics—devoted 
to them. And multiple academic journals are devoted to the topic. For the 
practical purpose of finding data for the prototype, descriptions of methods 
had to be glossed over. There is a danger in assuming that the statistical 
methods are appropriate, and therefore the estimates of effect trustworthy.
Heterogeneity and uncertainty
These two concepts suffused selection and use of evidence in the prototype. 
In an ideal world, data would be uniform—that is, what is measured, how it 
is measured, and its encoding and documentation would be identical from 
source to source. However, that is obviously not the case. Systematic reviews 
and meta-analyses bring a sense of uniformity to evidence by applying 
advanced statistical methods to data. A good deal of the prose in these scholarly 
publications is devoted to explaining heterogeneity and defining more uniform 
concepts to organize the data in the review. For example, consider the 
following excerpt under the heading “Evidence base” from Jansen et al. (2014), 
a systematic review of the comparative efficacy of biologic DMARDs on PROs in 
patients with an inadequate response to conventional DMARDs. Bold emphasis 
was applied to highlight statements addressing heterogeneity.
Most of the trials were multi-centred and included patients 
predominantly from Europe and North America. The RCTs were 
generally considered to be good quality ( Jadad score range 3–5). 
All included trials were double blind with appropriate description of 
drop out of subjects, although the method of randomisation and 
blinding was not always reported. The majority of the studies 
included adult patients with diagnosis of RA based on the ACR 
1987 revised classification criteria. All studies included DMARD-
IR patients. Although the definition of DMARD-IR [intolerant or 
inadequate response] varied somewhat between the studies, it was 
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most commonly defined as patients with active disease despite of [sic] 
previous treatment with traditional DMARDs. The traditional DMARD 
was often specified to be MTX [methotrexate], although in fewer 
studies it was unspecified. Other definitions included inadequate 
response to prior DMARDs, or patients who are either intolerant to 
MTX, or the use of MTX is inappropriate. The TEMPO trial included 
patients who were non-responders to DMARDs but disqualified patients 
who had failed MTX treatment. Given this difference, the study was 
excluded from the network meta-analysis. The definitions of active 
disease varied in terms of the minimum levels of ESR (10 mm/h, 
28 mm/h) and CRP (2 mg/dl, 1 mg/dl, 1.5 mg/dl, 7 mg/ml), as well as in 
terms of the minimum number of required tender and swollen 
joints. Not all studies reported whether RA disease duration and 
DMARD treatment duration determined eligibility.
( Jansen et al., 2014)
Here is another example from Wee et al. (2012), a systematic review of the effect 
of biologic DMARDs on work participation, under the heading of “Statistical 
analysis:”
A meta-analysis to assess the overall effect of biological agents on 
work participation in RA could not be performed due to extended 
heterogeneity with respect to study populations, outcome measures 
and statistical analysis. Therefore, narrative summaries are provided.
(Wee, Lems, Usan, Gulpen, & Boonen, 2012)
Heterogeneity in outcomes, measurement, populations, intervention details, 
follow-up time, study design, etc. all contribute to the difficulty of comparing, 
synthesizing, harmonizing, or even just “bringing together” findings from 
multiple sources. From the same systematic review is this note about 
heterogeneous outcomes:
Almost all studies used different approaches to assess work outcome 
comprising self-composed questionnaires, validated instruments 
or existing databases reporting on work outcomes. Although 24 
instruments are available to assess absence from work and/or 
presenteeism, only few a studies used one of these instruments (work 
productivity and activity impairment questionnaire, RA work impact 
scale, work productivity survey—RA, work limitations questionnaire, 
workability index and health and labour questionnaire). Even then, 
comparability remains limited as these instruments also differ in 
recall, concepts of absenteeism and presenteeism and whether or not 
impact on work should be attributed to RA or overall health. Moreover, 
some studies presented results on a group level (means/median) while 
others on the individual patient level (proportion of patients with sick 
leave or presenteeism). Also, most studies used different definitions to 
describe employment status such as: being employed, additional years 
worked, work disability rate (official or self-perceived) and job loss. For 
example, one study defined employment status as differences between 
groups in gaining or remaining employed. Another study reported on 
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hours working per week, which made it unclear whether this referred 
to employment status (contract hours) or also included productivity 
loss due to sick leave.
(Wee et al., 2012)
These situations are enough to make one throw up one’s hands in exasperation 
and defeat, especially when there is otherwise little evidence about the domain 
of interest—for example, RA treatments and work-life outcomes. In some cases 
statistical methods exist for pooling and estimating effects from studies that 
use different measures, but these methods require substantial expertise and 
thus could not be applied in an automatic way. In many cases, heterogeneity 
(especially in terms of the population that was studied) was simply accepted—
however, it severely limits the applicability of data in the prototype to decision 
making. A candidate for future work is a rich and applicable encoding 
system for the population to which findings apply, so that users could tailor 
presentation to only include evidence that is more likely to be relevant to them.
With respect to uncertainty, there is no best place to begin. In many sources, 
findings were noted as not being statistically significant—especially comparing 
medications to one another or to placebo. That note was never recorded, 
although from other data in the schema (population sizes, confidence intervals, 
etc.) rough approximations of statistical uncertainty could be recreated in 
software. For the purposes of the Navigator prototype, even those confidence 
intervals have been omitted from visualizations. This is a serious weakness of 
the prototype and an area for future work—especially in terms of visualizing 
uncertainty and studying how understandable those visualizations are (Gresh, 
Deleris, & Gasparini, 2012; Roth, 2012; Spiegelhalter, Pearson, & Short, 2011).
Encoding and data schema
Findings were extracted by reading source articles and manually typing them 
into a spreadsheet. They were encoded in a schema which emerged during the 
course of development. Findings were not encoded systematically: Although 
the encoding strategy accommodates many kinds of outcomes, and therefore 
many kinds of data, the focus was on data points that would demonstrate 
practical value for some of the top issues RA patients might be concerned with, 
described in the next section. For any source, a limited high-level set of findings 
were extracted and encoded. Those are the data that power the Navigator 
prototype and are discussed in more detail in the next section. When findings 
were encoded, they were encoded as completely as possible according to fields 
in the schema.
Although the schema for outcomes itself is not fixed (it is constantly changing 
as the prototype continues to develop), as of February 2016 it consisted of the 
following fields, all visible in the Google Spreadsheet referenced earlier in this 
chapter:
which intervention | comparison | population 
Which of an intervention, comparison (comparator), or population the 
line of the spreadsheet (finding) is about. For any case where there 
is an intervention versus a comparator, there will be two lines in the 
spreadsheet for that comparison: One where the which is comparison 
(the baseline or assumed risk, or comparator data point) and one where 
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the which is intervention (the intervention data point as compared to 
the comparator case).
measure 
Which outcome this finding is about. Each time a new outcome was 
encountered, it was added to the Measures spreadsheet. Examples 
include acr_50 (ACR50 response) and serious_ae (serious adverse event).
measure_detail 
Additional details about the measure. For instance, for ae (adverse 
event or side effect), this field has the name of the adverse event (e.g. 
headache).
metric 
The statistic used to record the outcome. Each time a new way was 
encountered, it was added to the Metrics spreadsheet. Examples 
include ar_100 (absolute risk or frequency out of 100), rr (relative risk), 
mean_score (mean score), and count.
value 
The numerical value, expressed as expected by the metric. For 
example, 24 is a suitable value for ar_100 (meaning 24 out of 100 or 
24%).
value_ci_low 
The lower bound of the 95% confidence interval. Only 95% CI is 
supported; it would have been possible to support other measures of 
confidence and to include a field in order to indicate what measure was 
being used (e.g. interquartile range or 95% CI) but it was not deemed 
relevant for patient exploration of evidence—yet. This is expressed in 
the same metric as value.
value_ci_high 
The upper bound of the 95% CI.
grade 
The GRADE level of evidence for this finding, if available. This probably 
should be renamed quality or certainty and redesigned to include a 
field indicating what system is used.
n 
The number of participants in the study or studies, if applicable.
n_type 
If only the overall n is available (i.e. for all the participants who 
participated in a series of studies), this value is total. If the n refers to 
the number of participants who were in a particular group (e.g. the 
intervention group or the comparison group), this value is the same as 
in which (e.g. intervention).
duration_low 
The earliest or only follow-up time, expressed as an integer.
duration_high 
The latest or only follow-up time, expressed as an integer.
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duration_interval 
The period (i.e. unit of time) that the duration is expressed in. For 
example, day, week, or month.
population 
A description of the population that was studied, if appropriate. This 
is not broken into machine readable parts, because it was not deemed 
necessary for the prototype—yet.
intervention 
A comma-separated list of therapies that made up the intervention. In 
general, generic medication names are used. The primary intervention 
is listed first. The generic name is used by the data processing code to 
look up basic medication information, perform filtering, etc. Examples 
include methotrexate or tocilizumab,dmard.
comparison (comparator) 
A comma-separated list of therapies that made up the comparator. 
If the finding is not about an intervention on its own, devoid of 
comparison, this is blank. If the finding did involve a comparison 
(as is the case when a relative risk was reported), the comparator is 
listed just as intervention would be. Examples include placebo or 
placebo,methotrexate.
dosage 
If which is comparison, the dosage of the comparator, if appropriate. 
If which is intervention, the dosage of the intervention. Dosage if 
usually expressed as a number, then a space, then a unit. Dosage is 
compressed into a single string here, since it can relatively easily be 
parsed if necessary. The individual parts of the dosage string being 
encoded separately did not seem relevant to the high level exploration 
of evidence by RA patients. Examples include 8 mg/kg and 25 mg.
dosage_form 
Like dosage, refers either to the comparison or intervention. This is the 
dosage form or route of administration. Any string of text is valid here; 
in general the values are oral, intravenous, or subcutaneous.
dosage_frequency 
Like dosage, refers either to the comparison or intervention. This is 
how many times the comparator or intervention was taken per dosage 
interval. The interval is calculated by the next two fields.
dosage_multiple 
This is how many dosage_interval periods elapse per dosage_
frequency. For example, if this is 4 and dosage_interval is week, that 
means “every 4 weeks.”
dosage_interval 
The period (i.e. unit of time) that the dosage interval is expressed in. 
For example, day, week, or month.
source 
A hyperlink to the source from which this finding was extracted or in 
which it was found.
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notes 
Any notes or other important annotations about this finding.
kind 
The kind of source that this finding came from. This is not strictly 
enforced, but could be just as metric and measure are. Values include 
systematic review, randomized trial, and meta-analysis.
What people want to know about 
RA treatments
There is evidence about patient preferences for information about RA 
treatments. In general, people with RA prefer to be fully informed about 
treatment options and alternatives (L. Fraenkel, Bogardus, Concato, & Felson, 
2001). However, specific outcomes that patients care about are incompletely 
studied (domains of interest are known, but measures are still in development) 
and relatively infrequently reported. In a survey of 254 RA patients in the U.K. 
(99% of them White) in which respondents rated the importance of plain-
language outcomes, the top 6 were: “Less pain, doing everyday things, no 
more (visible) joint damage, more mobility, enjoy life, and more independent” 
(Sanderson, Morris, Calnan, Richards, & Hewlett, 2010). Pain, ability to perform 
everyday activities, fatigue, psychological distress, ability to cope, overall 
well-being, sleep, and work and social life are all important outcomes to RA 
patients (Gossec, Dougados, & Dixon, 2015). When weighing benefits and risks 
of treatment options, they may value reduction in the risk of bothersome (e.g. 
diarrhea) and grave (e.g. serious infection) side effects more than the likelihood 
of feeling better (L. Fraenkel, Bogardus, Concato, Felson, & Wittink, 2004), 
although benefit (improvement in RA) is still of high utility. The RA Choice 
decision aid issues—onset, cost, side effects, route of administration, and 
other considerations like pregnancy, alcohol consumption, and concomitant 
tuberculosis risk—also underscore kinds of information valuable to both 
patients and clinicians in decision making (Barton et al., 2014). What people 
want to know depends in part on awareness of what there is to know, which 
tools like the RA Choice DA can help make explicit.
What the research community produces
Research on treatments for RA is produced by and for the biomedical 
community. OMERACT, a research collaboration on clinical trial outcome 
measures in rheumatology, formed in 1992 and has over the past two decades 
performed research in and promulgated standardized outcome measures in 
RA clinical trials (Boers et al., 2014). The most well-known and commonly used 
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measures are the “core set” that was adopted (published) by the American 
College of Rheumatology (ACR) in 1993 (Felson et al., 1993):
1. Tender joint count (TJC). Assessed by a physician by physically 
manipulating and examining 68 joints and classifying joints as either 
tender or not.
2. Swollen joint count (SJC). Assessed by a physician by physically 
examining 66 joints as either swollen or not.
3. Patient’s assessment of pain. Assessed by the patient, without 
mediation by a clinician (therefore a PRO), using an instrument like a 10 
cm visual analog scale, Likert-type scale, or similar. The question asked 
and scale anchors vary.
4. Patient’s global assessment of disease activity. Assessed by the 
patient, without mediation by a clinician (therefore a PRO), using a 10 cm 
visual analog scale, Likert-type scale, or similar. The question asked and 
scale anchors vary.
5. Physician’s global assessment of disease activity. Assessed by a 
physician, using a 10 cm visual analog scale, Likert-type scale, or similar. 
The question asked and scale anchors vary.
6. Patient’s assessment of physical function. Assessed by the patient, 
without mediation by a clinician (therefore a PRO), using a validated 
instrument. There are many potential instruments or measures; the 
heterogeneity in these measures introduces harmonization challenges.
7. Acute-phase reactant value. A laboratory assay, either erythrocyte 
sedimentation rate or C-reactive protein level, both ways of measuring 
systemic inflammation.
That these measures exist and are standardized is extremely helpful for 
comparing treatments to one another. These outcomes are used extensively 
in clinical trials research and in systematic reviews and meta-analyses of 
RA treatments. Changes (improvement) in these measures form the base 
of evidence underlying RA clinical practice guidelines and evidence-based 
practice. Improvement is usually measured using a dichotomous outcome 
measure based on the core set. ACR20, for example, means that someone 
showed improvement of at least 20% in both TJC and SJC, as well as in 3 
of 5 additional measures. However, there remains the question of whether 
these measures make sense to patients—especially when someone has a new 
diagnosis, how might they understand the meaning of an improvement in 
tender joint count? Would they understand what ACR20 feels like? Would 
they understand the meaning of a 2 cm reduction in their “global assessment 
of disease activity,” if they started at the 7 cm point on a scale? There is an 
understanding among the research community that patients have concerns that 
might not be addressed specifically by these measures, and that development 
of a “patient core set” to complement the research-oriented outcomes may be 
valuable ( J. R. Kirwan et al., 2009).
Incorporating patient-reported outcomes in research about RA medications 
has been a slow process relative to the pace of change in technology—though 
that is understandable given the rigor with which such outcomes must be 
researched and developed. At the OMERACT 5 meeting in 2002, a research 
agenda on patient-oriented measures was described ( J. Kirwan et al., 2003), 
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but as of 2015 PROs in many important domains remained more or less absent 
from clinical trials on RA medications (Gossec et al., 2015). In the intervening 
time, smart phones had become ubiquitous along with high-speed wireless 
Internet access, and so to almost all data-driven online resources that are 
commonly used today by the general public (e.g. GPS navigation applications, 
travel booking tools, etc.). With or without ready-made PROs, “the challenge 
remaining for rheumatologists is how to effectively communicate the risks 
and benefits related to the many options now available for the treatment 
of RA” (L. Fraenkel et al., 2001).
Can whether people thrive be measured?
Given what matters to RA patients, finding ways of communicating evidence 
about treatment options on their terms should be a priority. Directly applicable 
PROs are ideal, and they might help answer the question of whether an 
intervention will help them thrive, and in what ways. It is naïve to think that a 
clear answer would magically emerge from PROs; it is nevertheless a legitimate 
aspiration to want to be able to frame exploration of evidence in terms that 
are as closely aligned as possible to the mental models or ways of thinking 
and concern that people adopt when learning about treatment options and 
engaging in medical decision-making. There are common scenarios in which 
the evidence in the scholarly literature that is available may be difficult to 
communicate:
 There is relatively little evidence on an outcome that matters to 
patients. For example, on work and social life, or sleep.
 There is a good deal of evidence but it is recorded using measures 
that indirectly bear on health domains or concepts that matter to 
patients. For example, ACR50, which means 50% improvement in TJC 
and SJC as well as on 3 of the 5 additional ACR core set outcomes. It is 
difficult to map or translate that outcome onto patient-important domains 
(e.g. pain, sleep, work, etc.). Adverse events are another illustrative 
example. Clinically-oriented evidence, like systematic reviews, frequently 
report the proportion of people who withdrew from clinical trials of a 
medication due to a serious adverse event. That is an important measure 
of medication safety, but does not necessarily address the fact that 
patients consider non-serious side effects like nausea and diarrhea as 
important as serious side effects.
 PROs are used, but data are subsumed by composite measures. 
For example, someone “experiencing” ACR50 (i.e. 50% improvement) 
probably experiences a reduction in pain, but not necessarily a reduction 
that they would report as a 50% improvement on a 10 cm visual analog 
scale. The data on pain reduction itself are obfuscated. Even still, 
there is the legitimate question of whether someone who is not used to 
“recording” their own experience of pain would even understand the 
data if it were available.
In these cases, it is probably important to translate findings into a more 
understandable form. Since it is more or less impossible to explain precisely 
what happens to the whole physical, psychological, and social experience of 
someone who experiences 50% improvement, translation is certainly difficult. 
There are some basic techniques that might be applied:
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 Summarize in prose. For example, after 1 year of treatment with Enbrel 
(etanercept), it is estimated that about half the people taking it would 
experience a 50% improvement in their RA—tender and swollen joints, pain, 
and ability to do their daily activities.
 Use visualizations. These could include icon arrays, line charts, or other 
graphics.
 Complement with other evidence about what people who have 
experienced this outcome may also experience. For example, people 
who had a 50% improvement in their RA after 6 months were doing pretty 
well in terms of their ability to keep working 5 years later. On average, they 
only had to take about 4 days off work per year.
 Complement with anecdotes from people who have experienced 
this outcome. Interviews—in text, audio, or video formats—with people 
who “just” experienced the outcome (e.g. ACR50—50% improvement—
after 6 months or 1 year) could enrich understanding of the measure.
Of course, there is also the problem that these data are not commonly available 
in machine-readable form, so they cannot even be easily integrated into an 
automated system for translating evidence.
Settling for an issue focus
To facilitate exploration of evidence in the prototype, and to achieve a 
modicum of automated “translation” of extant data, an effort was made to 
support retrieval of evidence in terms of issues. Like the Mayo Clinic decision 
aids (see Chapter 2 for references), RA Choice decision aid (Barton et al., 2014), 
and MAGIC decision aids (Agoritsas et al., 2015), the Navigator prototype 
organizes evidence presentation according to these topics. Put simply, an issue 
is a patient-important question or concern. There is theoretically no conceptual 
boundary around how vague or abstract an issue can be; for practical 
purposes, it makes sense to consider issues as at the level of “exercise” or 
“feeling well” or “daily routine” as the most abstract, and “pain” as the lowest-
level, or closest to atomic clinical measures.
The prototype platform supports arbitrarily tagging outcome measures with 
plain language terms that reflect these issues. The Navigator prototype UI 
demonstrates use of just a few of these tags to help people understand the 
impact of RA medications in terms of a few of those important areas:
 Basic issues. Practical concerns like medication names, cost, route of 
administration, contraindications, etc.
 Overall improvement. Reduction in the signs and symptoms of RA. 
In other words, the benefits of treatment on the disease process and its 
symptoms.
 Pain. Reduction in pain.
 Work. Ability to continue working.
 Side effects. Both serious and non-serious adverse events associated with 
medications.
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Subsequent discussion focuses on the practical problems of working with and 
designing for evidence used in the Navigator prototype, though it applies more 
broadly. Before diving into those five issues, it is necessary to explain how 
evidence is “translated.”
Harmonization & translation 
layer
Because there is sometimes a disparity between what people want to know 
about RA medications and the outcomes found in research data, it is not 
enough to just encode findings. Imagine that you have just been diagnosed 
RA, and have a question about how well you will generally feel if you take 
methotrexate by injection, once a week. “How well you feel” is a subjective, 
complex evaluation of your experience, but in this case it can reasonably be 
reduced to a composite of how the medication might make you feel, how it 
might affect your RA, and how that change in your RA is likely to affect how 
you feel and consequently how your life might change. If you feel better, and 
the medication is tolerable, perhaps you will feel a lot better than you do 
now, partly because of the relief you will experience from the medication but 
also because you might exercise more, eat differently, and so forth. Although 
no evidence can answer the question fully nor predict the likelihood of 
methotrexate working, there are sources that address some of the questions 
individually:
 How the medication might make you feel. Data about adverse events, 
testimonials or other anecdotal evidence from patients who have taken 
methotrexate, the advice of a physician based on clinical experience with 
hundreds or thousands of patients, etc.
 How it might affect your RA. Data from clinical trials or systematic 
reviews, clinical practice guidelines, epidemiological studies, testimonials 
or other anecdotal evidence from patients who have taken methotrexate, 
physician knowledge, etc.
 How the change in your RA is likely to affect you how feel. 
Epidemiological studies, clinical trials, cohort analyses from patient 
registries, testimonials or other anecdotal evidence from patients who 
have taken methotrexate, physician knowledge, etc.
For each rough category (such as data about adverse events) there are many 
potential sub-sources. In that case, they may include product literature, post-
marketing safety surveillance databases like openFDA (Kass-Hout et al., 2015), 
various kinds of retrospective studies, clinical trials, systematic reviews, and 
even anecdote. Each source may have—in fact is likely to have—its own way of 
encoding findings. For example, there may be detailed data about how likely 
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a particular side effect is, or there might be a single number describing how 
many people in a given population stopped therapy because of any adverse 
event. The same general category of adverse event (say, gastrointestinal distress 
of some sort) may described using any number of idiosyncratic terms. Perhaps 
a given adverse event was more common when methotrexate was combined 
with another DMARD in a common therapeutic scenario. The challenge of 
harmonization is finding a conceptually and technically adequate way of 
aligning these data points, such that they can be presented sensibly to someone 
with a question like “how well will I generally feel if I take methotrexate by 
injection, once a week?” Data-oriented harmonization might focus on ensuring 
maximum quality and consistency in the data. User-centered or patient-
centered harmonization might focus on abstracting away unnecessary nuance 
to provide useful conclusions. The practice of medicine is messy, and with 
imperfect evidence decisions must still be made.
The prototype as originally envisioned would feature the capacity to harmonize 
(or make comparable) similar findings measured with slightly different 
outcomes. Then, it would use data visualization or interactive UI to make the 
data more understandable than if it were presented in a table or paragraph 
of text. Because of time constraints, lack of expertise, and a combination of 
homogeneity in certain outcomes and lack of evidence for others, only a very 
limited capability has been built so far. It effectively has two parts:
 A controlled vocabulary to “organize” findings and guide user navigation.
 Data visualizations (also guided partially by the controlled vocabulary) to 
take arbitrary outcome data and visualize them.
Figure 3-3 shows how the prototype “retrieves” evidence according to the 
user’s request, given a top-level issue of concern like overall improvement. 
Data processing code and individual data visualizations employ the controlled 
vocabulary to find the appropriate data, process it, and display it in the desired 
form. In the future, qualitative data might be an effective complement alongside 
individual findings. For example, video interviews with patients describing 
their experience of pain relief could be retrieved alongside information about 
how well medications may reduce pain.
Controlled vocabulary
Controlled vocabularies—like that used by the Library of Congress to index 
publications—are sets of predefined terms, and sometimes relationships 
between them, that may be used to organize or describe concepts in a given 
domain and facilitate information retrieval. They are routinely used in 
medicine (Cimino, 1998). A simple controlled vocabulary for the prototype 
grew organically as findings were added. (The controlled vocabulary is also 
part of the data spreadsheet.) It is disentangled from data, such that someone 
reviewing evidence and adding findings to the data spreadsheet does not have 
to be at all concerned with translating to patient-friendly terms. The translation 
layer of this vocabulary and UI and data visualizations “takes care” of that 
translation.
 Measures. These are the various ways that effects of RA medications are 
gauged or coded—generally outcomes. For example, in the prototype ACR 
50 is considered a measure (though ACR 50 is itself a composite measure), 
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and so is erythrocyte sedimentation rate. Typically, these measures are the 
key kinds of findings that are reported in research about RA medications. 
Ordinarily they are reported in jargon, and represent investigations of 
outcomes or factors important to science rather than necessarily to issues 
that patients are likely to understand or care about. Each data point in the 
spreadsheet reports a finding for one of these measures.
 Metrics. A single statistic, recording a finding in a given measure, has 
to be reported in a certain way. For example, if the outcome was people 
who achieved the ACR 50 level of arthritis improvement, how was this 
improvement measured? The relative chance someone might achieve 
ACR 50 with one treatment compared to another? A count of people who 
achieved it? The absolute frequency—out of 100, or perhaps 1000—of 
people who achieved it? These are the details described by the metric. 
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Figure 3-3
Schematic diagram 
of the prototype’s 
simple controlled 
vocabulary.
Each data point in the spreadsheet reports a finding using one of these 
metrics.
 Tags. Because measures are usually researcher-oriented, even a well-
visualized representation of a particular statistic might mean nothing to 
an ordinary patient. After all, one might ask “what does ACR 50 mean?” 
A succinct description helps, but is insufficient to provide a kind of 
wayfinding guidance given a potentially confusing array of measures 
and apparently endless research. In order to provide straightforward 
navigation to research that may bear on patient-important issues, 
measures are tagged with plain language terms that describe what 
the measure is about. For example, ACR 50 is primarily about overall 
improvement, and therefore tagged as such. TJC (tender joint count) 
is mostly about pain (as in painful joints), so it is tagged as such. These 
“tags” are used by the data processing code to find and group data.
The controlled vocabulary is ultimately responsible for finding the evidence 
relevant to a given high-level issue like pain.
The Navigator prototype: 
Exploring evidence about 5 issues 
related to RA medication options
Basic issues
As described in the introduction, living with RA is complicated. Medical 
treatment is an overarching concern in that its effects suffuse the experience 
of living with RA, but contrasted with living with RA, deciding on a medication 
is a relatively small effort. However, the medication itself does demand 
tangible effort and attention. The first category of information in the 
Navigator prototype deals with these tangible concerns and basic facts about 
the medications—many of which (e.g. cost, route of administration, and 
concerns like pregnancy and alcohol consumption) emerged from the user-
centered research process employed to develop the RA Choice decision aid 
(Barton et al., 2014). They include:
 Medication name and brand names. It may be important to know that 
drugs go by multiple names, and that material that someone encounters 
could refer to the medication by any of those names.
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 Drug class or type. People may hear about “biologics” or “TNF alpha 
inhibitors,” so medications that fall into this category should be clearly 
marked as such.
 Route and schedule of administration. People may have preferences 
for one form over another; for example, someone might refuse to 
perform a self-injection. Others may not feel comfortable with their 
capacity to take two pills a day, and still others may not want to travel to a 
clinic for infusions.
 Cost. Although ultimate out-of-pocket cost varies with insurance 
coverage, a rough idea of the cost may be a critical concern for patients. 
Some of them can cost upwards of $40,000 a year.
 Lifestyle adjustments, comorbidity risks, and contraindications. 
Although a physician would obviously know and discuss these concerns 
with their patients, patients may want to know which medications are 
safer given their personal health status and lifestyle considerations. For 
example, someone who drinks alcohol regularly and does not want to (or 
cannot) give that up should be able to learn which medications are safer 
for them. That is equally true for people with comorbid conditions.
This information satisfies fundamental requirements around informing people 
about treatment options. It also may play a role in someone anticipating 
whether they have the capacity to integrate a treatment into their life, helping 
to find the “right care” that is minimally disruptive (Leppin et al., 2015). The 
data supplying this part of the platform largely came from the RA Choice 
decision aid (Barton et al., 2014) and a systematic review of use of biologic 
DMARDs in patients with RA and comorbid conditions (Richards et al., 2015). 
Additional evidence that might enrich this domain includes other lifestyle 
impacts (e.g. on eating and food), whether side effects are tied to the schedule 
of administration, and necessary clinical visits or routine tests associated with 
the medication.
93
Figure 3-4
Basic issues 
visualization in 
the Navigator 
prototype.
Because medications are the primary “object” of concern in the prototype, this 
basic medication information is encoded as a JavaScript object in the source 
code, instead of in a spreadsheet like other evidence.
Presentation
Each medication is represented in its own rectangle—a “card” of sorts (see 
Figure 3-4). The generic drug name is largest, and common brand names 
listed beside that. Drug names can be difficult to pronounce, so a phonetic 
transliteration sits beneath the generic drug name. The route and typical 
schedule of administration are relatively large, and situated next to typical 
cost. The bottom of the card has a “risk strip” of icons and titles corresponding 
to lifestyle considerations, comorbidities, and risk concerns. For each, the 
medication is labeled OK if it is safer, Unsafe if it is contraindicated, or Not sure 
if no evidence was encoded or it is unclear.
The cards respond immediately to filtering. The user of the Navigator prototype 
can tap or click on preferred dosage forms or preferences, such as a checkbox 
called “Safer for liver disease.” Medications that do not match the selected 
preferences are reduced in contrast. In the “risk strip,” each that conflicts 
with the user’s preferences is boosted in contrast so that the “reason” why a 
medication was disabled is expressed visually.
Overall improvement
This issue attempts to capture and present evidence about the benefit of 
medications (i.e. positive outcomes related to controlling RA and its signs 
and symptoms). For reasons already discussed, this is a particularly tough 
domain. One might expect patient questions like “will this medication help 
me feel better?” But it is hard to answer that question given the ways that RA 
medication effectiveness is measured in research. The ACR core set is the 
gold standard of measuring benefit outcomes. ACR20 (20% improvement) is 
considered sufficient for a drug company to claim a “reduction in the signs and 
symptoms of RA” (Food and Drug Administration, 1999), but it is not clear what 
that feels like from a patient perspective. ACR50 (50% improvement) and ACR70 
(70%) improvement are routinely reported. Other measures are also found in 
the literature, including several ways of measuring remission (absence of signs 
and symptoms of RA disease activity), the component measures or instruments 
of the ACR core set (e.g. disease activity score, health assessment questionnaire 
scores, etc.).
Working with evidence about overall improvement
For most of the 12 DMARDs in the prototype, there was evidence available 
in systematic reviews from the Cochrane Collaboration library (Katchamart, 
Trudeau, Phumethum, & Bombardier, 2010; Lethaby et al., 2013; Lopez-Olivo et 
al., 2014; Lopez-Olivo, Amezaga Urruela, McGahan, Pollono, & Suarez-Almazor, 
2015; Maxwell & Singh, 2009; Mertens & Singh, 2008; Navarro-Sarabia, Ariza-
Ariza, Hernandez-Cruz, & Villanueva, 2005; Osiri et al., 2003; Singh et al., 
2009; Singh, Beg, & Lopez-Olivo, 2010; Suarez-Almazor et al., 2000). Other 
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sources were also consulted (Golicki et al., 2012; Jansen et al., 2014; Katchamart 
et al., 2010; Smolen et al., 1999; Strand et al., 2014; Williams et al., 1985).
As is the case for all the findings encoded in the Google spreadsheet, data 
were manually re-encoded in the schema that emerged during development. 
They were not systematically and completely encoded. For the purposes of 
prototyping and according to the guiding principle of sufficiency, only some 
findings were extracted. Since the prototype is intended to demonstrate that 
findings from multiple sources could be shown side by side in the prototype, 
it was not necessary to extract all outcome data. During the development 
process, enough literature had been reviewed and that ACR50 outcomes as 
reasonable for prototyping purposes. Other outcome data were sometimes 
extracted and can be seen in the Summary of findings prototype UI and in the 
Google spreadsheet.
What is perceived as effective in terms of overall improvement?
This question dominated the process of extracting data to show “overall 
improvement.” Although ACR20 is considered a “response” to a DMARD, it 
may not be sufficient for a patient to consider themselves significantly relieved. 
FDA guidance to manufacturers says that a claim of “major clinical response” 
requires statistically significant response of ACR70 continuously for 6 months 
in an adequately controlled clinical trial of at least 7 month duration (Food and 
Drug Administration, 1999). FDA cites data showing reference response rates at 
end of trial in a “comparative multicenter trial” of methotrexate (n=119) versus 
auranofin (n=118) of:
 Methotrexate 
ACR20: 65% 
ACR50: 35% 
ACR70: 9%
 Auranofin [gold salts] 
ACR20: 29% 
ACR50: 18% 
ACR70: 6%
Since even FDA does not consider a response below ACR70 to be sufficient 
to support a claim of “major clinical response,” it seems that ACR20 is an 
unreasonably poor response to communicate to patients as “effective” in 
terms of overall improvement. Cochrane reviews of DMARDs routinely report 
estimates of effect for an outcome of ACR50 at certain point (e.g. 12 months 
after treatment begins), which is also below the FDA standard of major 
response. This outcome is rephrased as “major improvement” in the Cochrane 
review of methotrexate for RA; the estimate of effect from that review is 23% of 
patients showing ACR50 at 12 months (Lopez-Olivo et al., 2014). Corresponding 
evidence in reviews for other results—such as functional outcomes—provide 
context for what ACR50 response means for those more granular outcomes. 
Secondary analysis of clinical trials whose primary endpoints were ACR 
responses also provide context. For example, such an analysis of data from 
the FIN-RACo trial of multiple-therapy with conventional DMARDs and 
corticosteroids looked at work capacity and disability 5 years after treatment 
began, stratifying participants into groups by their response at 6 months. 
Patients who had ACR50 response at 6 months also had better work and 
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disability outcomes at 5 years than those who had achieved an ACR20 response 
or lower (Puolakka et al., 2005). Considering the prevalence of ACR50 response 
in systematic reviews, and additional context, it emerged as a reasonable 
endpoint to report for overall improvement. However, an unsolved problem is 
how to truly help patients make meaning of that figure.
There is considerable heterogeneity even among Cochrane systematic reviews 
in terms of estimates of effect and follow-up time for ACR50 response. 
Occasionally estimates are produced based on a long follow-up time—for 
example, 79% of patients seeing ACR50 at about 3 years for therapy with 
etanercept plus another DMARD (Lethaby et al., 2013). In other cases, the 
follow-up is much shorter—for example, 30% of patients seeing ACR50 at about 
6 months for therapy with tocilizumab plus methotrexate (Singh et al., 2010). 
That presents immediate challenges for communicating clearly to patients 
about these medications: Does one have to wait for 3 years to see the full effect 
of a medication? Would the ACR50 response for tocilizumab plus methotrexate 
be sustained at 1 year, 2 years, or 3 years? Also, is 30% of patients seeing a 50% 
improvement a good outcome? Is 79%? In studies of how RA patients rated 
the utility of statements about medications in terms of “trading off” between 
alternative treatment options, the phrasing “75% (75 in 100) of people receiving 
this drug will feel much better” (mean score 61) received a much higher utility 
score than “45% (45 in 100) of people receiving this drug will feel much better” 
(mean score 7) (L. Fraenkel et al., 2004). The latter example is much closer to 
the typical ACR50 outcome data found for inclusion in the prototype, which 
might be a concern. People might find the “truth” about the medication’s 
effectiveness—as measured by ACR50—to be not useful. PROs for improvement 
might be a preferable alternative, should they come to be used more frequently.
It is obvious that any serious spelunking in the RA literature by a motivated 
patient would require some guesswork about the meaning of these measures. 
First, the population studied in each of the sources of evidence may be 
different—and in fact, they usually do vary. Biologic DMARDs are usually 
a second or third-line treatment, and estimates of their effects are thus 
usually derived from research on their use by people who have not achieved 
an adequate response with methotrexate or other first-line treatments. 
Every person has their own unique understanding of their body and well-
being, and consequently of their experience of RA, if they have it. Thus 
each patient has their own mental model of benefit and harm, although it 
is likely a flexible model. Without aid, to help someone form a specific—and 
hopefully somewhat realistic, in spite of the subjective nature of experience—
mental model for each measure, there is likely to be limited consistency and 
usefulness in the interpretation of data. In other words, one person might 
think 50% improvement means complete success while another might think it 
is insufficient—indeed, there is no right or wrong answer. Such interpretation 
depends on where someone is in their life, in their disease process, their social 
support system, and other context. Qualititative research about the human 
experience of these outcomes might prove useful.
Presentation
Outcomes are evaluated at a certain point in time (follow-up time). These 
follow-up times may be heterogeneous from study to study, since there are not 
necessarily standards for the evaluation of all outcomes. While the follow-up 
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time may not be of interest to patients for all outcomes, for some they may be 
essential to a full understanding of the evidence. For example, if one wants 
to know both when a medication might take effect and how long a particular 
benefit (e.g. 50% improvement) might be sustained, reporting data about that 
outcome at various time points—say, 3 months, 6 months, 1 year, and 2 years—
may be appropriate. In other cases, simply knowing that an outcome had 
occurred by a particular time is adequate—for instance, evidence that within 1 
year, 5 people out of 100 in a clinical trial would have stopped a medication due 
to a serious side effect.
Overall improvement data from systematic reviews reported ACR50 at a 
variety of follow-up times, sometimes as a range. In a review of etanercept, 
the estimate of ACR50 was reported with trial follow-up times as a range from 
24 to 156 weeks (Lethaby et al., 2013). When such a range was reported, the 
prototype uses the upper bound. For the purposes of this visualization, it is 
assumed that treatment effects are cumulative—for instance, by the upper 
bound of the follow-up range, a certain number of trial participants would have 
experienced the ACR50 outcome.
In order to illustrate this outcomes “over time,” an abstract schematic outcome 
timeline (see Figure 3-5) was designed to plot outcomes on a horizontal display. 
In order that the icon arrays could remain large enough, the timeline is large—
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Figure 3-5
Overall 
improvement 
visualization in 
the Navigator 
prototype.
potentially indicating the need for a large display on which to visualize multiple 
medications. The Navigator prototype UI is responsive, meaning that it adapts 
to different display sizes. On smaller displays, the timeline is collapsed so that 
milestones (time points) at which there are no data for a given drug, are hidden.
Pain
Like fatigue, pain is a pervasive and cross-cutting symptom of RA. Even among 
patients who say their RA is “somewhat-to-completely controlled” a large 
proportion are dissatisfied with pain control, and those people report greater 
fatigue and poorer outlook (Taylor et al., 2010). Inadequate pain control is 
associated with worse psychosocial health status; it is also a factor that can be 
manipulated to have a positive effect on psychosocial health (Courvoisier et al., 
2012). Pain is also a top treatment priority for RA patients (Sanderson et al., 
2010). Treatment with anti-inflammatory drugs—such as NSAIDs like ibuprofen 
or celecoxib—may have an effect on symptomatic inflammation and pain. But 
treating the RA disease process itself with DMARDs should also have an effect 
on patient pain, so it is reasonable to report data on their effect on pain. After 
all, other pain relievers may be undesirable to or contraindicated for some 
patients. Pain is a by nature a patient-reported outcome (PRO) but rarely the 
primary endpoint of studies about RA treatments. It is part of the ACR core set, 
as mentioned in the prior section on overall improvement outcomes.
Working with evidence about pain outcomes
In many studies, including reports from trials included in Cochrane systematic 
reviews of DMARDs (For example in Lopez-Olivo et al., 2014), pain outcomes 
(usually recorded a 10 cm or 100 mm visual analog scale or VAS) are reported 
using a mean difference statistic: The difference between the mean pain score 
for people in an intervention group and the mean pain score in a control 
group, at a certain time point, such as 6 months after starting treatment . In 
some trials, mean change in pain score (not difference between intervention 
and control) is reported, sometimes with initial baseline scores (For example 
in Smolen et al., 1999). However, sometimes both these and other statistics are 
used, even in systematic reviews (for example in Steiman et al., 2013), making 
extraction of findings more difficult. Mean change or mean difference on a VAS 
may be common ways of reporting pain outcomes, but they are not the only 
ways: A review of 241 trials of interventions for fibromyalgia found 75 pain-
related outcomes (Reported in Busse et al., 2015).
In an article on behalf of OMERACT recommending strategies for reporting 
pain outcomes in clinical trials, Busse et al. (2015) ask important questions 
related to the meaning of measuring and reporting on pain to patients, such 
as: “10 mm on a 100-mm visual analog scale (VAS) for pain may be statistically 
significant, but is it important to patients?” (Busse et al., 2015). They point out 
that because not everyone will experience that “average” effect, it may be more 
beneficial to communicate the proportion of patients who “report an important 
reduction in their pain.” But then, what is important? That depends on the 
patient, obviously, and their experience of pain and how it interferes with their 
life. As Busse et al. note, 10 mm on a 100 mm scale is considered a minimally 
important difference (MID) based on studies of the instrument, but that may 
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not map to an important difference for 
patients: “In the absence of consensus 
on what constitutes a patient-important 
threshold in pain relief, it is reasonable 
to provide a range of options. To provide 
guidance in this regard, participants 
of the 2014 OMERACT Workshop 
advocated for reporting either an 
appreciable reduction from baseline 
pain (e.g., 20%, 30%, or 50%),” or a 
number of dichotomous outcomes, 
which in investigating evidence for the 
purposes of this prototype were rarely 
encountered (Busse et al., 2015).
The prevailing format of pain-related 
outcomes encountered during research 
for the prototype were mean changes 
on a VAS. Many of the challenges in 
harmonizing data reported using other 
scales (like effect size) with VAS scales, 
including conversion to a meaningful 
standardized unit, have been deferred 
to future work with the prototype. Two 
pain-related outcomes are supported—
mean change (from baseline), and 
difference in mean change between 
placebo and intervention (mean 
difference). In the prototype, a simple 
process standardizes findings as an 
overall estimate of change in pain in 
MID units. All findings must be represented as a mean change. Findings that 
report a mean difference must have a reasonable placebo mean added to the 
difference, so that it becomes an overall mean change from baseline, no longer 
a difference. Instead of taking the placebo mean from the source estimate, all 
placebo means for all intervention vs. placebo comparisons are pooled, and 
their unweighted mean calculated—the pooled placebo mean change. (That 
assumes—perhaps naïvely—that placebo estimates are reasonable to compare 
from source to source.) The pooled placebo mean change is added to the 
intervention’s mean difference value, turning it into a final mean change in 
score that can be converted to MID units. A more sophisticated method would 
consider sample sizes, variance, heterogeneity (e.g. of dose, in duration of 
follow-up, or population), and perhaps pool findings for each intervention to 
determine an overall effect size for that intervention—effectively, automated 
meta-analysis. For now, each individual estimate is simply reported as a mean 
change in pain as MID units.
Presentation
The need to show change in a standardized unit—which could be MID, standard 
deviations, or some other metric—led to the development of a generalized 
display loosely based on a visualization in certain decision aids published 
by the Mayo Clinic (See the Depression Medication Choice and Diabetes 
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Figure 3-6
Sketch of 
interactive 
change in pain 
visualization. Data 
for this sketch 
from Steiman et 
al. (2013). The 
methotrexate 
estimate is the 
center of the range 
reported in those 
data (20 mm to 31.4 
mm lower). The “if 
you start at” line 
is fictitious; the 
data do not report 
change from that 
specific baseline 
value.
Medication Choice decision aids from Mayo Clinic Shared Decision Making 
National Resource Center). Earlier sketches (see Figure 3-6) explored displaying 
change in pain on an interactive representation of the visual analog scale. On 
that design, the user might specify an initial (baseline) pain score, and see 
the relative change with each medication. However, that presented obvious 
challenges since the estimated change in pain might extend past the scale’s 
edges if someone felt they had especially mild pain and the medication effect 
was large. Such an interactive scale would require data about the relative 
strength of effect given different baseline pain levels.
Instead of an interactive display, the current visualization (see Figure 3-7) 
shows the expected change in square blocks representing MID units. The 
expected placebo change is at the top of a vertical list. Each intervention can be 
compared to the other interventions visually. Fine differences (less than 1 MID) 
are omitted visually to simplify the presentation. Although this visualization 
is here described in terms of change in pain scores, it can be adapted to show 
changes in any standardized unit, and the MID customized.
Work
Although “working” is not necessarily a top treatment priority for RA patients, 
enjoying life and being able to do everyday things are (Sanderson et al., 2010). 
For someone who has been forced to stop working, because of fatigue, pain, 
loss of function, or depression, returning to “normal” may include being able 
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Figure 3-7
Change in pain 
visualization in 
the Navigator 
prototype.
to work. It also may mean the capacity to earn a living and be financially stable. 
When it comes to any medical treatment, a reasonable question is: Does this 
treatment help people live the way they want to live? This is absolutely the 
kind of outcome that is exceedingly difficult to measure. But if medications to 
treat RA are evaluated by their ability to reduce symptoms and slow disease 
progression, perhaps there is an association between primary outcome 
measures—like the ACR core set—and quality of life outcomes like ability to 
work. And perhaps communicating such evidence could give people an idea of 
what they might expect not just in the next few months, but the next few years.
Evidence about work-related outcomes
Predictably, there are myriad ways to measure work-related outcomes. They 
include employment status, absenteeism, presenteeism (attending work 
while ill), days worked, years worked, likelihood of stopping work, hours 
of productivity lost, utilization of disability resources, retirement rate, 
work productivity impairment, and other outcomes. These may be patient-
reported (e.g. self-reported impairment) or gathered from other sources, like 
government data about disability benefits distribution. Perhaps because of the 
difficulty in teasing apart the effects of individual medications themselves on 
work-related outcomes, it is easier to find research where such outcomes were 
analyzed secondary to usual RA outcome measures, and where medications 
are grouped and compared—for example, looking at biologics generally versus 
conventional DMARDs.
Out of 12 systematic reviews in the Cochrane library which were used as 
sources for data for the DMARDs included in the prototype, only the one on 
methotrexate included analysis of a specific work-related outcome (Lopez-Olivo 
et al., 2014). Other studies seem more representative of work-related evidence. 
For example, secondary analysis of data from a trial of combination therapy in 
a cohort of Finnish RA patients (Puolakka et al., 2005) found that patients who 
saw the greatest benefit from treatment at 6 months—remission or ACR50—had 
lower work loss 5 years later, regardless of the therapy. Eriksson et al. (2013) 
compared change in work loss for people with RA who did not respond well 
to methotrexate, and were then randomized to combination therapy—biologic 
(infliximab plus methotrexate) or conventional (hydroxychloroquine, plus 
sulfasalazine, plus methotrexate). Treatment adjustments were permitted: 
“Both sulfasalazine and hydroxychloroquine could be discontinued and 
replaced by cyclosporin A (2.5 mg/kg/d in divided doses; increase allowed to 
5 mg/kg/d), and infliximab could be discontinued and replaced by etanercept 
(50 mg/wk)” (Eriksson et al., 2013). Prior to randomization, the mean days of 
work loss per month for those non-responders was 17 (SD 13). This study found 
that either kind of combination therapy decreased the median days of work 
loss over time, with the maximum improvement seen between 8 and 12 months 
after randomization. By 21 months, the group receiving conventional treatment 
fared slightly better, but the authors concluded that there was no significant 
difference between treatment groups.
While the OMERACT collaboration has helped standardize many RA outcome 
measures, the heterogeneity in work outcomes and related study design 
makes working with such data more difficult. A systematic review of the 
effect of biologic DMARDs on work participation concluded that biologics 
probably show positive results on absenteeism and presenteeism compared 
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Figure 3-8
Sketch of a work-related outcome visualization. In this visualization, the medications themselves 
are deprioritized in favor of explicating that the work-related outcome at 5 years is secondary to a 
primary overall improvement outcome at 6 months. Data from Puolakka et al. (2005).
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with usual care “although no pooled effect size could be calculated due 
to the heterogeneity of all data ”(Wee et al., 2012). The authors discuss 
shortcomings in the included studies that hamper comparability, including 
that work participation was a secondary outcome in all but 2 of 19 studies, that 
populations varied significantly from study to study, and that the evidence left 
unresolved questions like whether biologic DMARDs have additional benefit 
compared with intensive DMARD treatment since “few of the studies in this 
review compared TNF with intensive DMARD treatment.” They conclude their 
review by saying: “To enhance the comparability of studies, consensus on 
preferred outcome instruments and recommendations on the conduct and 
reporting of studies on work participation is recommended.”
One additional wrinkle in looking at these outcomes is that work participation 
at diagnosis or start of treatment may be one of the best predictors of later 
status (Olofsson et al., 2014). It may be that effective communication to patients 
about how RA treatment might help them sustain, improve, or return to work 
has to do with tailoring evidence to their current status. Regardless of how well 
treatments work to improve symptoms, it may be that someone whose RA has 
driven them to leave work may have difficulty returning even after improving.
Implications for the prototype
The upshot of the evidence on RA treatments’ effect on work seems to be that 
a good response to medications (ACR50 or better), ideally before RA has led 
one to reduced employment or productivity, is associated with decreased work 
disability over the longer term—regardless of the specific treatment. Attempting 
to find and work with evidence about work participation was challenging, 
providing a forceful counterpoint to the hypotheses of this project itself, and 
to methods chosen to work with other kinds of evidence. First, there may not 
be a sufficiently broad and clear base of evidence to draw from. Second, the 
evidence may not be easily encodable—due to heterogeneity, a much more 
sophisticated schema might be necessary to encode all the relevant details. 
Third, the data might be difficult to harmonize and display for similar reasons: 
It may be that the populations, study designs, and outcomes are simply too 
different to report in a coherent and consistent way, as per Wee et al. (2012). 
Fourth, individual medications or combination therapy may not matter much, 
although the prototype is entirely geared towards findings about individual 
medications. It may be that evidence generalizable to “biologics” could be 
“copied” to each medication, but that might be disingenuous in presentation, 
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Figure 3-9
Sketch of an 
alternative work 
loss outcome 
visualization. Data 
from Puolakka 
et al. (2005).
as if there was research on each medication when in fact there was not. 
Ironically and to summarize the counterpoint to this project, it may be that 
a few sentences more clearly communicates the upshot of evidence on work 
participation.
At the time of writing, the prototype contained very little evidence about 
DMARDs’ effects on work participation and status, and the question of how to 
combine heterogeneous data remained unresolved.
Presentation
In order to present evidence about work-related outcomes, the prototype 
probably needs to accommodate and clearly explain the “grouping” of 
treatments. In other words, whereas the other major issues are reported on a 
per-medication basis, somehow data would need to be grouped to show that it 
applies to all biologics or to conventional DMARDs, generally. It also probably 
needs to similarly accommodate and display outcomes secondary to a given 
primary outcome. In that case, users might be prompted to understand what 
they might expect if whatever treatment they choose leads to remission, vs. ACR 
50, vs. ACR 20, etc. In that way, it may be that this kind of secondary outcome 
evidence would help answer the question, “what does it mean to have a 50% 
improvement?” Sketches for communicating evidence about work participation 
explored these possibilities, but the prototype has not yet been extended to 
support them (see Figure 3-8 and Figure 3-9).
Side effects
Intuitively, knowledge about potential harms of medications—side effects or 
adverse effects—are essential to informed medical decision making. Like any 
pharmaceutical products, DMARDs can produce side effects, bothersome 
and serious. Relatively non-serious side effects may play an outsized role in 
patient preferences for RA medications (L. Fraenkel et al., 2004). Adequate 
balanced presentation of evidence about side effects is desirable because of 
their importance to patients in medication choice. The side effect profile of a 
medication can give someone a sense of what to expect from it, perhaps more 
so than focusing on a single side effect. However, because of heterogeneity in 
both study and reporting of side effect data, these may be particularly difficult 
to harmonize and present in a non-misleading way. Consider the following 
principles which might underlie effective presentation of side effect data:
 Show that the side effect is a true side effect of the medication, rather 
than a common experience of humans in general, or people with RA (i.e. 
that it occurs at a rate statistically greater than placebo). Good data would 
disambiguate RA symptoms from medication effects, and from baseline 
human experience.
 Show how common the side effect is (i.e. incidence or frequency).
 Communicate likely onset and duration of the side effect (i.e. when it is 
most likely to occur and how long it tends to last). Some are associated 
with each dose, some with the body adjusting the medication, while 
others might happen after a long duration of use.
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 Communicate severity or intensity of the side effect, including whether or 
not that intensity is dose-dependent. Put another way, how much the side 
effect interferes with feeling well or living well, and whether that effect 
varies with the dose.
With such information, one could learn that one medication tends to cause 
intense nausea in half of people who take it for the first few days, but that it 
tends to go away. Another might increase the risk of non-serious infection 
slightly but only with use for a year or so. Or another might cause rarely cause 
slight dizziness, but if it did, cause it with each weekly dose and never really 
go away. Such information is a kind of guidance about what to expect with the 
medication. Unsurprisingly, the great heterogeneity in side effect data means 
that answering such questions is rarely possible. A brief discussion of certain 
sources of side effect data illuminates this problem.
Sources of side effect data
Sources of side effect data include product monographs (Structured Product 
Labeling or SPL), registries of patient data, post-marketing surveillance 
databases (including electronically through openFDA), patient-reported 
outcome data (Web sites like PatientsLikeMe for example), post-marketing 
clinical trials and systematic reviews or meta-analyses of such post-marketing 
data. Each source has weaknesses in terms of biases related to data collection 
and reporting, intended audience, and access.
Product literature. An obvious starting point for side effect data is literature 
supplied by pharmaceutical companies. Such literature summarizes side effect 
(adverse reaction) data from clinical trials of drug products before they are 
brought to market, and updated with some data about side effects observed 
after they are brought to market (post-marketing data). There is considerable 
variation in the ways that side effect data are studied and reported in product 
literature, partly owing to flexibility afforded manufacturers by regulators (See 
Guidance for Industry on Adverse Reactions in Food and Drug Administration, 
2006). These sources report adverse effects heterogeneously enough so as to 
make aggregation both impractical and potentially misleading. Data may be 
trapped parenthetically in sentences, non-systematically reported, with or 
without incidence rates. Even when data are presented in a table, they are not 
semantically encoded and easily machine readable. Even more concerning 
are data disparities which do not make comparison from monograph to 
monograph straightforward.
For example, the SPL for etanercept (“ENBREL labeling,” 2015) reported 
adverse effects in RA patients observed during the course of relatively 
long clinical trials—from six months to two years. The SPL for tocilizumab 
(“ACTEMRA labeling,” 2014) reported adverse effects in RA patients from trials 
of 24 weeks’ duration—even though the labeling itself indicates that thousands 
of patients were studied for much longer, up to 3 years. In the etanercept 
SPL, infection rates (bacterial, viral, or fungal) in the 2-year study were 81% 
for people taking etanercept vs. 86% for people taking methotrexate (the 
comparator), and 50% for etanercept vs. 39% for placebo in 6-month studies. 
In the tocilizumab SPL, infection rates were not pooled together, and reported 
for the 24 week trial duration. For tocilizumab monotherapy at a dose of 8 mg/
kg, upper respiratory tract infections (7%), nasopharyngitis (7%, common cold), 
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and bronchitis (3%) were reported separately and do not differ significantly 
from reported rates among patients treated with methotrexate alone or placebo 
infusion plus another DMARD. Nasopharyngitis and bronchitis are plausibly 
outcomes resulting from viral or bacterial infection, but not indicated as such. 
If none of those three outcomes occurred concurrently for trial participants, 
the true rate of any infection could be 17% or higher. But because the side 
effects were reported individually, there is no way of knowing. The two SPLs 
present side effect data that are difficult to reconcile.
An ordinary person might consider respiratory infections, the common cold, 
and bronchitis to be similar—although perhaps a common cold to be less 
serious. The same might go for muscle pain, muscle weakness, musculoskeletal 
pain, and joint pain, which may be difficult to disambiguate. Nevertheless, the 
pharmaceutical company can effectively obfuscate the true incidence of side 
effects by reporting these separately and on their terms instead of in patient 
terms. There is an inherent risk of bias or distortion in that the research is 
usually funded by the manufacturer, and submitted to regulators as part of 
the drug approval process, to prove that the drug is safe. Moreover, terms like 
nasopharyngitis and asthenia are technical. A controlled vocabulary to translate 
or group these terms into patient-relevant language would be necessary, or they 
need to be manually translated at the time of encoding into a data source like 
the spreadsheet for the prototype.
Registries. So-called “patient registries” are databases of observations 
of patients in the real world. They vary in design: Some may feature 
representative samples of patients with a single condition and detailed 
longitudinal data, while others may have limited data for much more diverse 
populations. Particularly for adverse effects, they may be a more reliable 
source of data than product literature and clinical trials, since they often allow 
researchers to “follow” patients for a greater length of time (years instead of 
weeks or months), and may feature more consistent reporting of side effects 
from drug to drug. A number of RA patient registries exist, with surprising 
variation in patient comorbidities, average RA disease activity, and other 
characteristics (Curtis et al., 2010). While registries might be a good source of 
side effect incidence, their data are not generally openly available. Because 
research agreements might have been required to access data, they were not 
pursued as data sources for the prototype.
Post-marketing surveillance databases. National or supra-national regulators like 
the Food and Drug Administration (FDA), Health Canada, and the European 
Medicines Agency, operate surveillance systems to monitor the safety of 
medications once they have been approved and are for sale. Access and 
machine-readability of such data varies. Of these three agencies, only FDA 
supplies machine-readable data suitable for integration with software like the 
prototype (Kass-Hout et al., 2015). Although openFDA provides an application 
programming interface (API) for real-time inquiry of up-to-date adverse 
reaction data, the format of the data limits their value in the prototype. For one 
thing, it is not possible to query a priori for results in which the medication in 
question was the primary or suspect drug; such processing must be done on 
the whole set of reported adverse events. Furthermore, data are unvalidated, 
causal relationships between the drug and reaction need not be proven for a 
report, reporting is voluntary, and there is no way to estimate the incidence 
of such side effects in the population at large (See Drugs API reference on 
openFDA, FDA, n.d.).
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Patient-reported data online. Web sites like PatientsLikeMe have patient-reported 
side effect data, though they are not made available to external developers (see 
Online consumer health resources in Chapter 2). These data benefit from being 
reported on patient terms and in a naturalistic setting (the real world), but they 
are unvalidated. As such, they might well complement controlled study data.
Post-marketing clinical trials, systematic reviews, and meta-analyses. Research 
specifically investigating the safety or adverse effects associated with RA 
medications might establish individual side effects as endpoints of interest. 
From a clinical perspective, though, it may be more important to investigate 
serious or life-threatening side effects than less-serious ones. Systematic 
reviews routinely report a broad serious adverse event outcome, and frequently 
on withdrawals from clinical trials due to adverse events, but not always on 
detailed but patient-important side effects. Data on individual side effects may 
be reported using heterogeneous measures, and with varying levels of detail 
on side effects, not unlike product literature. A thorough 291-page review of 
Leflunomide for RA (Osiri et al., 2003) devotes space to a few specific side 
effects or groups of side effects: Alopecia (hair loss), elevated liver function 
(sign of liver injury), GI symptoms generally, allergy or rash, hypertension, 
weight loss, and infections generally. A more recent review of methotrexate 
for RA (Lopez-Olivo et al., 2014) has data for 28 individual adverse reactions, 
ranging from diarrhea to stroke and even death.
Working with side effect data
In order to compare the relative likelihood of side effects with one medication 
or another, sources that provided an estimate of incidence were preferred. 
The outcome measure is dichotomous—the side effect occurred, or has not 
occurred, by the follow-up time. Onset, intensity, and duration of side effects 
were not reported features of side effect data. Like other data, side effects were 
manually encoded into the spreadsheet. Purely because side effect naming (and 
therefore identification) is so heterogeneous, these data call out for at least 
limited harmonization. Variation in follow-up time, population and setting, and 
dose are also sources that indicate the need for harmonization. The primary 
metric—frequency of side effect—is generally consistent, so converting to other 
scales or measures is generally unnecessary. Occasionally they are reported in 
relative terms, as a relative risk or odds ratio versus a competitor.
Grouping side effects into patient-important clusters (for example, those 
suggested in L. Fraenkel et al., 2004) requires both an ontology and a method 
for determining an appropriate frequency to report. Without a comprehensive 
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Figure 3-10
A side effect 
visualization in 
the Navigator 
prototype.
ontology, aligning side effect terms (e.g. gastrointestinal distress with GI 
symptoms with stomach upset) is a non-trivial challenge. It is important to 
know when terms are synonymous, and when terms subsume others—for 
instance, that infection of any kind encompasses upper respiratory tract 
infection. Even if side effects can be aligned or grouped it is not clear which 
frequency of which side effect is an appropriate estimate. The highest reported 
frequency might be a rough guide—so as to say, “up to 30% of people taking this 
medication got an infection of any kind.” A range may be more appropriate, 
if harder to interpret. Displaying frequencies for a larger number of more 
specific side effects may mislead by appearing to underestimate the chance of 
experiencing a side effect, but more accurately represent the real likelihood.
Since the prototype does not employ an ontology, the chief harmonization 
challenge is one of follow-up time. Given the etanercept vs. tocilizumab 
example above, it is misleading to report side effects without a notion of the 
follow-up time. However, a good solution to this problem remained unresolved 
at the time of writing, since follow-up time in data about adverse events was so 
heterogeneous. Ultimately, a mixture of sources—including product literature 
and systematic reviews—was used to populate the prototype.
Presentation
Since data to show onset, intensity, and duration of side effects had not been 
found for the prototype, only reported frequency is displayed using an icon 
array visualization as with data on overall improvement (like ACR 50). One side 
effect can be viewed at a time in the Navigator prototype (see Figure 3-10 for an 
example). Each medication has its own “slot” to display data for the selected 
side effect. In the event there is no estimate of the frequency of that side effect 
for a given medication, that is clearly indicated and the icon array is dimmed. 
This is an area of the prototype that would benefit from devoted improvement.
Technical architecture
There is a proliferation of contemporary and free-to-use software development 
technologies and tools. They range in scope from programming languages, to 
databases, to instrumentation systems, to frameworks and libraries that speed 
development, permit communication between software systems, or facilitate 
creation of certain parts of software. Such libraries may be used for converting 
data from one format to another, or controlling user interface elements, or 
creating data visualizations. These may be combined in virtually limitless ways, 
as needed, into what is called a stack of technologies—a software project’s 
architecture from soup to nuts. For any software project—and particularly those 
whose source code is to be shared with a wider community—the choice of tools 
is important, because it to some extent dictates and constrains the potential 
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of the software. Projects written esoteric programming languages will be less 
maintainable and readable by other developers. Projects that employ a less 
popular platform may benefit from fewer helpful and ready-made libraries, 
which means that their developers must shoulder more of the programming 
burden—sometimes reinventing the wheel, as it were. While a thorough 
discussion of technology-choice tradeoffs is beyond the scope of this thesis, it 
is an important feature of the prototype, so a brief elaboration of the specific 
choices follows.
Programming language and platform
The prototype is written primarily in JavaScript, a popular programming 
language used especially widely for Web-based software. JavaScript is a good 
choice because many parts of the prototype, from its underlying platform to 
user-visible data visualizations, can be written with it, and benefit from ready-
made frameworks also written in JavaScript. Thus fluency gained while working 
on one part of the prototype was easily transferable to work on other parts. 
JavaScript also smooths interactions between data and logic; in most cases 
data not in the spreadsheet in the prototype is represented in JavaScript Object 
Notation ( JSON), a format readily processed by logic written in JavaScript, 
and also widely used on the Internet for transfer of data between services. 
JSON is a “lightweight” key-value pair data representation format, simpler 
than alternative data formats like XML—indeed, it has been called “the fat-free 
alternative to XML” (Crockford, 2006). Basic medication data (from JSON) and 
spreadsheet data (outcome data) are processed and converted to JavaScript 
objects by the prototype.
The prototype is built with Node.js (Node) as the underlying platform or run-
time environment. Node was chosen because it is open source, its primary use 
case is Web-based applications, Node applications are written in JavaScript, 
and there exists a significant repository of Node-based open-source libraries 
and frameworks to speed application development. For example, the prototype 
uses Express.js—a Web server—to “listen” to HTTP requests and “serve” or 
respond with Web pages from the prototype. It also uses lodash, a library to 
speed up data manipulation.
Data encoding, storage, and retrieval
One of the most significant questions early in the development process was 
that of what technology to use to encode data, and how it could be retrieved 
by the prototype. A few dominant concerns governed the choice of Google 
Spreadsheets over other options—mainly a database technology like MySQL, 
PostgreSQL, or MongoDB, storing the data in files (such as text files), or 
encoding or storing the data directly in the software, alongside logic. These 
concerns revolved around ease of development, and satisfying one of the 
prototype’s key objectives: To demonstrate ease of adding, updating, and 
ultimately using data. To choose a convenient or reliable technology, but one 
which did not satisfy that important requirement, would be inappropriate.
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Briefly, the most important requirements for data encoding and storage 
included the following:
 Data should be quickly and fluidly entered, ideally using a familiar user 
interface.
 Some structure, to guide input, could be easily imposed, but also changed 
easily.
 No programming skill should be necessary to add data.
 Multiple contributors should be able to collaborate and add data.
 It should be possible to annotate data.
 Data should be easily updated or added, with real-time reflection of the 
new.
 There is no need to build a user interface de novo to manage data input 
and editing.
 One system should accommodate all the data necessary for the prototype.
 The system should be free of charge.
 Data should be easily exported, should needs change.
Several options and dimensions were considered to arrive at a minimally 
effective solution.
Data in code. Situating data in the software code itself, alongside data, is 
generally unsuitable because it would be difficult for non-specialists to use. 
Although it would be checked in to a source-management system (GitHub), it 
would generally require some programming skill, and would not satisfy the 
requirement for fluid data entry using a familiar user interface. In general, data 
would be stored in text files and highly structured—perhaps in JSON format, 
which features an idiosyncratic and strict syntax—but not in a way that is 
easily changed or annotated. In such cases, it would be nearly impossible to 
“see” or filter an overview of data. Depending on the organizational scheme 
chosen, it could also be that the data themselves could become entangled with 
or encroach on the logic code, which would make it difficult to disentangle 
and share reusable parts of the code without the data. Basic medication data is 
stored “in code,” though in its own file, separated from logic.
Text files. Storing data in text files suffers from most of the same problems as 
situating it in source code itself; in fact, it is a nearly identical solution except 
that there would be a strict separation of logic (code) and data. There would 
remain the same problems of accessibility, organization, format, and so on.
Databases. At first glance, it would seem that many database technologies 
satisfy the requirements outlined above. However, there are more arguments 
against them, chief among which is that there only rarely are accessible 
user interfaces for editing data in databases. In most cases, graphical user 
interfaces for editing databases are designed for and used by administrators of 
the database; those interfaces serve as control or maintenance mechanisms, 
rather than authoring tools. For a database that would be hosted alongside the 
prototype, an additional tool would need to be found and hosted elsewhere, 
and special credentials provided to contributors—more work than is ideal. For 
commercial database services hosted by a third party provider, such as Mongo, 
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authoring access would depend on their tools, which are more complex than 
a spreadsheet, or a custom interface would have to be created from whole 
cloth specifically to support the needs of collaboration, annotation (generally 
not supported by any database administration user interface), and a flexible 
structure.
Schema. Indeed, the second major argument against using a database has to do 
with structure, or schema. Most database technologies require that the fields 
and overall structure and connections between data be defined a priori. That 
is not a universal requirement, but it is most common, especially among freely 
usable database technologies. The prototype required flexibility of structure; 
the “right” ways of organizing data needed to emerge as the prototype was 
developed. Thus a more restrictive, schema-requiring database technology was 
not ideal.
Cost, licensing, and other issues. The remaining significant issues with using 
a database technology include cost and licensing, ease of configuration and 
maintenance, quantity of data and protocols for retrieving and using it in the 
prototype, and capacity to export data. Since the prototype is intended as 
a demonstration of repeatable methodologies for creating useful interfaces 
with medical evidence, it was preferable to avoid any third-party services with 
notable cost or licensing restrictions, or (admittedly subjectively evaluated) 
difficult setup or maintenance schemes. Relatively “open” (readily licensed or 
integrated) and unrestrictive database technologies, like MySQL, have more 
onerous and complicated configuration and maintenance, while those featuring 
easier setup (for instance, services offering database hosting) can cost money 
(such as the provider Compose.io).
Quantity of data and protocols. The prototype uses a minuscule quantity of 
data—several dozens of kilobytes—that easily fits in working memory. The 
prototype’s source data are also heterogeneous and richly interconnected by 
their relationship to a small number of entities of interest (RA treatments), 
with any given user activity requiring records throughout the dataset. In other 
words, a typical scenario benefits from the software being able to “work with” 
the whole dataset in memory, alongside the running prototype. If the prototype 
used a typical database model, it is likely that multiple queries would have to 
be made to the database in sequence, slowing the software down to the point 
that it could interfere with the user’s perception of its speed; with the data in 
memory, it can be manipulated much faster, with minimal latency. Although a 
database technology could be used, and queried by the prototype to retrieve 
all documents to store them in memory, its other strengths would have to 
outweigh relative weaknesses, since the most obvious benefits (efficient storage 
and querying of large datasets) are practically insignificant for the prototype.
Data portability. Although it is preferable for the prototype’s data storage 
technology to remain in service and useful for as long as possible, that it may 
not is a risk. The best way to mitigate that risk is to choose a technology that 
provides for data portability: A straightforward way to get the data out of the 
store, in a format that can easily be repurposed and reused. Some database 
technologies support export, using administrative tools, but in many cases 
software would have be written from whole cloth to do just the export. As 
in the immediately prior case, relative weakness in terms of data portability 
would have be outweighed by other major benefits to argue in favor of using 
a database technology; the most readily used database technology, MySQL, 
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supports this export by way of multiple queries and third-party administrative 
tools, but imposes some burden.
The solution: Data in Google Spreadsheets
During initial stages of the prototype’s development, Google Spreadsheets (GS) 
was used for encoding and exploration of structures for data. It offers a familiar 
spreadsheets user interface, is free to use, and enables rapid entry of data, and 
relatively quick structural changes. When it came time to find a way to export 
or use data in the prototype software itself, it became clear that it was actually 
a suitable data store for the prototype, satisfying most of the requirements: 
The key discovery was that Google provides a JSON API that can be used to 
query a spreadsheet in real time, returning the data in its cells in a way similar 
to how a database might be queried. The working prototype thus uses GS as its 
data back-end, in lieu of a typical database technology. An example of a similar 
product using GS as a back-end—Snake Oil Supplements—was discovered during 
development and is reviewed in Chapter 2. The benefits of using GS are:
 An easy to use user interface that future contributors could easily use to 
add data to the prototype.
 Similarly, a user interface that supports collaboration and annotation and 
public viewing of the evidence.
 Fast data entry and real-time updates. Data or parts of the controlled 
vocabulary can be edited in the spreadsheet, with changes reflected 
immediately in the prototype.
 A readymade API for querying data and returning it as JSON, easily 
processed by the prototype.
 Data can be easily exported.
 Schema-free design, so that the data schema can emerge and change, 
which is necessary for a rapid iterative development process.
The very same reasons GS was an attractive tool for early data-encoding 
experiments make it a suitable choice for the prototype, especially as it 
is intended to demonstrate a workflow or model for non-programmer 
researchers, designers, and clinicians to collaborate. It features a user interface 
accessible in almost any contemporary Web browser and updated frequently by 
Google; the user interface exploits a common mental model (the spreadsheet) 
familiar to many computer users. Thus GS facilitates rapid data entry and 
editing. Moreover, unlike administrative interfaces for databases, GS supports 
revision control, real-time collaboration by multiple parties, and annotation of 
individual data elements—annotations that are visible in the spreadsheet, but do 
not have to be exposed in the software. The collaborative nature of GS extends 
beyond editing the spreadsheet: It also features a graphical form designer that 
creates Web-based submission flows that could be used to solicit data.
Multiple kinds of data are stored in the spreadsheet: Adverse event data, 
measure names and descriptions, metric names and descriptions, a controlled 
vocabulary of patient-centered issues, and more. The spreadsheet model 
supplies adequate structure. While it is possible for anyone working with the 
source data to make errors in data entry (about as easily as with any of the data 
storage options), and perhaps more likely to make schema errors (putting the 
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wrong kind of data in the wrong place or in the wrong format) they are easily 
corrected—though by whom is a question of collaboration and quality control 
outside the scope of this research paper.
Most importantly, because the total quantity of data used by the prototype is 
so small, it’s suitable to store it all in memory; a quick workflow or pipeline 
from data entry or edit through to use in the prototype is both desirable and 
possible. The GS API enables such a pipeline: The prototype uses the API to 
query for all the data in all the spreadsheet, reprojects it into a useful JSON 
format, and stores it in memory. The query happens once—when the prototype 
is opened by a user—and returns all necessary data to the client (the user’s 
browser). Subsequent filtering and manipulation is handled by the prototype 
logic, as needed. However, this model facilitates such rapid iteration that 
a value can be changed in a spreadsheet and immediately reflected in the 
prototype.
Because GS is a service provided by a third party, Google, there are a pair of 
notable risks to using it. First is that although the service is reliable, there is a 
chance that it (or its API) could suffer a service interruption or be changed, thus 
interfering with the prototype. In the case of an interruption, the prototype 
would temporarily hobbled, unable to retrieve data. A caching strategy could 
mitigate this risk—but was not developed due to time constraints—to ensure a 
recent “copy” of the data were always available to the prototype. In the case 
of an API change, the part of the prototype that queries for data from the 
spreadsheets might have to be rewritten to conform to the new protocol. The 
second major risk is that Google, who operates GS, could permanently disable 
the service (or begin selling it at a cost). In these cases, a new home would 
need to be found—or the cost paid. Luckily, because GS offers excellent data 
portability, it is easy to maintain backups of the full dataset in formats that can 
be readily moved into a new data store.
Front-end and user interface technologies
Contemporary Web-based applications designed for use on desktop computers 
and mobile devices tend to be built using (Hypertext Markup Language) HTML, 
CSS (Cascading Stylesheets), and JavaScript. HTML is a markup language that 
is used to describe the content and—along with CSS—appearance of Web pages. 
Although a typical Web page might be understood as a digital, interactive 
extension of the model of a printed page, a Web-based application as complex 
as Facebook (with all its attendant features, including streaming video, real-
time chat, etc.) is ultimately no different than any other Web page. It is simply 
a more complex one, still reliant on HTML and CSS to describe its content and 
display. However, much of such applications’ complexity comes from additional 
code, usually written in JavaScript. There is no single standard application 
framework for such Web-based software, although almost every Web browser 
renders HTML and CSS, and executes JavaScript; thus they are reliable 
foundational technologies.
The prototype does not demonstrate any novel or complex data processing or 
computation, nor is it intended to be used in any way other than as an example, 
so the most ordinary JavaScript is sufficient for its core logic. However, its user 
interface is the key part of the project, so greater attention was paid to finding 
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an appropriate front-end and user interface framework. A discussion of the 
details of these libraries and their strengths and weaknesses is far beyond the 
scope of this paper, but a brief summary of the chosen framework is germane 
to the orientation of the thesis as a demonstration.
Many user interface frameworks quite strictly separate the JavaScript code 
(which often performs logic to determine what and how to present in the user 
interface) from the HTML code itself. It is often the case that the logic produces 
output data that is “merged” into the HTML using a template system, in much 
the same way that a database of addresses might be used to do a “mail merge” 
and produce neatly designed envelopes. By way of analogy, the envelope 
design would be crafted in HTML and CSS, while some JavaScript code would 
collect the addresses from a database, correctly title the proper nouns and 
check the postal codes, and the template system would finally be used to take 
the output from that code and inject it into the HTML envelope design. While 
a common pattern, it presents several disadvantages for the prototype; the 
most significant is that it would be nearly impossible to neatly present a single 
file that demonstrates a whole user interface concept, such as an icon array 
visualization to show absolute risk. Instead, it would be more likely that two 
or even three separate files would be necessary. If an open-source viewer or 
potential re-user were to want to learn how the visualization worked or even to 
re-use it, they would have to piece together its function from three files.
A second feature of many Web user interface frameworks is that they require 
manual manipulation of the Document Object Model (DOM). Without getting 
too specific, the DOM is structured, hierarchical representation of all of the 
elements on a Web page. Manual manipulation effectively means that any 
part of a Web page that interacts with, or is touched by the JavaScript logic 
of the application, must be manually added, tracked, altered, or removed, as 
appropriate. For a complex interactive application, where user interactions 
might change hundreds or thousands of elements on a page, this can be 
onerous—even when some of the manipulation is automated. One of the most 
widespread such libraries, jQuery, depends on—and effectively is a technology 
for—such DOM manipulation. It is possible to write user interfaces using jQuery 
that minimize the code that is strictly about DOM manipulation, but it is still 
necessary. Such code is overhead, or a kind of “tax” that is not essential to the 
demonstration of the user interface; thus it is preferable to avoid it.
The solution: React.js for front-end programming
React.js (Facebook, n.d.) is an open-source JavaScript library for building Web-
based user interfaces that effectively abstracts these problems, and by doing 
so, is a suitable choice for the prototype: It facilitates the creation of compact, 
self-contained components that stand on their own to demonstrate necessary 
logic and presentation. For example, the same absolute risk icon array 
visualization can be represented using React.js as a single file, neatly presenting 
what it does and how it works to an open-source developer. In a nutshell, 
React.js components are written in JavaScript, and produce (for Web-based 
applications) HTML as their output. To reuse the envelope analogy, the React.js 
component is both the envelope and the template engine: It is simply given the 
addresses, and all the necessary logic for lightly processing the addresses and 
outputting appropriately designed envelopes is in one, self-contained package.
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Even more usefully for complex Web-based applications, React.js automatically 
manipulates the DOM. There is no need for programmers to manually manage 
elements on the Web page; the React.js code simply needs to describe what any 
element should look like and how it should behave, and all of the manipulation 
necessary to respond to user interaction is handled by React.js itself.
115
Chapter 4
Discussion
This project began with a naive optimism and wide scope. The iterative design 
and development process, which always included reviewing and working 
with sample evidence, revealed layer upon layer of complexity that called 
even the premise of the project into question. Counter-arguments abound. 
Some patients do not want or would not directly benefit from greater access 
to medical evidence. Data on patient-important outcomes can be difficult to 
source. Evidence is ordinarily not machine readable. Innumerable social and 
technical barriers hold back the provision of such evidence. Heterogeneity in 
reported outcome measures, study methodologies, sources, data quality, and 
even outcomes themselves—conflicting data about the effects of medications—
is common. Data may not conflict per se, but may be uncertain—because 
of the balance of benefits and harms, or merely statistically uncertain. The 
challenge of harmonizing heterogeneous outcome data alone is enormous, let 
alone synthesis that may ultimately be required to truly make sense of them. 
Even straightforward data about fairly consistently measured outcomes (e.g. 
ACR50) must be translated into language or images that the general public can 
understand, itself a complete domain of inquiry. They may need to be framed 
in terms that a patient cares about, such as effects on daily routine, exercise, 
feeling well—issues. There is the also, of course, question of when and how 
a resource that solved some or all of these problems and presented medical 
evidence to the interested person would actually be discovered and used. 
In other words, the role it might ultimately play in medical decision making, 
patient education or engagement, and so on. There are countless ways in which 
the data might be misinterpreted or misunderstood. Rigorous evaluation of 
design, usability, and evidence-understandability is thus necessary. Together, 
these make up the tidal forces against data-driven resources to enable wider 
access to medical evidence—frankly, for both patients and clinicians.
While all of these concerns were tacitly acknowledged and at least superficially 
understood at the outset of the project, their significance was under-
appreciated. It took a great deal of in-depth experimentation and reading to 
peel back enough layers of the onion, so to speak, for the magnitude of their 
force to become clearer. The path from patient interest to evidence and back 
to the patient again—identifying information needs, finding evidence, encoding 
it, manipulating it, designing presentation of it, and creating a user interface to 
retrieve it, is difficult. 
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One initial purpose of the project was to find a way to bring together evidence 
on multiple outcomes (e.g. pain, overall improvement, side effects, and patient 
anecdote) to “explain” how they might interact and bear on a practical question 
like will this medication help me ride my bike again? It is crystal clear that such 
a purpose was deferred in favor of merely trying to present a minimal set of 
outcomes (e.g. pain, overall improvement, etc.) in isolation—such that someone 
might try to integrate the individual findings themselves and figure out on 
their own how those outcomes interact and bear on the question of playing 
tennis. (A doubtful prospect, indeed.) The original purpose might have been a 
better focus for the user interface design challenges, and perhaps would have 
produced a more meaningful outcome. However, the line of inquiry that was 
pursued, and that led to the prototype that was actually developed, at least 
serves the function of clarifying just how tricky it is to build an application 
that works with medical evidence. Criticism of existing online resources—data-
impoverished text-based Web sites like WebMD—might seem righteous and 
simplistic in light of the realities of developing a data-driven alternative. In 
fairness, there are good reasons for WebMD to be like WebMD. In this thesis, 
expressed skepticism of the status quo is borne of awareness of the potential 
for something better, not utter ignorance. Even if that something better is much 
richer and more sophisticated than the prototype as it stands today—which it 
would have to be. Thankfully, it is ready to support such future work.
Limitations
This thesis is peppered with descriptions of the project’s limitations. It is worth 
mentioning more of them in detail. First and foremost, the prototype itself is 
not suited for use by patients with RA or their caregivers yet. It is accessible, 
because it is open source, but it is restricted from being indexed by search 
engines and therefore unlikely to be accidentally discovered by a casual 
searcher. It is ready for future evaluation by such an audience as a prototype, 
in a suitable research context, and by others who work in the production and 
design of health communication resources.
Independent work and limited skillset
As a self-directed interdisciplinary project, building the prototype required 
“hard skills” in several domains, none of which were fully exercised in service 
of the concept. (Such is the nature of working independently.) The prototype 
is severely bound by the limits of its author’s attention and skill in these 
domains—including user interface design, programming, data manipulation, 
interpretation of medical evidence, data visualization, basic statistical literacy, 
and so forth. The challenge of communicating information about DMARDs’ 
effects on pain—dealing with heterogeneous outcome data, even just from a 
similar suite of systematic reviews, presenting them in a statistically faithful 
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and comprehensible way—illustrates how these skills were stretched, in light 
of balancing work on the written portion of the thesis and other parts of 
the prototype. More time would have allowed deeper investigation and skill 
development.
No “option of doing nothing”
In all medical decisions, one option is doing nothing. In effect, that is a 
potential “medication choice” that is not represented in the Navigator 
prototype. In contrast, many decision aids explicitly include such an option to 
contrast potential outcomes from interventions. Such data could be useful as a 
comparator in the prototype platform. Or, pooled placebo information could be 
used to provide similar context—it is already available.
Unvalidated data
As only one person read, entered, and reviewed data, there is the possibility 
that data have been erroneously encoded into the Google spreadsheet. Figures 
could be wrong or mis-typed, incorrect metrics might have been specified by 
accident, or the wrong level of detail transcribed about some factor of a finding. 
In a more robust system, a validation process would be necessary.
Design shortcomings
Focusing less on the user experience of a patient-facing design and more 
on building a soup-to-nuts prototype was a deliberate decision. Given time 
constraints, it was a tradeoff: Either the design could be (hopefully) more novel 
without development of a basic elastic platform, or the design could be more 
pedestrian with a stronger foundation for future work—including improved 
user interface design—developed instead. The “patient-facing” or part of the 
prototype lacks. A low-literacy conscious design, or perhaps even a full decision 
aid, could have been (and can now be) built on the prototype platform. So 
could additional tailoring options—to duration and severity of RA disease 
activity, for example.
Limited evidence
This significant limitation has two parts: A restriction in the kinds of findings 
that can be encoded today, and a cap on the quantity of evidence currently 
encoded. No single data schema is appropriate for all kinds of evidence, but 
some structure is necessary for machine readability. The schema developed 
so far cannot accommodate all data that might be of interest to patients. In 
some cases, even straightforward outcome data must be contorted to fit the 
schema. One particular shortcoming is that it does not accommodate arbitrary 
measures of statistical variance or uncertainty alongside individual findings—
just 95% confidence intervals. The schema should change to support other 
methods, like interquartile ranges, standard deviation, and so on. It is also 
optimized for population-intervention-comparison-outcome data (PICO), with 
a weakness in the population dimension. The prototype eschews an existing 
PICO ontology (Cochrane Collaboration, n.d.-b) in favor of a simpler one that 
works in Google spreadsheets and is sufficient. Evidence such as treatment 
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algorithms, quantification of severity of contraindications and risk factors, 
patient anecdotes (e.g. drug reviews or video interviews), and others, require 
their own schemata.
The prototype is limited not only in terms of the type of evidence that it can 
accommodate, but also the quantity. It is obviously non-exhaustive, but there is 
no obvious way assess and communicate just how little evidence it contains, or 
what proportion of “valuable” evidence it contains or summarizes.
No feedback from patients and clinicians
Perhaps the biggest limitation of this project is that it did not involve real 
RA patients or caregivers, whose feedback would be necessary to guide 
future work on design. What is it that they find valuable about certain UIs, 
visualizations, or pieces of evidence? This evaluation could shift the perspective 
and direction of the project, or perhaps reveal that it is entirely not of value 
for their decision making. To a designer, it is obvious that without the human 
experience of people living with RA and of their caregivers and clinical care 
teams—those actually making decisions about these medications and observing 
their effects in the real world—any product intended for their use will likely fall 
short. What has so far been built largely represents an interpretation gained 
by reading literature, through the lens of personal experience as a designer 
and with online health resources, and projected through a philosophy and 
intent around a particular design artifact. It is the product of an pragmatic 
and intentional design experiment, rather than a comprehensive need-driven 
investigation.
Future work
Evaluation with target audiences
All three target audiences—patients and caregivers, clinicians and researchers, 
and designers and programmers—possess experience and knowledge that are 
invaluable to development of this work and that can only be discovered by their 
participation and feedback. While some decisions—such as the priority issues 
and kinds of data to focus on—are informed by prior research, a priority for 
future work is evaluation of the design, utility, and usability of the prototype 
and resources built with it. Among other facets, such study might include:
 Comprehensibility of specific prototype user interfaces and data 
visualizations.
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 Following more thorough development on specific products (e.g. a 
decision aid) built with the prototype platform, such products’ effects in 
shared decision making.
 Acceptability of spreadsheets as a useful for data entry, and the schemata 
for findings.
 Utility of technical components—for example, data visualization modules.
Some feedback can be gathered informally, such as by sharing the prototype 
in conversation with other designers and developers. In the event that a 
full decision aid were built using the platform, evaluation would have to be 
conducted according to medical-ethical imperatives in a more careful and 
rigorous way.
Design and “translation” of findings
User-facing components of the Navigator prototype—the overall user interface, 
visualizations, and so forth—are for the moment rather simplistic. As mentioned 
in the last section, true design investigation was limited in the work so far. 
Questions of user experience, data visualization, and so on, warrant deeper 
investigation and creative work. Some of the most obvious candidates for more 
work are: 
 Tailoring. It might be possible to find evidence for specific populations—
early RA, failed initial DMARD therapy, or by sex and age—that can be 
used to tailor which evidence is presented. Presentation of evidence 
about pain relief, for example, might be customized by allowing 
someone to specify their “starting point” or baseline. Then, the question 
would be how or whether the studied approach would be sufficient for 
generalization to other outcomes.
 Much more sophisticated translation. Overlooked outcomes—like 
disease progression, which is critical to the notion of why DMARDs are 
necessary in the treatment of RA—deserve attention. How can a faithful 
representation of evidence reflecting the imperative for disease control 
be “translated” into terms that matter to patients? Going further, the 
abandoned initial purpose of the prototype—to find a way to bring 
together disparate data that might together answer questions in true 
quality-of-life terms—could be taken up again.
 Low-literacy, low-numeracy, and other design approaches entirely. 
As the project progressed, it tended further and further away from 
attention to “patient-facing” design and more towards a generally useful 
platform for future work. One of its strengths is that the evidence in it 
can be presented in many different ways. The range of human needs and 
capacities to understand health information indicates experimentation 
with low-literacy design, low-numeracy design, multilingual design, 
finding more parallels from consumer technology and applying them, and 
so on. For example, there exist visualization methods for findings from 
multiple sources—forest plots commonly used in systematic reviews, for 
example. Perhaps modification of these existing techniques would work 
better than novel approaches? A more rigorous design process—with 
wider literature review—could provide fertile ground from which new 
data-driven designs could sprout.
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More and different data
Limited data narrows the scope of any product built with the prototype 
platform. A deeper or wider evidence base would change its potential. One 
approach would be to focus exclusively on one type or suite of outcomes, 
such as the ACR core set, and to attempt to exhaustively encode data on that 
set. Another would be to enhance the prototype’s capacity for any outcomes, 
including richer and more nuanced capture of measures and metrics, statistical 
variance, population characteristics, data quality, and so forth. Aforementioned 
evidence like patient-reported outcomes, treatment algorithms from clinical 
practice guidelines, are obvious candidates for new data. More historical data 
could be archived, or (probably more usefully) an effort could be made to 
focus on keeping the prototype up to date with the latest evidence. A product 
that might guide such a decision is one intended to keep people up to date 
with the latest findings on medications; the lion’s share of effort for such a 
product would more likely be a social or community effort around encoding the 
findings, not a significant change to the prototype’s capacity to handle data.
Elaborated harmonization and synthesis
One way to consider the presentation of heterogeneous findings from multiple 
sources is that it is a spectrum. At one extreme, data points are reported as is, 
in a format appropriate to the specific outcome and any idiosyncrasies. In this 
method, 15 findings about pain, using 15 different outcomes and measures, and 
gathered with 15 different methodologies, might be presented in 15 different 
ways, leaving the reader to interpret the meaning of all of them as a whole. In 
a way, that is the easiest to support technically, and potentially the worst for 
the end user. At the other extreme, all the data are expertly synthesized—they 
may be aligned to a single way of presenting them, and shown side by side, or 
perhaps even summarized as a single graphic or text conclusion. (Perhaps only 
statistically significant data would be shown.) This requires intimate knowledge 
of the data, advanced statistical methods, and proficiency in communicating 
in frames that the end user understands. It is by far the most difficult 
approach. Between those extremes is harmonization—the aforementioned 
notion of transforming or aligning findings, either statistically or just in terms 
of presentation, such that they are made similar enough to be applicable 
and understandable. The prototype currently uses a controlled vocabulary 
to “bring together” diverse adverse event-related outcome data under a 
more patient-friendly “side effects” banner, and some basic statistical and 
presentational harmonization of pain outcomes in a data visualization, but little 
else. Future work might include enhancing these capabilities, or even pursuing 
basic analytical synthesis capabilities—only if the data support it, and only with 
collaboration with people who possess the right skills.
A digital version of the RA Choice decision aid
Since the prototype began with a basic digital version of the RA Choice decision 
aid (Barton et al., 2014), perhaps that could be expanded to support new 
issues—including evidence about the issues in the Navigator prototype like 
pain and overall improvement, along with new patient-reported outcomes like 
sleep and fatigue (pending their quality and availability). Such a project, if the 
RA Choice authors were interested, might bridge the prospect of a data-driven 
online resource with the established value of a decision aid.
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Conclusion
The project undertaken for this thesis intended to demonstrate that public 
engagement with medical evidence could be facilitated by building a software 
application with readymade and widely used development tools and design 
parallels from consumer Web products. Put simply, if Kayak and Google Maps 
can build popular, useful applications that help people derive meaning from 
vast troves of data, why not also in medicine? Through a research process of 
working with medical evidence, encoding it, designing with it, and developing 
with it, some answers emerged indicating significant challenges to overcome 
before such resources become widespread.
The unique and sensitive nature of medical data preclude its straightforward 
use in uncomplicated analogs to data-driven consumer Web applications. At 
the time of its production, evidence about rheumatoid arthritis medications 
is imbued with biases and essential qualities that govern its safe application 
—and that ultimately limit applicability in patients’ lives and conclusions 
that may reasonably be drawn. An incomplete list of such qualities includes 
heterogeneity in populations studied or to whom findings may apply, methods 
of production, outcomes observed, study and statistical methodologies, 
representativeness and statistical significance, omission of data or details, limits 
imposed by data encoding and publishing format, and numerous sources of risk 
of bias. Access to such evidence—in both print and digital, machine-readable 
formats suitable for ingestion and use by software—is often restricted. It is not 
made systematically available, likely in part due to the aforementioned extreme 
heterogeneity. In these ways, medical data may differ from those that fuel 
consumer Web applications—meteorological data, road and navigation data, or 
flight schedule and price data, for instance. Sophisticated methods are required 
to finesse medical evidence for provision in a public-facing user interface to 
explore it. At every stage of working with the evidence, deliberate decisions 
shape the ultimate product—sourcing it, deciding which dimensions to encode 
and at what level of detail, processing it, translating it to patient-friendly 
terms, and ultimately displaying it. Nuance may be traded for clarity, but not 
without the introduction of a caveat. Each decision—like whether to articulate 
in detailed and machine-readable terms the details of the person to whom a 
finding applies—defines the ways that person can interact with the information.
This project has demonstrated that indeed there are tools (e.g. Google 
Spreadsheets and open-source software development frameworks) and tactics 
(e.g. risk communication visualizations and user interface designs) that can be 
assembled into a platform for engagement with medical evidence. However, its 
success is sharply limited by shortcomings that continue to emerge as data are 
added and the platform develops. Creating a platform for public engagement 
with various kinds of evidence about medications that treat rheumatoid 
arthritis is an aspiration without a specific endpoint, and of a scope far beyond 
that of an undergraduate thesis project. It demands the participation of patients 
and caregivers, researchers, designers, clinicians, programmers, and other 
specialists. Together they can discover different approaches not only to the 
design of such a platform, but also to future research methodologies, patient-
reported outcomes, and data-publishing practices. Hopefully, such discoveries 
will permit a thread to be drawn from real-world needs to the production of 
knowledge about medications, made visible through accessible user interfaces.
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